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General introduction (en)
?
Although conventional treatment options of cancer such as chemotherapy, radiation and 
surgery have experienced significant advances over the past few decades, they remain far 
from optimal. Nanotechnology, led by the development of nanoparticle-based drug delivery 
systems and imaging contrast agents, has had an important role in diagnosis, prevention, and 
treatment of the disease. The use of nanotechnology for cancer therapy and imaging is
expected to overcome the limitations of conventional treatments, such as poor drug 
bioavailability, nonspecific systemic drug distribution, inadequate drug concentrations 
reaching the tumor and inability to monitor therapeutic responses in real time. Some 
nanotechnology-based formulations have been already approved by the US Food and Drug 
Administration, like Doxil
®
, Abraxane
®
 However significant challenges remain regarding 
in particular the methods used to produce sophisticated multifunctional nanoparticles. Most of 
the procedures developed to date to prepare nanoparticles involve the use of toxic solvents 
and surfactants, which require intensive postprocessing purification.
Nanoengineered capsules composed of sequentially assembled polymer layers hold promise 
for a variety of biomedical applications. These capsules are prepared by the layer-by-layer 
assembly of oppositely charged polyelectrolytes onto a sacrificial colloidal template followed 
by core removal. The assembly process allows for nanoscale manipulation of the properties of 
the capsules, including size, composition, permeability, stability, surface functionality as well 
as sensitivity to chemical or physical stimuli. However, their hydrophilic multilayer shell and 
their aqueous cavity pose difficulties to incorporate hydrophobic drug molecules. In this 
context, we proposed to develop an original and versatile approach to selectively encapsulate 
hydrophobic molecules in the nanoshell of multilayered capsules. We focused on the design 
of biocompatible and biodegradable multilayer capsules using hyaluronic acid (HA) as the 
polyanion partner, based on previous work performed in our laboratory showing the ability to 
prepare multilayer capsules from this natural polysaccharide
1
, and to obtain various functional 
derivatives of HA under mild aqueous conditions
2-4
. Moreover, HA can be specifically 
recognized by the CD44 receptor that is over-expressed by several cancer cells including 
human breast epithelial cells
5
and human ovarian tumor cells
6
. This unique property may 
provide a distinct advantage over other macromolecular building blocks that may be used for 
the fabrication of drug delivery systems.
In this regard, this polysaccharide has been recently exploited to design nanogels. Nanogels 
are swollen nanosized networks composed of hydrophilic or amphiphilic polymer chains.
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They are developed as carriers for the transport of drugs, and can be designed to 
spontaneously incorporate biologically active molecules through formation of hydrogen bonds, 
electrostatic or hydrophobic interactions. One part of this thesis includes the synthesis, the 
physico-chemical characterization and the investigation of the biological properties of
hydrophobic anti-cancer drug loaded nanogels based on HA.
The work presented in this thesis were performed in the group "Structure and Modification of 
Polysaccharides" of the CERMAV. One of the objectives of the researches performed in this 
group is to obtain structurally controlled tailor-made biopolymers with potential applications 
in the cosmetic, pharmaceutical and biomedical fields, in particular. The PhD work were 
made possible thanks to close collaborations with the Professor Catherine Picart (Laboratory 
of Materials and Physical Engineering (LMGP)-Minatec, INP Grenoble) and the Professor 
Bruno De Geest (Ghent University, Belgium) who provided strong scientific support for the 
physico-chemical and biological characterization of the carrier systems. They were 
additionally supported by the Agence Nationale de la Recherche ("BIOCAPS" project of the 
PNANO program). 
This thesis manuscript is divided into four sections:
The first chapter overviews the NPs for cancer therapy and imaging, including their 
general characteristics, their passive and active targeting toward tumors and their controlled 
drug release properties.
The second chapter describes two types of capsules prepared with alkylated HA 
derivatives and quaternized chitosan (QCHI) or poly(L-lysine) (PLL). A hydrophobic dye nile 
red and an anti-cancer drug paclitaxel (PTX) were incorporated individually in the shell of 
capsules. The amount of the dye or drug entrapped per capsule was determined. The stability
of the alkylated HA/QCHI capsules and the alkylated HA/PLL capsules in culture media was 
also investigated. Finally, we examined the cytotoxic effect of PTX loaded alkylated HA/PLL 
capsules on breast cancer cells.
In the third chapter, we report on the design of another type of capsules based on HA 
which can also incorporate water-insoluble molecules in the shell. Our strategy for the design 
of such capsules was based on the use of a HA derivative possessing pendant ?-cyclodextrin
molecules (HA-CD) as a polyanion. This derivative can form host-guest complexes with 
hydrophobic molecules through inclusion in the hydrophobic CD cavity. PTX was thus 
encapsulated in the capsules and their effective loading and release properties were studied. 
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Similarly to the capsules based on alkylated HA, we examined the cytotoxic effect of PTX 
loaded capsules prepared from HA-CD on breast cancer cells.
The last chapter presents self-assembled nanogels based on HA. A thermosensitive
copolymer of diethyleneglycolmethacrylate and oligoethyleneglycolmethacrylate was grafted 
onto HA chains leading to a graft hybrid copolymer (HA-poly(DEGMA-co-OEGMA)). Upon
increasing the temperature at the body temperature, HA-poly(DEGMA-co-OEGMA)
spontaneously formed nanogels and encapsulated PTX in their hydrophobic nanodomains.
The PTX-loaded nanogels exhibited a high selectivity towards cells overexpressing the CD44 
receptor for HA on their surface.
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Introduction générale (fr)
Malgré les progrès réalisés ces dernières années en chimiothérapie, en radiothérapie et en
chirurgie pour traiter le cancer, ces méthodes conventionnelles sont encore loin dêtre 
optimales. Parmi les différentes approches issues des nanotechnologies, l'utilisation de 
vecteurs nanoparticulaires, cargos de taille nanométrique, s'est imposée comme une des 
solutions envisageables pour augmenter l'efficacité des traitements existants, tout en réduisant 
leur toxicité systémique. Ces vecteurs permettent doutrepasser les limitations des approches 
conventionnelles non seulement en thérapie mais aussi en imagerie et en diagnostic, en 
améliorant par exemple la solubilité en milieu aqueux des principes actifs, leur efficacité 
thérapeutique (en favorisant leur accumulation au niveau du tissu cible), la capacité à évaluer 
les réponses thérapeutiques. Certaines formulations ont été approuvées par l'agence 
américaine de réglementation des médicaments et des produits alimentaires (FDA), comme le 
Doxil
®
, lAbraxane
®
 Néanmoins, ces systèmes nanoparticulaires ne remplissent pas toutes 
les caractéristiques nécessaires pour pouvoir véhiculer un principe actif sélectivement vers des 
cellules ou tissus cibles et le libérer de manière contrôlée. Ces caractéristiques constituent des 
défis importants qui passent par la conception de nanoparticules plus sophistiquées, 
combinant plusieurs fonctions. Par ailleurs, à ce jour, la plupart des procédés utilisés pour 
préparer des nanoparticules impliquent lutilisation de solvants toxiques et/ou des tensioactifs, 
ce qui impose des étapes de purification et de post-traitement intensifs.    
Les capsules préparées par assemblage couche-par-couche de polymères de charges opposées 
sur un support colloïdal, suivi de sa décomposition, sont apparues comme une nouvelle 
approche prometteuse pour transporter des principes actifs. Le procédé dassemblage permet 
de moduler facilement les propriétés des capsules, notamment leur perméabilité, leur stabilité 
ainsi que leur leur interaction avec les espèces biologiques via leur fonctionnalités en surface. 
Cependant, leur paroi hydrophile et la cavité aqueuse engendrent des difficultés pour intégrer 
des molécules hydrophobes. Dans ce contexte, nous nous sommes proposés de développer des 
approches originales et modulables pour encapsuler sélectivement des molécules hydrophobes 
dans la paroi de capsules multicouches. Ces travaux sappuient sur des études antérieures 
menées au sein de notre laboratoire et portant sur la conception de capsules biocompatibles et 
biodégradables à base dacide hyaluronique (HA)
1
, ainsi que de différents dérivés de HA en 
milieu aqueux.
2-4
Par ailleurs, le HA est un ligand du récepteur protéique CD44 qui est 
surexprimé par plusieurs cellules cancéreuses, notamment les cellules épithéliales (carcinome) 
de la glande mammaire
5
et les cellules tumorales ovariennes
6
. Cette propriété unique de HA 
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offre un avantage distinct par rapport aux autres macromolécules pour lélaboration de 
systèmes de vectorisation dagents anti-cancéreux.
A cet égard, ce polysaccharide a été récemment exploité pour la conception de nanogels. Les 
nanogels sont des réseaux tridimensionnels de taille nanométrique composés de chaînes de 
polymères hydrophiles ou amphiphiles. Du fait de leur capacité à incorporer divers types de 
(macro)molecules actives par formation de liaisons hydrogène, dinteractions électrostatique 
et/ou hydrophobes, ces systèmes suscitent un intérêt croissant pour transporter des 
médicaments. Une partie de cette thèse est ainsi consacrée à la synthèse et la caractérisation 
de nanogels à base de HA capables dencapsuler des agents anti cancéreux hydrophobes.
Les travaux présentés dans ce manuscrit ont été effectués au sein de l'équipe "Structure et 
Modification des Polysaccharides" du CERMAV et sinscrivent parmi les thématiques du 
groupe visant à développer de nouveaux polysaccharides modifiés en vue dobtenir des 
structure contrôlée sur mesure de biopolymères avec des applications potentielles dans les 
domaines cosmétiques, pharmaceutiques et biomédicales, en particulier. Les travaux de thèse 
ont été rendus possibles grâce à la collaboration étroite avec le Professeur Catherine Picart 
(Laboratoire des Matériaux et Génie des Procédés (LMGP)-Minatec, INP Grenoble) et le 
Professeur Bruno De Geest (Ghent University, Belgique). Le projet est financé par lAgence 
Nationale de la Recherche.
Ce manuscrit de thèse est divisé en quatre chapitres :
Le premier chapitre est consacré à un mise au point sur les nanoparticules utilisées 
pour la traitement du cancer et limagerie. Il décrit leurs propriétés générales, leur 
caractéristiques en termes de ciblage passif et actif vers les tumeurs ainsi que les stratégies de 
libération contrôlée de médicaments.  
Le second chapitre présente deux types de capsules préparées à partir de dérivés 
alkylés de HA et de dérivés du chitosane quaternisé (QCHI) ou de poly (L-lysine) (PLL). Une 
sonde fluorescente et un agent anticancéreux hydrophobes (le Nile red et le paclitaxel (PTX), 
respectivement) ont été incorporés individuellement dans la paroi des capsules. La quantité de 
molécules hydrophobes encapsulées a été déterminée. La stabilité des capsules HA-alkylé 
/QCHI et HA-alkylé /PLL dans un milieu de culture a également été étudiée. Lactivité 
biologique des capsules HA-alkylé/PLL vis-à-vis de cellules du cancer du sein (MDA MB 
231) a été étudiée.
Dans le troisième chapitre, nous décrivons la synthèse et létude dun autre type de 
capsules préparées à partir de HA capables également dincorporer des molécules 
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hydrophobes dans la paroi. Cette stratégie a été réalisée par greffage de la ? -cyclodextrine sur 
le HA pour conduire à des biopolymères (HA-CD) capables de former des complexes 
dinclusion avec des molécule hydrophobes. Le PTX a été encapsulé dans ces capsules. La 
quantité de PTX incorporé dans la paroi et la libération de PTX ont été étudiées. Lactivité 
biologique des capsules HA-CD /PLL vis-à-vis de cellules du cancer du sein (MDA MB 231)
a également été évaluée.
Le dernier chapitre porte sur lélaboration de nanogels auto-assemblés à base de HA. 
Un copolymère thermosensible, le diéthylèneglycolméthacrylate -
oligoéthylèneglycolméthacrylate (poly(DEGMA-OEGMA)), a été greffé sur des chaînes de 
HA (HA-poly(DEGMA-OEGMA)). Lors du chauffage à 37 °C, les dérivés HA-
poly(DEGMA-co-OEGMA) synthétisés conduisent à la formation de nanogels, dans lesquels 
le PTX peut être incorporé. Les nanogels chargés en PTX montrent une cytotoxicité 
importante vis-à-vis de cellules cancéreuses CD44+ (cellules du cancer ovarien SKOV-3, 
surexprimant le récepteur CD44).
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1.1. Résumé (fr)
Depuis une quinzaine dannées et les avancées en nanotechnologies, les chercheurs ont eu 
pour idée d'utiliser des nanoparticules comme moyen de "locomotion" dagents anti-
cancéreux afin d'être plus précis et de n'attaquer que la tumeur. Des spécialités 
pharmaceutiques à base de vecteurs de médicaments à visée anticancéreuse ont été lancées 
récemment sur le marché. De ces progrès résultent déjà aujourdhui une diminution des doses 
prescrites, une baisse de la toxicité et une meilleure tolérance thérapeutique. Lutilisation de 
systèmes transporteurs dagents anti-cancéreux offre également lespoir dune approche 
thérapeutique combinatoire, par lingénierie de nanoparticules délivrant plusieurs drogues 
destinées à neutraliser différentes cibles au sein dune même tumeur. Par ailleurs, le 
développement de nouveaux outils pour limagerie offre aujourdhui lespoir dun diagnostic 
précoce et non-invasif du cancer, ce qui devrait permettre de réduire le nombre de cas de 
cancers évoluant vers un stade terminal. Ainsi, lapplication biomédicale des outils issus de la 
nanotechnologie permet denvisager lévolution vers une médecine personnalisée, dans 
laquelle chaque patient et chaque cancer seront traités comme des cas individuels. 
Ce chapitre a ainsi pour but de situer le travail dans son contexte bibliographique en faisant 
une mise au point sur les stratégies de vectorisation développées à ce jour dans le domaine de 
la thérapie anti-cancéreuse. 
Celles-ci reposent de manière générale sur la mise au point de formulations nanoparticulaires 
de nature organique (particules constituées de lipides, de polymères, de protéines ou encore de 
peptides) ou inorganique. Il est important de souligner que grâce à leur taille submicromique,
ces systèmes transporteurs s'accumulent préférentiellement dans les tissus tumoraux dont le 
système vasculaire présente des porosités (400 - 600 nm). Cet effet "EPR" (Enhanced 
Permeability and Retention) permet ainsi un "ciblage passif" des tumeurs. Couplée à dautres 
caractéristiques chimiques, lutilisation de systèmes nanoparticulaires permettrait également 
de proposer des stratégies de "ciblage actif" des cellules cancéreuses. La possibilité de 
fonctionnaliser la surface des particules avec différents agents de ciblage devrait ainsi 
permettre d'améliorer significativement les propriétés pharmaceutiques de tels systèmes. 
Dautres stratégies « intelligentes », conçues en guise de ciblage, consistent à exploiter les 
propriétés caractéristiques des cellules cancéreuses et des tumeurs. En particulier leur 
métabolisme très actif associé à lacidification de lenvironnement tumoral, à la sécrétion de 
protéases (métalloprotéases) peut être avantageusement utilisé pour favoriser le ciblage 
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spécifique des nanoparticules thérapeutiques (présentant un élément activable par le pH ou 
par clivage protéolytique) vers les cellules cancéreuses. Toutes ces approches passent par la 
fonctionnalisation chimique adéquate des vecteurs, ce qui peut être un frein au développement 
à plus ou moins grande échelle de ces systèmes " sur mesure ".
La mise au point de nouveaux vecteurs selon des procédés modulaires, utilisant des molécules 
biocompatibles est donc un axe de recherche important dans ce domaine. La technique de 
dépôt couche par couche de polyélectrolytes sur des surfaces solides constitue à ce titre une 
approche particulièrement intéressante pour concevoir des systèmes transporteurs dont les 
propriétés peuvent être facilement modulées. Cette technique, basée sur ladsorption alternée 
de polyanions et de polycations sur des particules colloïdales sacrificielles, a permis dobtenir 
à la fin des années 1990 de nouvelles formes de vecteurs multicompartiments, appelés 
capsules multicouches. Depuis une dizaine dannées, ces assemblages suscitent une attention 
considérable liée à la possibilité de conférer à la paroi des fonctionnalités diverses en fonction 
de sa composition chimique. Selon la nature des polyélectrolytes utilisés, il est ainsi possible 
de concevoir des capsules pouvant répondre efficacement à des stimuli physiques ou 
chimiques permettant une libération programmée des principes actifs encapsulés et/ou 
capables dinteragir sélectivement avec certaines cellules. Bien que la taille de lordre de 
quelques micromètres limite encore les applications in vivo de nouveaux systèmes 
transporteurs, certaines équipes ont commencé à développer des nanocapsules. 
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1.2. Introduction
Cancer causes one in eight deaths worldwide, which represents more deaths than AIDS, 
tuberculosis, and malaria combined. According to recent World Health Organization 
projections, cancer has replaced ischemic heart disease as the overall leading cause of death 
worldwide in 2010. The total cancer deaths in 2008 were 7.6 millions (about 21,000 cancer 
deaths a day)
1
. Cancer is a generic group of diseases that can affect different parts of the body. 
Cancer occurs because of mutations in genes that control cell cycles. Four major 
characteristics of cancer cells are uncontrolled growth (uncontrolled division), invasion of 
adjacent tissue, metastasis (spreading to other locations in the body), and immortality 
(protection against programmed cell death).
2
Therefore, the increase in the efficacy of cancer 
treatment is an essential task for modern medicine.
Although localized tumors can be successfully removed by surgery, the treatment of 
spreading or metastatic tumors requires high-dose chemotherapy.
3
Current cancer therapies 
are largely limited by 1) the difficulty to deliver poorly water-soluble drugs; 2) the non-
specific delivery and poor biodistribution of drugs; 3) the inability to bypass biological 
barriers; 4) the drug resistance of cancers and 5) the lack of an effective modality for 
treatment monitoring.
3-6
The application of nanotechnology to cancer therapy has the 
potential to overcome these challenges by enabling the engineered nanomedicines to navigate 
the body in very specific ways. Theranostic nanomedicines, mostly nanoparticles (NPs) 
carrying therapeutics, are designed to improve current cancer therapies by addressing the 
specific existing limitations. Nanoparticles may be constructed from a wide range of materials 
and used to encapsulate or solubilize chemotherapeutic agents for improved delivery in vivo 
or to provide unique optical, magnetic and electrical properties for imaging and therapy. One 
major advantage of nanoparticles is their potential to be used as non-invasive diagnostic tools. 
Another advantage is the capacity to combine multiple modalities in only one system, 
enabling higher sensitivity to be achieved and deeper insight gained into in vivo processes. 
The combination of molecular imaging and local treatment of lesions is unique for nano-
objects and has the potential to change the current medical paradigm of see and treat to 
detect and prevent.
7
Several functional nanoparticles have already been demonstrated, 
including some clinically approved liposome drug formulations and metallic imaging agents. 
The next generation of nanoparticle-based research is directed to the consolidation of 
functions into strategically engineered multifunctional systems, which may ultimately 
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facilitate the realization of individual therapy. These multiplexed nanoparticles may be 
capable of identifying malignant cells by means of molecular detection, visualizing their 
location in the body by providing enhanced contrast in medical imaging techniques, killing 
diseased cells with minimal side effects through selective drug targeting, and monitoring 
treatment in real time.
The enhanced permeability and retention (EPR) effect
The term cancer identifies a large group of complex and multifaceted diseases that are 
characterized by cells that have undergone mutations of their genetic material and whose 
growth is unregulated. Cancer cells tend to replicate at a higher rate than normal cells. The 
abnormalities present in the tumor tissue result in extensive leakage of blood plasma 
components and other macromolecules.
8
The greater permeability of tumor vessels to 
macromolecules compared with normal vessels, and the impaired clearance of these 
macromolecules from the interstitial space of the tumor (contributing to longer retention of 
these molecules), is called enhanced permeability and retention (EPR) effect
9
(Figure 1.1). 
Figure 1. 1. Schematic illustration for enhanced permeability and retention (EPR) effect.
This effect, though not universally accepted, has been described as particularly relevant for 
particles with diameters greater than 100 nm
10
and will depend on tumor type and stage. The 
ability of macromolecules and NPs to accumulate specifically in tumor tissue has been studied 
extensively since Maeda et al.
11
first described the EPR effect twenty years ago. Inspired by 
Tumor cell
Endothelial cell
Nanoparticles
Small molecules
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the EPR effect, many passive targeting strategies have been applied to deliver nanoscale drugs, 
therapeutics and imaging contrast enhancers to the tumor site, in which such agents are 
injected into the blood stream with the aim of accumulating preferentially at the tumor site. 
Nowadays, most drug delivery systems for cancer are being designed based on this principle,
also with some clinical products.
12
1.3. Nanoparticles for cancer therapy and imaging
1.3.1. Type of nanoparticles currently applied in cancer 
therapy
The utility of nanoparticles for the delivery of small molecule chemotherapeutics in vivo is 
now well established, with various formulations of doxorubicin (DOX), daunorubicin and 
paclitaxel (PTX) already commercially available (Table 1.1). These drugs are the most potent 
chemotherapeutic agents used in cancer treatment. They are usually administered at a higher 
quantitative dosage because of their poor aqueous solubility, which increases the undesirable 
side effects. In general, nanoparticles are designed to circumvent limitations of conventional 
drug delivery systems, including nonspecific biodistribution and targeting, low aqueous 
solubility, poor bioavailability and low therapeutic indices stemming from insufficient drug 
concentration at disease sites. 
Table 1. 1. Selected examples of nanomedicines for cancer treatment (approved or in clinical 
development).
Carrier type (size) Active ingredient Nanomedicine Approval/clinical testing
Liposome (100 nm)
13 Doxorubicin Doxil
®
Approved for multiple 
cancers
Liposome (100 nm)
14 Daunorubicin DaunoXome
®
Approved for Kaposis 
sarcoma
Liposome (100 nm)
15 Doxorubicin, 
thermal release
ThermoDox
®
Phase III: liver/HCC
a
Phase II: metastatic cancers
Colloidal albumin (123 
nm)
16
Paclitaxel Abraxane
®
Approved for metastatic 
breast cancer
Polymer-drug conjugate
b,
17
Paclitaxel CT-2103
(Xyotax)
Phase III: ovarian, NSCLC
c
PEG-PLA micelle
d,18,19
Paclitaxel Genexol-PM Phase III: brease
Cyclodextrin-PEG micelle 
(30 nm)
20
Camptothecin CRLX-101
(formerly IT-101)
Phase II: lung (NSCLC
c
), 
ovarian
Cyclodextrin-PEG micelle 
(100 nm)
21,22
siRNA (anti-
RRM2)
CALAA-01
(Cyclosert)
Phase I: solid tumors
Aminosilane-coated Magnetic NanoTherm
®
Approved (EU) for 
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SPIOs
e
(16 nm)
23
hyperthermia glioblastomas
Gold nanoparticle (27 nm)
24
Tumor Necrosis 
Factor
CYT-6091
(Aurimmune)
Phase I: solid tumors
CM-dextrane
f
-Fe3O4 NPs 
(40-60 nm)
25
Imaging agent 
(MRI contrast)
Resovist
®
Approved for liver/HCC
a
imaging
a
HCC: hepatocellular carcinoma.
b
Polymer-drug conjugate: poly(L-glutamic acid)-Paclitaxel.
c
NSCLC: non-
small-cell lung cancer, the most common type of lung cancer.
d
PEG-PLA micelle: micelle formed from block 
copolymers of poly(ethylene glycol) and poly(D,L-lactic acid). 
e
SPIO: superparamagnetic iron oxide.
f
CM-
dextran: carboxymethyl dextran.
By a general definition, nanoparticles applied as drug delivery systems can include liposomes, 
other polymeric NPs, and inorganic NPs.
1.3.1.1. Liposomes
Liposomes are composed of natural lipid layers, and are classified according to the number of 
lipid bilayers as either unilamellar or multilamellar. The one or several lipid bilayers can 
solubilize hydrophobic drugs. Alternating aqueous compartments can entrap hydrophilic 
drugs
26,27
(Figure 1.2). Liposomes offer several advantages as drug delivery carriers. They are 
generally non-toxic and biocompatible. They are relatively easy to prepare and prevent 
accumulation of drugs in normal organs which reduces their toxicity and improves 
pharmacokinetic effects. Liposome properties such as size, surface charges, membrane 
rigidity and the phase transitions within the bilayer can be controlled either by selecting 
appropriate lipid compositions or by changing external conditions such as temperature, pH of 
the medium or the presence of specific agents
28,29
. When coupled with antibodies, liposomes 
can be used for active targeting
30-32
. At present, a few liposomal formulations are available in 
the market for the treatment of AIDS related Kaposis sarcoma, breast, ovarian and other
tumor types
33,34
. These liposomes employ the EPR effect to reach tumors where they act as 
drug depots. Release in the interstitium occurs mainly via disruption of the liposomal bilayer 
and through tumor uptake and subsequent drug release.
Figure 1. 2. Structure of a carrier liposome. Hydrophilic drugs can be loaded in the liposome interior, 
while hydrophobic drugs can be loaded between the lipid layers.
Hydrophobic drugHydrophilic drug
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Although clinically successful in some applications, liposomes also have limitations. One of 
the problems with liposomes as drug delivery carriers is their lack of stability in biological 
fluids and during storage, nonspecific uptake by the mononuclear phagocytic system and 
rapid drug release profiles in vivo.
35
Consequently, drug molecules leak to normal tissues and 
cause undesirable side effects.
1.3.1.2. Polymeric nanoparticles
One class of polymeric NPs includes polymeric micelles (Figure 1.3.a) consisting of 
amphiphilic diblock and triblock copolymers, which can self-associate in selective solvents. 
The core regions of the micelles serve as reservoirs for hydrophobic drugs
36-39
, whereas the 
hydrophilic exterior imparts stability to the carrier in aqueous environments
40,41
. Since their 
structures are primarily retained by noncovalent interactions, there is a need for further 
improving the in vivo stability of polymeric micelles. Another class of self-assembled 
structures of amphiphilic copolymers is that of polymersomes (Figure 1.3.b) which are 
characterized by a high stability and tunable membrane properties as allowing the triggered 
release of drugs.
42,43
Due to their multicompartment structure, these systems can encapsulate 
or integrate a broad range of hydrophilic or hydrophobic drugs. Several work focused on the 
design of polymersomes for targeted drug delivery.
43-45
In particular, the development of 
stimuli-reponsive polymersomes to further control the release of drugs by switching the 
stability and permeability of the membrane has attracted a lot of interest.
46-52
To minimize inherent instability and degradation limitations associated with liposome and 
micelle formulations, other polymer-based drug carriers were developed. Compared with 
liposomes and micelles, polymeric systems demonstrate a series of attractive properties as 
pharmaceutical carriers, including high drug loading capability, prolonged circulation time 
stemming from higher stability in vivo, and slower rates of dissociation that allow retention of 
loaded materials for a longer period of time. In addition, the delivery systems can be designed 
to provide either controlled release or triggered release of the therapeutic molecule. In 
nanocapsules (Figure 1.3.c), the shells are usually filled with an aqueous or oil solution, 
which can contain water-soluble or oil-soluble drugs. Nanospheres (Figure 1.3.d) consist of a 
solid mass, which may be impregnated with an anticancer agent.
53-55
Drugs can be loaded into 
polymeric NPs by physical entrapment or chemical conjugation. Finally, nanogels (Figure 
1.3.e), which are polymeric three-dimensional networks of nanometer size (< 1000 nm) 
capable of absorbing high amounts of water, are emerging as promising carriers. These soft 
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particles have unique physicochemical characteristics, including reversible swelling 
properties, which resemble those of the living tissues
56,57
.
Figure 1. 3. Main types of polymeric NPs. a) Micelles. b)Polymersomes. c) Nanocapsules. d) 
Nanospheres. e) Nanogels.
The polymers used in these systems can be broadly divided into natural and synthetic 
materials. Natural polymers that have been investigated for drug delivery applications include
polysaccharides such as alginate
58,59
, hyaluronic acid
60
, dextran
61
and chitosan
62-64
as well as 
polypeptides such as collagen
65
, albumin
66,67
, elastin
68
, and gelatin
69,70
. These materials are 
well tolerated in vivo and are available in abundance in nature. Synthetic polymers include 
polyesters based on lactide, glycolide, caprolactone, and dioxanone, polyanhydrides based on 
sebacic and adipic acid, as well as polyamides, polycarbonates, polyorthoesters, and 
phosphate-based polymers, which have been reviewed in detail elsewhere
71-74
. These
polymers are often hydrophobic in nature, and are ideally suited for long-term delivery. A
significant drawback of synthetic materials is that many form acidic degradation products that 
can accumulate and cause inflammation at the implant site. 
As can be seen from Table 1.1, several polymer NPs are now in various states of preclinical 
and clinical development as carriers of chemotherapeutics. Abraxane
®
, an albumin-taxol NP 
for the treatment of metastatic breast cancer have achieved FDA approval for use in cancer 
therapy. Genexol-PM
19
, a micellar vehicle for delivery of paclitaxel is now in Phase II clinical 
trials. Doxorubicin-conjugated dendrimers were investigated in preclinical studies by Lee et 
al.
75
. The past decade has seen increasing attention on the development of NPs capable of
delivering short RNA duplexes, called small interfering RNA (siRNA), into the cytoplasm of 
tumor cells as a potential means of combating cancer. CALAA-01
21
, a cyclodextrin 
containing polymeric NP, which was the first ever NP-based siRNA delivery system  entered 
a phase I clinical trial in 2008. 
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1.3.1.3. Inorganic nanoparticles
Much attention has also been focused on inorganic nanoparticles in cancer treatment 
applications. Of the wide number of materials available, nanoparticles based on gold, 
semiconducting metals (quantum dots, QD) and iron oxides are of particular interest owing to 
their scientific and technological significance in microelectronics, optoelectronics, and 
cellular imaging. Nanoparticle probes can endow imaging techniques with enhanced signal 
sensitivity, better spatial resolution, and the ability to relay information about biological 
systems at the molecular and cellular levels.
Simultaneous imaging, therapy and sensing of the release of a conjugated drug can be 
achieved by activation of the QDs fluorescence. For example, a QD-aptamer(Apt)-
doxorubicin conjugate was prepared for specific delivery of doxorubicin to prostate cancer 
cells (Figure 1.4).
76
The double-stranded A10 prostate specific membrane antigen (PSMA)
aptamer intercalates DOX but also recognizes the extracellular domain of the PSMA. When 
DOX intercalated into the aptamer, quenching of fluorescence from both the QD and DOX
was found to occur via a Bi-fluorescence resonance energy transfer (Bi-FRET) mechanism.
Binding of DOX to the QD (donoracceptor) diminished QD fluorescence, while the binding 
of DOX to the aptamer (donorquencher) decreased DOX fluorescence. Release of DOX
from the NPs by physical dissociation from the conjugate, or biodegradation of the PSMA 
aptamer by enzymes present in lysosomes, induced recovery of fluorescence from both the 
QD and drug.
76
Paclitaxel has also been covalently attached to gold NPs with high loading 
density and in a controlled mode.
77
Figure 1. 4. (a) Schematic illustration of QD-Apt(DOX) Bi-FRET system. In the first step, the 
CdSe/ZnS core-shell QD are surface functionalized with the A10 PSMA aptamer. The intercalation of 
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DOX within the A10 PSMA aptamer on the surface of QDs results in the formation of the QD-
Apt(DOX) and quenching of both QD and DOX fluorescence through a Bi-FRET mechanism: the 
fluorescence of the QD is quenched by DOX while simultaneously the fluorescence of DOX is 
quenched by intercalation within the A10 PSMA aptamer resulting in the OFF state. (b) Schematic 
illustration of specific uptake of QD-Apt(DOX) conjugates into target cancer cell through PSMA 
mediate endocytosis. The release of DOX from the QD-Apt(DOX) conjugates induces the recovery of 
fluorescence from both QD and DOX (ON state), thereby sensing the intracellular delivery of DOX 
and enabling the synchronous fluorescent localization and killing of cancer cells.
76
There are concerns about the use of QDs for medical purposes because of their composition of 
heavy metals (the high toxicity of cadmium and selenium) and their instability to photolysis 
and oxidative conditions, which could result in dissolution of the QD core. A subsequent
study demonstrated that QDs toxicity was reduced after surface modification with N-
acetylcysteine, while the nonmodified QDs induced lipid peroxidation in the cells.
78
The issue 
of toxicity has been studied by several groups who have reported that the release of toxic 
metals might be limited with biocompatible surface coatings, such as poly(ethylene glycol) 
(PEG) or micelle encapsulation.
79,80
Notwithstanding this, there has been considerable 
research into the development of cadmium-free QDs, such as CuInS 2
81
, as safe and non-toxic 
probes for biological use.
1.3.2. Main characteristics of nanoparticles used for cancer 
therapy
Although the EPR effect is the major effect that is exploited for the diagnosis and treatment of 
cancer using NPs, other properties including size, shape, composition and surface also 
influence the biodistribution and clearance of NPs from the body and are thus important 
considerations in NP design. 
1.3.2.1. General nanoparticle characteristics
The size of nanoparticle is a key property that affects its biodistribution in vivo and the 
cellular uptake rate. Particles less than 6 nm will be cleared and filtered from the blood. As 
the normal endothelium has an average effective pore size of ca. 5 nm, particles smaller than 
this will rapidly extravasate across the endothelium.
82
Studies have shown that particles with 
sizes between 10 nm and 5 µm are typically internalized into cells via endocytosis.
83
Endocytosis is an energy-dependent process by which particles are engulfed and encapsulated 
within a lipid bilayer that isolates them from the cytoplasm of the cell. This process is highly
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dependent on cell type, internalization mechanism, and properties of the interacting materials.
Typically, endocytosis can be classified into two categories: phagocytosis (cell eating), by 
which cells internalize only solid material, and pinocytosis (cell drinking), where cells take up 
a significant amount of liquid from the extracellular environment along with the internalized 
material. While phagocytosis is generally limited to specialized cells such as macrophages 
and dendritic cells that interact directly with large material (>250 nm), pinocytosis occurs in 
almost all cells.
83
The efficiency of particle delivery is often found to vary from one study to 
another. Experiments using liposomes of different mean sizes suggest that the threshold 
vesicle size for extravasation into tumors is ~ 400 nm, but other studies have shown that 
particles with diameters < 200 nm are more effective.
84
The observed range in efficacy has 
been attributed to the extent of particle extravasation, which depends strongly on the degree of 
tumor vascularization and angiogenesis.
85
NPs smaller than 200 nm have been suggested to be 
ideal for cancer therapy
86,87
because of their favorable biodistribution and 
clearance/accumulation behavior.
88
Most NPs are easily cleared by the reticuloendothelial system (RES) or mononuclear 
phagocytic system (MPS).
89
The RES is part of the immune system and consists of 
phagocytic cells like monocytes and macrophages that are located in the spleen, lymph nodes, 
and Kupffer cells in the liver. The main functions of the RES are to remove senescent
(ageing) cells from the bloodstream and to produce phagocytic cells for immune and 
inflammatory responses. In order to reduce the premature clearance by the RES, steric 
stabilization shielding groups have been introduced onto surface of NPs. PEGylation is one 
preferred method.
34,88-90
PEGylation refers to the process of covering the NPs with PEG or its 
derivatives by grafting, entrapping, adsorbing or covalently binding these molecules to the NP 
surface.
91
The most widely accepted theory for this increased circulation time is that PEG 
reduces the protein interactions on the surface of the NPs and prevents their binding to 
opsonins.
91
This may be due to the hydrophilicity of PEG and the attraction of water to the 
surface which repels the protein. One study showed that PEG modified gelatin NPs increased 
circulation half-life from 3 to 15 h over unmodified NP in total body clearance.
92
1.3.2.2. Passive and active targeting
Strategies on delivering drug-encapsulated nanoparticles to cancerous tissue have been 
focused on passive and active targeting (Figure 1.5). As previously noted, passive targeting 
can be achieved by taking advantage of the EPR effect, which allows NPs to access tumors by 
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way of their leaky vasculature.
87,93
Another passive targeting method exploits the tumor 
microenvironment (pH and redox potential)
94
; here, pH- or redox-responsive prodrugs are 
converted into an active drug when they reach the acidic, hypoxic microenvironment of the 
tumor target. A number of passively targeting nanocarriers were developed in the 1980s and 
1990s, and some of them were approved for clinical use. One of the examples is Doxil
®
,
which has shown enhanced circulation time compared to free doxorubicin, good drug 
retention, and is up to six times more effective than free doxorubicin.
95
It should be noted that passive targeting can be limited by PEG molecules which are used to
prolong the circulation time of nanoparticles. The PEGylated surface can prevent not only the 
interaction between the NPs and opsonins but also that between the NPs and cell surface.
96-99
The reduced interactions inhibit effective uptake of the payload by the tumor cells.
Figure 1. 5. Schematic representation of nanocarriers that passively or actively target tumors. Both 
types of nanocarriers reach tumors selectively through the leaky vasculature surrounding the tumors. 
Upon arrival at tumor sites, nanocarriers with targeting molecules can bind to the target tumor cells or 
enter the cells via specific receptor (cell)  ligand (carrier) interactions, whereas stealth nanocarriers 
are less efficient in interacting with tumor cells. 
To improve targeting efficiency of nanoparticles, the concept of active targeting, that is, the 
use of biomolecular recognition molecules, has been introduced to provide a greater degree of 
specificity (Figure 1.5).
100,101
Examples of targeting molecules include antibodies, ligands, 
peptides, nucleic acids, and other molecules that bind directly to a receptor overexpressed on 
a tumor-cell surface.
Tumor cell
Endothelial cell
Nanoparticles with
targeting molecules
Nanoparticles
Passive targeting
Active targeting
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- Folate-based targeting molecules
One of the most extensively studied small molecule targeting moieties for drug delivery is 
folic acid (folate). The high-affinity vitamin is a commonly used ligand for cancer targeting 
because folate receptor has been frequently associated with the development of malignant 
tumors.
102
Folate receptors that deliver folic acid into cells have shown 100- to 300- fold 
overexpression in a wide spectrum of cancer cell.
103
In a recent study, polymer cross-linked 
liposomes loaded with doxorubicin were modified with folate.
104
It was shown that folate-
funtionalized liposomes bound tumor cells differentially as a function of the folate receptor 
expression levels on the cell membrane.
104
These carriers were shown to be 50-fold more 
potent than the untargeted agent toward a panel of cancer cells overexpressing the folate 
receptors in vitro. Recently dendrimer-based targeted anticancer therapeutics using folate 
have demonstrated promising in vivo efficacy in terms of targeting and specific killing of 
cancer cells via multivalent interaction.
105
- Monoclonal antibodies (mAb)
A wide variety of monoclonal antibodies targeting molecules have been assessed for their 
potential application in cancer therapy.
106,107
Overexpressed tumor-associated molecules used 
for mAb are growth factor receptors, which include the epidermal growth factor receptor 
(EGFR) and the human epidermal growth factor receptor 2 (HER2). Except the targeting 
efficacy, the conjugation of multiple antibodies to each nanocarrier enhances their avidity, 
and nanocarriers can be surface functionalized with multiple distinct antibodies to overcome 
tumor heterogeneity. For example, trastuzumab and rituximab have been conjugated to 
poly(lactic acid) NPs resulting in conjugates that exhibit a 6-fold increase in the rate of 
particle uptake compared with similar particles lacking the mAb targeting molecules.
108,109
Targeted liposomes using antibody derivatives as the targeting ligand have also been studied. 
Long-circulating doxorubicin encapsulated immunoliposomes conjugated to human HER2 
antibodies have been shown to mediate internalization of targeted liposomes and intracellular 
drug release.
110
- Aptamer targeting molecules
Nucleic acid aptamers are single stranded DNA, RNA or unnatural oligonucleotides that fold 
into unique structures capable of binding to specific targets with high affinity and 
specificity.
111
Aptamers offer the substantial advantage of synthetic materials that can be 
produced in preparative scale with high purity and reproductivity. The consideration of such 
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favorable characteristics of aptamers has resulted in their rapid progress into clinical practice. 
Farokhzad et al.
112
have developed docetaxel loaded NP functionalized with the A10 
aptamer
113
, that target the prostate specific membrane antigen (PSMA), a transmembrane 
protein that is upregulated in a variety of cancers. This formulation was further evaluated in 
vivo.
114?It was shown that a single intratumoral injection of aptamer modified NPs allowed all 
the treated mice to survive more than three months in contrast to other controls. This result 
indicates that the NPs-aptamer is more efficient than nontargeted docetaxel therapy.
- Hyaluronic acid
Active targeting of bioactive molecules by physicochemical association with hyaluronic acid 
(HA) is an attractive approach in current nanomedicine because HA is biocompatible, non-
toxic and non-inflammatory. HA receptor CD44 and RHAMM are overexpressed in many 
types of tumor cells.
115,116
HA-decorated liposomes with drugs such as DOX
117,118
and 
mitomycin C
119
were investigated in cancer treatment. In vitro cytotoxicity of the drug-loaded 
liposomes was examined after incubation with both CD44-positive and CD44-negative cell 
lines and compared with the non-targeted liposomes. Loading the drug to the HA-coated 
liposomes resulted in a substantial increase of toxicity against the hyaladherin-overexpressing 
cells; non-targeted liposomes led to a slight reduction in cell cytotoxicity. El-Dakdouki et al. 
reported a hyaluronan-coated superparamagnetic iron oxide NPs (HA-SPION).
120
When 
incubated with cancer cells, HA-SPIONs were rapidly taken up and the internalization of HA-
SPION by cancer cells was much higher than the NPs without HA coating. Furthermore, 
doxorubicin was attached onto the NPs through an acid responsive linker. DOX-HA-SPION 
was much more potent than free DOX to kill cancer cells. 
As mentioned above, recent work comparing non-targeted and targeted NPs has shown that 
the primary role of the targeting ligands is to enhance cellular uptake into cancer cells and to 
minimize the accumulation in normal tissue.
87
This behavior suggests that the colloidal 
properties of NPs will determine their biodistribution, whereas the targeting ligand serves to 
increase the intracellular uptake in the target tumor. A number of studies found that the 
targeting ligands did not improve the tumor distribution of nanocarriers.
121-125
A study 
comparing immunoliposomes and nontargeted liposomes showed that biodistribution of the
two liposomes was similar.
122
Epidermal growth factor receptor (EGFR)-targeted 
immunoliposomes were injected intravenously to mice bearing EGFR-overexpressing tumors, 
and their biodistribution was compared with that of PEGylated (nontargeted) liposomes.
122
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The antibodies did not increase the amount of liposomes at the tumor site nor did it shorten
the time for the nanocarriers to reach the target tissues.
122
Another example shows that HER2-
targeted immunoliposomes had no difference in biodistribution or tumor accumulation time
versus nontargeted liposomes.
121
Bartlett et al. reported a similar observation.
124
These 
observations indicate that the biodistribution of the targeted nanocarriers in tumors is mostly 
governed by the EPR effect rather than the interaction between the targeted nanocarriers and 
the target cells. Notably, the former group of studies suggests that the targeting molecules 
play a role after the nanocarriers are distributed in the tumor tissues. Although the tumor 
distributions of targeted and nontargeted nanocarriers were similar, only targeted nanocarriers 
could efficiently enter the tumor cells from the extracellular space. Studies using colloidal 
gold-labeled liposomes show that the HER2- targeted immunoliposomes accumulated within 
tumor cells, whereas nontargeted liposomes were located predominantly in the extracellular 
matrix.
121
Similarly, the extent to which the EGFR-targeted immunoliposomes were found 
inside the tumor cells was 6-fold higher than that of nontargeted liposomes.
122
In light of these 
results, the difference between targeted and nontargeted nanocarriers in tumor distribution 
observed by other studies,
126-130
can be interpreted alternatively. The superior tumor 
accumulation of targeted nanocarriers may be another reflection of their efficient entry to the 
tumor cells following extravasation. A study comparing antitumor effects of intratumorally 
injected nanoparticles implies that the nontargeted particles could be cleared from the tumor 
sites unless they were subsequently taken up by the cells.
114
Active targeting strategy improves the anticancer effect of a drug by facilitating cellular 
uptake and intracellular retention of the drug carriers. In particular, the active targeting 
strategy is a promising tool for overcoming the multidrug resistance, for which the passively 
targeted nanocarriers do not much avail,
85
as the actively targeted nanocarriers can provide an 
intracellular drug reservoir. On the other hand, tumor distribution of the targeted nanocarriers
is largely governed by the same principle as nontargeted nanocarriers (the EPR effect) and the 
targeting molecules do not seem to play a role until the carriers reach the target tissues.
Therefore, an ideal nanocarrier should attain both the EPR effect and the specific and avid 
interactions between the targeted nanocarriers and tumors, which will lead to maximum tumor 
distribution and cellular uptake of the nanocarriers, respectively. To this end, it is critical to 
design a nanocarrier system that is maximally targeted and maximally stealth.
131
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1.3.2.3. Controlled release strategies
Release cargo can be classified based on the type of stimulus as internally and externally 
controlled. Internal stimuli include activation by pH, redox potential and enzymes. External 
stimuli include light, ultrasound, electromagnetic fields or ionizing radiation.
132
- Internal stimuli
Tumor and inflammatory tissues show differences in pH-levels compared to healthy tissue. 
Due to their heavy dependence on glycolysis, tumors tend to have lower pH (pH ~ 6.5) values 
than physiological levels (pH ~ 7.4),
133
opening several avenues for controlling release. One 
example of pH-responsive system is a micelle based on poly(ethyleneglycol)-b-poly(?-amino
ester) block copolymer, in which the methyl ether poly(ethyleneglycol) (MPEG) part forms a 
hydrophilic shell and the poly(?-amino ester) a hydrophobic core (Figure 1.6). Poly(?-amino
ester) has a pKa of ~ 6.5 and allows formation of micelles (diameter ~ 40-60 nm) at pH >
6.9.
134
At pH 6.4 the micelles released > 71% of the drug in 6 h, whereas those at pH 7.4 did 
not release more than 20 % in 24 h.
134
The in vivo study in B16F10 tumor-bearing mice 
showed that the ability of the micelles to deliver doxorubicin effectively suppressed tumor 
growth and prolonged the survival as compared to free doxorubicin.
134
Figure 1. 6. Structure of MPEG-HPAE block copolymer. DOX-loaded MPEG-HAPE micelles under 
physiological pH were completely dissociated, and rapidly released DOX at weakly acidic pH 
environments.
134
Another example of pH-sensitive system is a polymer micelle with a covalently entrapped 
doxorubicin methacrylamide derivative (DOX-MA, Figure 1.7) within the core of 
poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate] (PEG-b-
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p(HPMAm-Lacn), Figure 1.7) micelles.
135
The structure of the DOX derivative is susceptible 
to pH-sensitive hydrolysis, enabling controlled release of the drug in acidic conditions. The 
entire drug payload was released within 24 h incubation at pH 5, whereas only around 5% 
release was observed at pH 7.4 over the same time period. The micelles showed better anti-
tumor activity than free DOX in mice bearing B16F10 tumors.
135
However, whether the pH-
responsiveness contributed to the effectiveness is not known, because it was not compared
with a pH-insensitive system.
Figure 1. 7. Chemical structures of (a) doxorubicin methacrylamide derivative (DOX-MA) and (b) 
poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate] (PEG-b-p(HPMAm-
Lacn).
135
Sawant et al reported a liposome system including a pH-sensitive linker which could achieve 
pH-responsive transformation from the stealth liposome to a cell-interactive form (Figure 
1.8).
136
This system includes a PEG layer attached to the liposome surface via a hydrazone 
linker, which cleaves at pH 5-6. The liposome surface is also conjugated to TAT peptide, 
which is shielded by the PEG layer at pH 7.4. At pH 5-6, the PEG layer detaches revealing the 
TAT peptide as the hydrazone linker hydrolyzes. A preliminary incubation of the pH-sensitive 
liposomes at pH 5 allowed the liposomes to enter the cells efficiently, whereas the pH-
insensitive liposomes were much less efficient.
136
A similar strategy is described by Bae et al 
in a study concerning a TAT peptide-based micelle system.
137
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Figure 1. 8. Interaction of the multifunctional pH-responsive pharmaceutical nanocarrier with the 
target cell. Local stimuli-dependent removal of protecting PEG chains or mAb-PEG moieties allows 
for the direct interaction of the cell-penetrating peptides (CPP) moiety with the cell membrane.
136
Polymersomes based on PEG-poly(lactic acid) (PLA) were reported by Ahmed et al.
49
Under 
acidic conditions, the PLA first underwent hydrolysis, and several hours later, pores formed in 
the membrane followed by final membrane disintegration. In vivo experiments demonstrated 
growth arrest and shrinkage of rapidly growing tumors after intravenous injection of the 
DOX- and PTX-loaded polymersomes. 
Redox-sensitivity is another switch functionality of major potential impact in intelligent 
nanomaterials. In vivo, a large difference in redox potential by factor of 1001000 between 
the oxidizing extracellular and reducing intracellular space has been reported.
138,139
Oxidative 
conditions exist in extracellular fluids and inflamed or tumor tissues, while intracellular 
compartments are known to be reductive.
140
Zhao et al. have shown successful protein
delivery into several human cancer cell lines and release through redox-responsive 
nanoparticles.
141
They demonstrated effective encapsulation of caspase-3 (CP-3) with 
positively charged, disulfide containing cross-linker polymers followed by internalization into 
cancer cells. Subsequent release into the cytosol induced cancer cell apoptosis due to active 
CP-3 in HeLa, MCF-7 and U 87MG cells. Kim et al. demonstrated a similar gate-keeping 
effect using mesoporous silica NPs covalently linked through disulfide bridges with 
cyclodextrin instead of polymers and loaded with DOX.
142,143
Cyclodextrin blocked the pores 
and inhibited undesired DOX release. In vitro studies using A549 cancer cells showed 
reduced cancer cell survival after incubation with DOX loaded mesoporous silica 
nanoparticles as a result of glutathione-induced controlled drug release.
143
Liposomes are also 
under investigation for redox-sensitive drug delivery.
133,144,145
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The use of enzymes can also be exploited for triggered release of drugs from NPs in a tumor-
specific manner. Perhaps the most exploited enzymes are matrix metalloproteinases (MMP), 
which are often overexpressed at tumor sites as well as in many cardiovascular diseases. The 
stealth PEG coating on liposomes can include a MMP cleavage site.
146
The PEG was removed 
upon exposure to MMP. The MMP-sensitive liposomes showed significantly higher gene 
transfection efficiency than MMP-insensitive liposomes in in vitro cell models overexpressing 
MMP. In an in vivo study, the MMP-sensitive liposomes showed three times higher gene 
transfection efficiency than the MMP-insensitive ones which indicates that the MMP 
overexpressed in the tumor extracellular matrix successfully removed the PEG from the 
liposomes and facilitated cellular uptake of the liposomes.
146
A disadvantage of enzyme 
triggered release is that no enzyme is solely expressed in the targeted region; therefore 
nonspecific release occurs throughout the body.
- External stimuli
Temperature sensitive NPs are made of temperature-sensitive polymers which possess a lower 
critical solution temperature (LCST) in aqueous solution. This means that these polymers are 
soluble in water below the LCST and turn into a collapsed state due to an increase of their 
hydrophobic character above the LCST. This feature has been used in anti-cancer therapy.
Some tumor cells are more sensitive to heat-induced damage than normal cells, rendering a 
combination of tumor hyperthermia and heat responsive nanomaterials promising.
12
Liposomes and dendrimers have been rendered temperature sensitive by incorporation of 
LCST polymers. Upon an increase in temperature above the LCST, the polymers collapse, the 
liposomal membrane bursts and a drug can be released.
147,148
Another example is a nanogel 
synthesized by light cross-linking from poly(L-lysine)-g-poly(ethylene glycol) (PLL-g-
PEG)/oligo(L-lactic acid)-b-pluronic F127-b-oligo(L-lactic acid).
149
The nanogels exhibited 
reversible size transition from ~ 150 nm at 37 °C to ~ 1.4 µm at 15 °C. The abrupt and 
dramatic intracellular volume expansion of the nanogels upon the brief cold-shock treatment 
severely damaged sub-cellular self-assembled network architectures and physically ruptured 
cellular membrane structures, resulting in necrotic cell death. To further enhance the extent of 
cell death, various targeting ligands recognizable by specific cells could be conjugated on the 
surface for guiding specific intracellular delivery. 
Light-responsive materials can be built through covalent incorporation of specific light-
sensitive chemical groups with the aim to release a payload by illumination.
150
Cabane et al. 
have reported the synthesis of a photocleavable amphiphilic block copolymer. They used an 
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o-nitrobenzyl linker as a photosensitive molecule, which they incorporated between the 
hydrophobic and hydrophilic blocks. Through self-assembly of the copolymers in buffer 
media, the formation of vesicles and micelles could be achieved. Rapid structural changes in 
size of the vesicles were observed in electron microscopy and dynamic light scattering after 
irradiation with UV-light, demonstrating successful photocleavage.
151
UV damage to the 
surrounding tissue is however a major limitation to broad clinical application of this chemistry. 
Na et al. reported a hyaluronic acid-bearing photosensitizer nanogel as a new type of 
photodynamic therapy agent.
152
After incubation of the HA/photosensitizer conjugate
nanogels with cells, the degradation of the HA by enzymes in endosomes and lysosomes was 
monitored as a dissipation of the autoquenching behavior. The nanogels also exhibited HA-
induced tumor-homing properties, resulting in a rapid internalization rate. Moreover, the 
nanogels indicated high cytotoxicity against cancer cells under light emission, which was 
comparable with the free photosensitized, but very low cytotoxicity without light.
Ultrasound is another method of triggered release of drugs from NPs. The mechanism relies 
on the ability of ultrasound to produce free radicals that degrade polymers, increase local 
temperatures, and permeabilize cell membranes.
153
Schroeder and coworkers recently 
demonstrated ultrasound-triggered drug release of cisplatin from liposomes in vivo.
154
Liposomes were injected intraperitoneally into mice bearing J6456 lymphomas, followed by 
administration of low frequency ultrasound 1 h later. Results show that approximately 70% of 
cisplatin was released following ultrasound, compared with approximately 3% without 
ultrasound. In the tumors receiving ultrasound, cisplatin levels were nearly three-fold higher 
than those in tumors receiving no ultrasound. In C-26 colon tumors in the footpad of mice, 
liposomes were injected intravenously, followed by ultrasound irradiation 24 h later. Findings 
demonstrate that tumor growth in the footpad was significantly suppressed in mice receiving 
cisplatin-containing liposomes and ultrasound when compared with free cisplatin with and 
without ultrasound after 29 days.
Other external stimuli systems, such as electromagnetically sensitive
155,156
, radiation 
sensitive
157,158
NPs have also been investigated for cancer treatment. A key challenge in 
externally controlled nanomaterials is tissue penetration and avoidance of undesired tissue 
damage. They require particular care in design of materials with optimal sensitivity to allow 
reduction of transmitted energy.
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1.3.3. Nanoparticles in cancer imaging
Tumor imaging plays a fundamental role in cancer therapy, from informing the diagnosis and 
consequent choice of treatment, to the pinpointing of diseased areas during treatments (e.g., 
radiotherapy), and extending to post-treatment monitoring. The ability to monitor treatment in 
real-time will allow physicians to adjust the type and dosing of drug for each patient, to 
prevent overtreatment that would result in harmful side-effects, or undertreatment that would 
lead to incomplete cancer remission. The ability to see when a drug reaches a maximum 
tolerable concentration in offtarget organs and a sufficient concentration in the tumor would 
be a significant advantage over current treatments. NPs can enable treatment monitoring by 
either attaching different imaging moieties or taking advantage of the intrinsic properties of 
some NP materials (e.g., super paramagnetism for magnetic resonance imaging (MRI)). While 
these theranostic NP formulations are more complex to develop, their potential clinical utility
substantiates the investment required at the front-end.
Many different types of nanomaterials have been developed to provide contrast in medical 
imaging, including liposomes and micelles, polymers and dendrimers, noble metals,
semiconductors, carbon nanotubes and fullerenes, transition metal oxides, metal-organic 
frameworks, and lanthanide series.
7,159,160
Some of these materials incorporate an imaging 
moiety into their design, while others provide contrast as a result of their intrinsic material
properties. Multiple imaging modalities can also be implemented into a single nanotheranostic 
design by incorporating multiple moieties to provide a more complete picture of the disease.
Molecular imaging can identify tumor cell location within the body, and aims to provide 
information such as metabolism, expression profile, and stage of the disease.
161
Furthermore,
molecular imaging can reveal early tumor response to therapy that will aid in improving 
treatment regimens.
4
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1.4. Polyelectrolyte multilayer capsules in drug 
delivery
Polyelectrolyte microcapsules have been extensively explored for their physicochemical 
properties since their advent in the late 1990s
162
, and more recently they have attracted 
attention for drug delivery applications
163-171
.
Polyelectrolyte multilayer capsules are synthesized by the layer-by-layer (LbL)
162
technique 
consisting in the consecutive deposition of polymers that can interact through electrostatic 
interactions, or hydrogen bonding, or other covalent interactions on a particle template. Their 
size can range from 10 nm to several microns
172,173
. After the LbL adsorption process, the 
cores can be successfully removed to obtain hollow and stable capsules (Figure 1.9) whose 
inner cavity and polymer wall can be loaded with a variety of substances such as molecular 
dyes, drugs, nanoparticles and biomolecules. The hollow capsules usually have a wall
thickness between a few tens and several hundred of nanometers
174
and a diameter ranging
from hundred of nanometers to several micrometers depending on the size of the original core 
template. Microcapsules have a higher payload capacity than smaller nanoparticles, and can 
accommodate multiple types of drug molecules. The layered nature of the assembly makes 
surface modification relatively simple for inclusion of targeting or stealth properties. It also 
makes it possible to include different degradation mechanisms within a single film. When all 
of these properties are combined, LbL assembled microcapsules are an ideal multifunctional 
platform for delivery of different therapeutic agents.
Figure 1. 9. Schematic representation of polyelectrolyte capsule fabrication by layer-by-layer (LbL) 
assembly. a) Initial electrostatic adsorption of a negatively charged polymer onto a positively charged 
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template core. b) Second adsorption of positively charged polymer onto the now negatively charged 
template. c) Multilayer growth via alternating adsorption of oppositely charged polymers. d) Removal 
of the template by dissolution to obtain a capsule with an empty cavity.
1.4.1. Size and surface chemistry
The size of capsules depends on the size of original core template. It can directly influence the 
mechanism for internalization. Due to the LbL method used for their preparation, the size of 
the capsules remain in the micron range which is  much larger than the range of sizes that are 
generally considered to be optimal for internalization by endocytosis. Although early studies 
showed that particles must be less than 500 nm to undergo cellular internalization by 
phagocytosis,
175
more recent investigations have shown that the internalization of much larger 
particles is possible.
176
For example, LbL capsules of 1 µm,
177
3 µm,
178
and even 6 µm
179
diameter have all been observed inside the cell. However, for chemotherapeutic delivery 
which requires the particles extravasate from bloodstream and enter tumor tissue through the 
EPR effect, the size of capsules should be rather below 200 nm. Gold nanoparticles (AuNPs) 
are attractive substrates for LbL assembly to fabricate capsules with a diameter below 100 
nm.
180,181
The surface of the delivery carriers is one of the most important aspects for designing drug 
carriers as it is generally the only interaction point with the body. It is important to 
functionalize the surface to ensure that it is processed in the desired way. As mentioned 
above, PEG was also used for the modification of the multilayer capsules surface to prevent 
non-specific protein adsorption and improve blood circulation half-life. Several factors 
contribute to reduced adsorption of proteins on PEG coated polyelectrolyte capsules. The 
hydrophilic character of PEG avoids hydrophobic interactions with proteins. Additionally, 
PEG shields charges of the capsules thereby minimizing potential electrostatic interactions 
with proteins and flexible PEG chains provide steric repulsion.
182
Heuberger et al. 
functionalized poly(acrylic acid) (PAH)/poly(styrene sodium sulfate) (PSS) capsules with 
poly(L-lysine) (PLL)-g-PEG. The PEG functionalized capsules exhibited a severe reduction 
of protein adsorption compared to PAH/PSS capsules.
182
Lipids may also be used to alter the 
surface chemistry of delivery vehicles. A lipid coating mimics the cellular membrane, and it 
may either enhance or reduce the interaction of the delivery vehicle with a cell. A lipid 
coating decreases the permeability of the capsule, allowing the entrapment of small molecules 
without conjugation.
183
Moreover, the use of capsules predefines the size of the lipid coating, 
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resulting in monodisperse populations.
184
Hammond et al. recently reported in vivo 
applications of AuNP (size ~ 20 nm) and quantum dots (size ~ 20 nm) templated
polyelectrolyte capsules.
185
These templates were not removed after capsules preparation and 
used as a tracer for in vivo studies. Degradable biopolyelectrolytes (PLL, dextran (DEX) and 
HA) were used as layer components. It was found that HA as outermost layer strongly 
enhanced the circulation time (~9 h) and minimized accumulation (~10-15% recovered 
fluorescence/g) in the liver, whereas using PLL or DEX as terminal layers strongly provoked 
accumulation of particles in the liver and spleen. Furthermore, the non-fouling properties of 
HA allowed the capsules to accumulate in xenografted tumors by virtue of the EPR effect.
185
1.4.2. Anti-cancer drug loaded capsules
The delivery of anticancer drugs by LbL capsules has been investigated by several research 
groups. As many potent anticancer agents are hydrophobic molecules, the development of 
LbL capsules for delivering such drugs has received significant attention. These drugs include 
doxorubicin, daunorubicin, paclitaxel, 5-fluorouracil, polyphenols (Figure 1.10).
180,186-188
Short interfering RNA (siRNA) as hydrophilic anticancer drug has been encapsulated into 
LbL capsules.
189,190
Figure 1. 10. Structures of doxorubicin, daunorubicin, paclitaxel, 5-fluorouracil, and an example of 
polyphenol, epigallocatechin gallate.
Four main strategies have been proposed for loading water-insoluble compounds into LbL 
capsules. The first method consists of filling the cavity of pre-formed hollow capsules with an 
oil phase containing the drug.
187,191,192
The capsules were dehydrated in ethanol and dispersed 
in a drug/oleic acid mixture to allow infiltration of the oil phase through the semi-permeable 
walls of the polymer capsules and filling of the capsules. FDA-approved oleic acid was 
chosen as an oil phase to solubilize two model chemotherapy drugs: doxorubicin and 5-
Paclitaxel 5-fluorouracil Polyphenol:
epigallocatechin gallate
Doxorubicin R = CH2OH
Daunorubicin R = CH3
R
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fluorouracil. The excess drug/oleic acid mixture was removed by centrifugation. This final 
preparation was dispersed in phosphate buffer , giving monodispersed drug-loaded oleic acid 
emulsions stabilized within polymer capsules.
191
The second approach is to embed a reservoir of hydrophobic drug into the LbL assembly. The 
reservoir could be polymeric micelles
193
or liposomes
194
. The latter was termed capsosomes
by Caruso group. Manna et al. used a micellar solution of pyrene in sodium dodecyl sulfate 
(SDS) as a model drug to exploit electrostatic interaction between chitosan and SDS to form 
LbL capsules.
193
In the case of capsosomes, polymer membrane was subsequently assembled 
by the alternating adsorption of poly(N-vinyl pyrrolidone) (PVPON) and thiol-modified 
poly(methacrylic acid) (PMASH) onto the preadsorbed layer of liposomes (Figure 1.11).
Upon removal of the silica template, stable capsosomes encapsulating the enzyme luciferase 
or b-lactamase within their liposomal sub-compartments were obtained.
194
This approach 
allowed stable encapsulation of both hydrophilic macromolecules (e.g. enzymes
194
) and 
hydrophobic molecules (e.g. anticancer drugs) within the liposomal compartments of the 
capsosomes.
Figure 1. 11. Schematic illustration of capsosome assembly. A silica particle (i) is coated with a 
cholesterol-functionalized polymer precursor layer (ii), liposomes (iii), and a cholesterol-
functionalized polymer capping layer (iv), followed by subsequent polymer layering (v), and removal 
of the silica template core (vi). Liposomes are adsorbed onto the polymer surface non-covalently with 
cholesterol-modified polymers (iva). Cholesterol is spontaneously incorporated into the lipid 
membrane (ivb).
194
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The third strategy consists in conjugating drugs to a polymer used as a chemotherapeutic 
prodrug and then incorporating into a multilayered film. Using this approach, Schneider and 
co-workers synthesized doxorubicin loaded LbL capsules.
180
They used ten nanometer sized 
gold nanoparticles (AuNPs) as template, which were LbL coated with a (PAH/PSS)2PAH 
multilayer film and were subsequently functionalized with a layer of a macromolecular 
prodrug based on doxorubicin. The latter is a N-(2-hydroxypropyl)methacrylamide) (HPMA)
copolymer carrying oligopeptide spaced doxorubicin side groups.
195
The DOX was linked to 
the polymer via an oligopeptide spacer that was a substrate for lysosomal enzymes (Figure 
1.12). Caruso et al. aslo reported doxorubicin loaded capsules. The drug was conjugated to 
alkyne-functionalized poly(L-glutamic acid) (PGAAlk) via amide bond formation 
(PGAAlk+DOX).
196,197
PGAAlk and PGAAlk+DOX were assembled via hydrogen bonding with 
poly(N-vinyl pyrrolidone) (PVPON) on silica templates. The films were subsequently
covalently stabilized using diazide cross-linkers, and PVPON was released from the 
multilayers by altering the solution pH to disrupt hydrogen bonding. After removal of the 
sacrificial template, single-component PGAAlk capsules were obtained.
Figure 1. 12. (A) From left to right: 13 nm sized AuNPs as obtained after synthesis, stabilized by 
adsorbed sodium citrate; AuNPs coated with five primer layers of PAH and PSS (i.e., 
Au5
+
:Au/(PAH/PSS)2/PAH,?the number 5 refers to the total number of layers and the charge +
refers to the charge of the outer layer); Au5
+
further coated with a external layer of F-HPMA (yielding 
MFNP). The red circles represent doxorubicin moieties (DOX) and are at scale with respect to the size 
of DOX molecules and the density of DOX moieties on the nanoparticle surface. (B) UV-vis spectra 
of native AuNPs dispersed in pure water (?, dotted line), Au5+ dispersed in pure water (?), 
B C
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multifunctional nanoparticles dispersed in pure water (?) and in PBS (?); (?) and (?) are 
undistinguishable. All spectra were normalized to yield the same absorbance value at the wavelength 
of 440 nm. (C) UV-vis spectra of MFNP before (?) and after (?) the dissolution of Au cores by an 
excess of potassium cyanide solution (KCN). Insets are TEM micrographs of MFNP before and after 
the dissolution of the cores.
180
?
The last approach entails encapsulation of water-insoluble drug into LbL capsules through 
their template. It can be achieved by using templates formed with therapeutic crystals.
198
Another approach consists in using interaction of template/drugs to encapsulate hydrophobic 
drug. Shutava et al. synthesized gelatin NPs template capsules in which they encapsulated 
polyphenols by hydrophobic association.
188
Natural polyphenols with previously 
demonstrated anticancer potential, epigallocatechin gallate (EGCG), tannic acid, curcumin, 
and theaflavin, were encapsulated into gelatin-based 200 nm nanoparticles consisting of a soft 
gel-like interior and a surrounding LbL shell of polyelectrolytes (Figure 1.13).
188
Decomposable mesoporous silica templates
199
were used as another mean to encapsulate 
hydrophobic drugs. After removal of the silica particles, the water-insoluble small compounds 
agglomerate into clusters, and are retained in the polymer capsules.
Figure 1. 13. Schematic presentation of preparation of LbL-coated gelatin nanoparticles containing 
EGCG.
188
Elbakry and co-wokers demonstrated that siRNA could be incorporated directly in multilayer 
assemblies onto AuNPs containing hyperbranched poly(ethyleneimine) (PEI) as polycation.
190
siRNA was not expected to easily wrap around small AuNPs because it is a stiff, rodlike 
molecule. To obtain well-defined particles onto which the polyelectrolyte can be adsorbed 
with high yield and to avoid interparticle bridging and flocculation, it was important to choose 
the appropriate polyelectrolyte concentration and ionic strength. Caruso et al. described the 
delivery of siRNA using LbL microcapsules.
189
The microcapsules are based on negatively 
charged poly(methacrylic acid) thin films containing  cross-linking disulfide bonds. One 
system is polycation-free and another contains PLL for siRNA complexation in the 
microcapsule core (Figure1.14). Receptor specific siRNA delivery mediated by AuNPs was 
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demonstrated by Lee et al. via functionalization of AuNPs with HA.
200
siRNA was 
encapsulated onto a cysteamine modified AuNPs.
Figure 1. 14. Schematic representation of siRNA loading methods. Preloaded microcapsules: (a) 
siRNA is adsorbed onto amine-functionalized silica particles; (b) LbL assembly of film is performed 
around the siRNA coated particles; (c) the film is cross-linked and the core removed. Postloaded 
microcapsules: (i) mesoporous silica particles are infiltrated with the polycation PLL; (ii) LbL 
assembly of film is performed around the polymer filled particles; (iii) following core removal, the 
siRNA is infiltrated into the particles and sequestered by the polycation core.
189
1.4.3. Interaction of capsules and living cells
1.4.3.1. Cytotoxicity
To evaluate the potential of polyelectrolyte capsules for cancer treatment it is important to 
understand their interactions with living cells. One of the most important issues is cytotoxicity 
because the uptake of large amounts of polyelectrolyte capsules could be toxic for cell. 
Several research groups have assessed it by performing in vitro cell-viability assays such as 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test or Trypan Blue. 
Generally, no severe toxicity was observed at moderate capsule concentrations. The main 
sources for toxicity come obviously from the polyelectrolytes composing the wall as well as 
from the functionalities embedded in the cavity and/or in the wall.
201
In this regard, a 
reduction of the cytotoxicity could be obtained by using materials that are biocompatible and 
biodegradable. The magnitude of the cytotoxic effect of the capsules is primarily 
concentration-dependent.
174,202
De Geest
174
et al. showed that cell viability was reduced by 80 
% after incubation with dextran sulphate and poly(L-arginine) (DEXS/PARG) capsules in a 
capsules to dendritic cell (DC) ratio of ~ 10
3
. For a capsule/cell ratio of 125 and below, more 
a) b) c)
i) ii) iii)
Chapter 1 Nanotechnology for cancer treatment - Bibliography review
39
than 60 % the cells survive. For a capsule/cell ratio of 30, cytotoxicity was low and 
approximately 80 % of the dendritic cells remained viable. Reduced toxicity was attributed to 
the reduction of aggregation of the capsules on the top of the cells. Additionally, it has been 
reported that polycationic polymers decrease cell viability.
203,204
Fisher et al. showed that the 
cytotoxicity of polycations is depends on their molecular weight, their cationic charge density 
and the flexibility of their structure.
205
However, some work demonstrated that capsules with 
a positively charged outer layer were ingested more than negatively charged ones. Thus, in 
the case of alginate (ALG)/chitosan (CHI) capsules, Wang et al. found that the positively 
charged outer layer of capsules was the key pathway to enhance the uptake efficiency of 
capsules via electrostatic interactions with MCF-7 cells membrane.
192
1.4.3.2. Mechanisms of capsules uptake by living cells
In general, microcapsule internalization appears not only to be dependent on capsule intrinsic 
factors (size, composition, charge) but also on the cell type taking up the particles. LbL 
capsules are readily internalized not only by professional phagocytes (DCs
206-208
and 
macrophages
209
), but also by numerous other cell types including breast cancer cells, 
hepatoma cells, fibroblasts,
210
epithelial kidney cells De Koker et al. demonstrated that, 
during the association of DEXS/PARG capsules with bone marrow mice dendritic cells (BM-
DCs), the cell membrane extends over the capsules, forming large cytoplasmatic extrusions to 
engulf polyelectrolyte microcapsules (Figure 1.15.a).
206
They proposed macropinocytosis as 
the mechanism of uptake of capsules by DCs. This hypothesis was further confirmed using a 
set of uptake inhibitors (Figure 1.15.c). Microcapsule uptake was inhibited by cytochalasin D, 
an inhibitor of actin polymerization that is known to block both phagocytosis and 
macropinocytosis, and blocked by incubation with rottlerin, a recently identified selective 
inhibitor of macropinocytosis.
211
Remarkably, both genistein and filipin III,
212,213
two known 
inhibitors of caveolae-mediated endocytosis, but not chlorpromazine,
214
an inhibitor of the 
clathrin pathway of endocytosis, inhibited microcapsule internalization. Caveolae-mediated 
uptake of polyelectrolyte microcapsules by tumor cells has been described recently,
215
indicating DCs and tumor cells might internalize polyelectrolyte microcapsules by similar 
mechanisms.
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Figure 1. 15. Images of bone-marrow-derived dendritic cells (BM-DCs) taking up dextran 
sulfate/poly-L-arginine microcapsules. The TEM image a) shows a BM-DC forming cytoplasmic 
protrusions to engulf the microcapsules (black arrow), which are visible as hollow disks with a dark, 
electron dense wall. Scale bar: 3 mm. b) Confocal microscopy images showing the formation of actin-
rich protrusions. The actin cytoskelet was stained with alexa 488 phalloidin (green). Microcapsules 
were labelled red by incorporation of RITC-poly-L-arginine. Nuclei were stained blue with Hoechst 
33258. Scale bar: 10 mm. c) Confocal images of the effects of cytochalasin D, rottlerin, filipin III and 
chlorpromazine on microcapsule uptake by BM-DCs. Scale bars: 50 mm.
206
Similarly, Yan et al. observed the formation of plasma membrane protrusions in human 
colorectal cancer cells when interacting with thiolated poly(methacrylic acid) (PMASH)
capsules, confirming that macropinocytosis and phagocytosis are the predominant routes for 
cellular uptake of capsules.
187
It has also been shown that the internalized LbL capsules are 
deformed and located in membrane-enclosed compartments, which further mature to late 
endosomes or lysosomes. 
Several groups have focused these researches on the intracellular fate of the capsules and have 
observed a substantial deformation of the capsules. Complete destruction and intracellular 
degradation were demonstrated by De Geest et al. by using degradable poycation.
215
Co-
incubation of cancer cells with capsules results in their internalization and gradual 
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disintegration over a period of 60 h, after which no intact capsules could be observed.
215
This 
process appears to be much faster for PLL/HA capsules which promptly deform and rupture 
upon cellular internalization.
209
The deformation of capsules may be due to an enzymatic 
or/and mechanic degradation. De Geest, Parak, and coworkers entrapped a nonactive prodrug, 
a self-quenched fluorescence-labeled protein, which needs to be enzymatically cleaved in 
order to become active in biodegradable LbL capsules.
216
Upon capsule uptake by living cells, 
the multilayer shells were actively degraded and digested by intracellular proteases. Shell 
degradation enabled intracellular proteases to reach the protein cargo in the cavity of the 
capsules. Enzymatic fragmentation of the fluorescence-labeled protein led to individual 
fluorescence-labeled peptides. In this case, only pro-drugs inside the capsules reaching cells 
are activated and those in capsules in an extracellular environment cannot be activated. In 
addition, they compared the accessibility of encapsulated proteins for proteases with non-
degradable PSS/PAH capsules in which the protein remained intact. This study clearly 
showed the importance of using degradable polymers which can be eroded and cleaved by 
intracellular proteases (Figure 1.16).  
Figure 1. 16. Enzymatic cleavage of protein cargo. Embryonic NIH/3 T3 fibroblasts were incubated 
with a) non-degradable PSS/PAH or b) degradable DEXS/PARG capsules filled with the fluorogenic 
protein cargo, DQ-ovalbumine (DQ-OVA). Images were taken immediately after addition of the 
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capsules (t) 0 h) over time up to 120 h with a confocal microscope in different channels, green, red, 
and transmission. An overlay of the different channels is presented in the figures.
216
1.4.3.3. Targeting capsules
To enhance the cellular uptake, drug loaded polyelectrolyte microcapsules were 
functionalized with cell-targeting structures which allow delivery of the cargo to a cell type of 
interest avoiding unwanted uptake. In this way, high drug concentration can be obtained in the 
target tissue using a minimum amount of drug loaded carriers. For targeting to a specific cell 
type, polyelectrolytes microcapsules have been functionalized with monoclonal antibodies, or 
magnetic particles. Cortez et al. described the functionalization of PSS/PAH microcapsules 
with human A33 monoclonal antibodies, which bind to the human A33 antigen expressed by 
95 % of all human colorectal cancer cells. This functionalization resulted in an enhanced 
uptake of capsules by cancer cells containing the A33 antigen compared to non functionalized 
microcapsules.
217
Magnetic drug targeting has been suggested as a method to locally 
accumulate drugs. It has been shown in vitro that polyelectrolyte capsules of which the shells 
are functionalized with magnetic nanoparticles, in a magnetic field gradient accumulated and 
followed internalization by breast cancer cells.
218
In the literature, there is few work involved in the cell targeting. This is because most of 
studies of capsules with cells remain in the in vitro stage. Biospecific interactions between 
capsules and cells are more important when capsules are applicated in vivo. Up to date, few 
papers have explored the in vivo behavior of LbL capsules. 
1.4.3.4. In vivo studies
A first detailed in vivo study was reported by De Koker et al. They subcutaneously injected 
biodegradable microcapsules composed of dextran sulfate/poly(L-arginine) (DEXS/PARG) in 
mice.
174
These capsules induced moderate inflammation, similar to adjuvants used for human 
vaccination such as aluminum hydroxide. Within sixteen days after injection, most of the 
microcapsules are internalized by the cells and start to get degraded, presumably due to the 
interplay of mechanical forces and enzymatic action exerted by the phagocyting cells (Figure 
1.17). Furthermore, the tissue response after pulmonary delivery of DEXS/PARG capsules 
was also addressed.
207
The capsules became relatively fast (timeframe of 1-2 days) 
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internalized by alveolar macrophages and dendritic cells, which transported the capsules to 
the draining lymph nodes. Only capsules debris remained after 2 weeks post-instillation. 
Although these findings clearly demonstrated that capsules degradation also takes place in 
vivo there is so far no data on the long term fate of these capsules with respect to clearance 
from the body. 
Figure 1. 17. Confocal microscopy images recorded at different time points of (A) tissue section from 
mice that were subcutaneously injected with degradable DEXS/PARG capsules, (B) cyotospins of 
alveolar macrophages and dendritic cells of mice that received capsules via pulmonary 
administration.
174
Recently, Hammond et al. reported in vivo pH sensitive quantum dots ( used in the study to 
allow in vivo florescence imaging and can easily be replaced by non-toxic templates when 
intended for therapeutic purposes) templated capsules to target acidified tissue induced by 
tumor hypoxia.
219
QDs were first coated with a PLL layer modified with iminobiotin (PLLib)
followed by a layer of the complementary protein neutravidin (nav) and finally capped with a 
layer of biotin end-functionalized PEG. The iminobiotin-neutravidin interaction is a pH 
dependent affinity bond, which is stable at pH 8-12 but decomposes at pH 4-6. The obtained 
capsules consisted of an acid removable PEG layer, revealing a cationic PLL surface that 
should enhance cellular uptake by electrostatic interactions. In mice with an implanted tumor, 
the PEG layer allowed prolonged retention of the capsules in the bloodstream while the pH 
sensitive capsules (QD/PLLib/nav/PEG) strongly accumulated in the tumor, compared to pH 
insensitive control capsules using PLL functionalized with biotin (PLLb) 
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(QD/PLLb/nav/PEG). Moreover, immunohistochemistry revealed that the capsules were 
indeed located in hypoxic regions (acidic tumor microenvironment) of the solid tumor as 
shown in Figure 1.18.
Figure 1. 18. (A) Spectrally unmixed lateral scan of representative MDA-MB-435 mice model and
biodistribution of nanoparticles in organs 48 h after administration. QD/PLLib/nav/PEG nanoparticle 
fluorescence was still present in tumors at 48 h, which suggests significant nanoparticle uptake by 
tumor cells. Red = tissue and food autofluorescence; teal = nanoparticle fluorescence. Li = liver; K = 
kidney; Sp = spleen; H = heart; Lu = lungs; Mu = muscle; LN = lymph nodes; T = tumor. Image is 
spectrally unmixed to separate the nanoparticle fluorescence from tissue autofluorescence. (B) Tumor
sections (20×) from mice given QD/PLLib/nav/PEG or QD/PLL/nav/PEG. In tumors given 
QD/PLLib/nav/PEG treatments, a co-localization between nanoparticle and HIF-1R positive regions 
was found. Nanoparticle presence was not significant in tumors given QD/PLL/nav/PEG. Red = LbL 
nanoparticle; green = hypoxia; blue = nuclei. Scale bar = 50 ?m.219
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1.4.4. Cargo release
Most polyelectrolyte capsules can be considered stimulus-responsive. For internal stimuli, 
changes in the pH value and/or ionic strength could evidently modify the interactions between 
the successive layers, and induce the release of encapsulated material in the core of capsules. 
Besides ionic strength and pH value, temperature, solvent polarity, glucose and oxidation 
have also been used to modify the permeability of capsules. In most of these capsules, 
however, the release of encapsulated drugs was a rapid burst release due to a rapid and large 
change in the capsule permeability induced by physiological triggers. For example, 
Sukhorukov and coworkers reported that encapsulated peroxidase was completely released 
from dextran sulfate/protamine capsules within 1 h by a change in pH.
220
Caruso and co-
workers reported that catalase was released from PLL/poly(L-glutamic acid) capsules within 
30 min by pH and ion strength changes.
221
Thus, it has been difficult to achieve sustained 
release of encapsulated drugs from hollow capsules. In addition, these parameters are non-
physiological triggers, which often hamper their in-vivo applications. 
Figure 1. 19. Confocal microscopy snapshots taken during the enzymatic degradation of dextran 
sulfate/ poly(L-arginine) capsules in the presence of pronase, incubated at physiological conditions. 
The scale bar represents 10 ?m.215
De Geest and coworkers demonstrated enzymatic release microcapsules.  This type of 
capsules formed with dextran sulfate and poly(L-arginine).
215
Figure 1.19 shows a series of 
confocal microscopy snapshots of the microcapsules incubated in a pronase solution at 37°C. 
Pronase is a mixture of enzymes able to quasi-cleave every peptide bond. As a function of
time, the capsules slightly shrink, crumple and disassemble. Using the enzymatic degradation 
of the capsule membrane, the membrane thickness and the permeability of the capsule can be 
expected to be gradually changed. Therefore, sustained release can be accomplished by 
optimizing the conditions of the enzymatic degradation of capsule membranes. Enzymatically 
degradable capsules are generally made from polypeptides or polysaccharides, and they rely 
on the presence of appropriate enzymes for their degradation. This is a useful technique as 
proteases and nucleases are present in many specific areas of the body, which provides control 
over the timing or location of degradation. With similar strategy, other research groups 
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reported later enzymatic degradable capsules.
222,223
It was also shown that the wall properties 
of capsules can be readily changed upon varying enzyme concentrations.
Disulfide bonds are readily formed by oxidation of thiol groups and are cleaved by the reverse 
process, reduction. Reducing environments occur at specific locations in the body, the cytosol 
of the cell and the colon;
224
whereas other locations are comparatively oxidizing, like the 
blood stream. Thus, redox-activated release is triggered on cellular internalization. Caruso et 
al. developed capsules using oxidative cross-linking of the thiol moieties in the shell.
225,226
The obtained capsules were broken down in vitro under reductive conditions. This technology 
was applied by the same group to encapsulate oligonucleotides, peptides, and low-molecular-
weight anticancer drugs.
227
Additionally, release from polyelectrolyte capsules might also be achieved by applying 
external stimuli. This has mainly been accomplished by incorporating metal nanoparticles or 
light-responsive dyes into the walls of the capsules.
228
By embedding gold, silver and 
magnetic NPs into the capsule walls, the release of encapsulated drug molecules from the 
cavities can be achieved upon exposure to an external physical trigger.
229-232
Figure 1.20
shows the mechanism of photoactivated release of cargo from the cavity of a polyelectrolyte
capsule containing gold NPs in the walls: laser irradiation leads to local heating of the metal 
AuNPs and subsequent opening of small pores within the capsule wall.
233
Alternatively to 
laser irradiation methods, high-frequency magnetic field (HFMF) has been proven to trigger 
the release of drugs from microcapsules prepared by loading ferromagnetic gold-coated cobalt
NPs into the walls.
234
In addition, ultrasound has also been used to trigger release from 
multilayered capsules by mechanically disintegrate the capsule walls.
235
Figure 1. 20. Controlled-release of cargo with light-responsive capsules. (i) Laser irradiation of 
AuNPs-functionalized capsules leads to (ii) local heating of the metal NPs, and (iii) subsequent 
rupture of the capsule wall.
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All these release studies were performed in vitro. For in vivo studies, biocompatible and 
biodegradable nanocapsules are required to investigate their pharmacokinetics.
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1.5. Conclusion
Although a vast amount of research has increased our knowledge of cancer biology and 
therapy, which has improved survival of cancer patients, the disease remains lethal. The 
limitations in current cancer therapies signal the need for novel therapies that attack these 
specific issues. Nanotechnology provides a unique opportunity to combat cancer on the 
molecular scale through careful engineering of nanomedicines to specifically interact with 
cancer cells and inhibit cancer cell function. Various NP formulations have already made their 
way into the clinic and have become the standard of care in some cancer patients. It should be 
evident that there is no magical formulation for a nanocarrier, as each needs to be specifically
designed for its application. A constant theme throughout nanoparticle mediated drug delivery 
is extension of circulation time to allow for extravasation across vasculature and into tissue; 
stable particles with a long circulation half-life are ideal. Additionally, achieving high 
specificity of nanoparticle accumulation in the area of interest is also optimal. Then, 
engineering a triggered release functionality with spatial and temporal specificity is also 
crucial for optimizing delivery. Lastly, the residue of nanoparticle after release of their cargo 
should degrade without aggregation in tissues.
Polyelectrolyte capsules have emerged as promising carriers for various drugs. Perhaps the 
biggest advantage of this approach is its versatility. Each application requires particular
specifications, and the LbL technique allows the surface chemistry, size, permeability, and 
degradability to be altered to suit the application. Highly specialized films have been created 
in recent years. Many different types of drugs can be efficiently encapsulated, either into the 
film or into the cavity of the carrier. The surface chemistry can be easily altered by adding 
layers of different polymers or attaching targeting moieties. The degradation and cargo release 
can be finely controlled by a variety of mechanisms. However, capsules with diameters below 
1 µm are required for intravenous administration, and studies of their biodistribution and 
biocompatibility are also needed to accelerate progress in developing LbL-engineered 
capsules for biomedicine.  
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2.1. Résumé (fr) 
Ce chapitre décrit la synthèse de capsules biocompatibles et biodégradables élaborées par 
dépôt couche-par-couche de biopolymères sur un support colloïdal, suivi de sa décomposition 
dans des conditions douces. Ces capsules sont destinées à la vectorisation de principes actifs 
hydrophobes incorporés sélectivement dans leur paroi. La paroi des capsules est formée dun 
film multicouche comportant des nanodomaines hydrophobes, qui se forment grâce à 
lappariement de dérivés alkylés dacide hyaluronique (HAC10) et de dérivés du chitosane 
quaternisés (QCHI). La synthèse de ces dérivés a été mise au point lors de travaux antérieurs 
au sein du laboratoire
1
. Dans cette étude, nous montrons que la stabilité des capsules est 
fortement affectée par le degré de substitution (DS, nombre moyen de substituants par unité
de répétition) des polysaccharides modifiés. Des capsules stables sont obtenues à partir de 
HAC10 ayant un DS de 0.2 (HA20C10, 20 = 100 × DS) et de chitosane quaternisé de DS =
1.1. Le film multicouche à base de HA20C10/QCHIDS=1.1 présente également une forte
capacité dincorporation dune sonde fluorescente hydrophobe, le Nile Red (NR), par 
comparaison avec les films préparés à partir de dérivés de polysaccharides possédant des DS 
plus faibles.
Lincorporation sélective du NR dans la paroi des capsules (HA20C10/QCHI DS=1.1)5 a été 
mise en évidence par microscopie confocale. Nous avons pu estimer la quantité de NR 
incorporée dans les capsules par spectroscopie UV après extraction du NR des capsules avec 
de léthanol. La quantité dans chaque capsule déduite de la courbe de calibration du NR dans
léthanol est de lordre de 0.17 pg. Ceci correspond à une concentration "effective" dans la 
paroi de la capsule de ~ 64 mM (diamètre de capsules : 5 µm, et lépaisseur de capsules : 110 
nm), cest-à-dire environ 6400 fois la concentration du nile red dans la solution aqueuse 
initiale de HA20C10 (CNile Red = 10 ?M). Lanalyse de la quantité de NR libérée par les 
capsules HA20C10/ QCHIDS=1.1 en fonction du temps met en évidence une libération lente sur 
plusieurs jours et ce, bien que le milieu aqueux environnant soit changé deux fois par jour. Ce 
résultat montre ainsi une affinité élevée de la molécule hydrophobe vis-à-vis de la paroi 
multicouche. Ceci démontre le potentiel de ces systèmes multicouches comme vecteur de 
principes actifs hydrophobes dans la mesure où pour quun tel vecteur soit efficace, la 
libération du médicament doit être négligeable avant datteindre la cible.
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Afin danalyser le comportement des capsules en présence de cellules, nous avons examiné 
leur stabilité dans le milieu de culture. Celle-ci sest avérée dépendre fortement de la présence 
de protéines dans le milieu. En présence de protéines, un gonflement des capsules est observé.
En revanche, les capsules dont la paroi est constituée dun film réticulé de HA20C10 et de 
poly(L-lysine) (PLL), ne présentent aucun déformation quelles que soient les conditions de 
milieu.
Sur la base de ces résultats, nous avons préparé des capsules HA20C10/PLL en remplaçant le 
NR par le paclitaxel (PTX) qui est un agent anti-cancéreux hydrophobe puissant, utilisé pour 
le traitement de cancers du sein, de lovaire et du poumon. Lactivité biologique des capsules 
vis-à-vis de cellules du cancer du sein (MDA MB 231) a été étudiée dans une deuxième 
phase. La viabilité de ces cellules sest avérée être fortement réduite en présence de capsules 
chargées en PTX et ce, de façon dose-dépendante. Lensemble de ces travaux a ainsi montré
le potentiel de capsules à base de HA alkylé contenant des nanodomaines hydrophobes 
comme systèmes de délivrance de médicaments peu solubles dans leau.
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2.2. Introduction 
The aim of this work was to synthesize multilayer capsules which were able to encapsulate 
water-insoluble molecules in the nanoshell. The multilayer capsules are prepared by the layer-
by-layer assembly of oppositely charged polyelectrolytes on a colloidal template, followed by 
its decomposition. Previous work in our laboratory showed the ability to prepare stable 
capsules containing hyaluronic acid (HA) as a negatively charged polysaccharide using 
CaCO3 particles as a template under mild conditions.
2
In order to encapsulate hydrophobic 
molecules, HA was chemically modified with alkyl chains. Our previous work showed the 
very high affinity of hydrophobic molecules for the hydrophobic nanodomains formed by 
alkylated derivatives of HA in aqueous solution or in multilayer films.
3
Among all of
alkylated HA derivatives, the HA20C10 (derivative with alkyl chains having 10 carbon atoms 
and degrees of substitution 20 per 100 disaccharide repeating units) showed the strongest 
ability to trap the dye into hydrophobic nanodomains. Therefore, we investigated the 
preparation of capsules able to entrap poorly water-soluble molecules in the polyelectrolyte 
shell based on the HA20C10 derivative.
In this chapter, we describe two types of capsules to selectively encapsulate a water-insoluble 
molecule in the nanoshell based on HA20C10, using a chitosan derivative which is water-
soluble at physiological pH (QCHI)
4
and a polypeptide poly(L-lysine) (PLL) as components 
of the nanoshell. Contrary to HA20C10/QCHI capsules, the HA20C10/PLL capsules require 
shell cross-linking to maintain the stable form.
Incorporation of a hydrophobic dye, Nile Red (NR), in the nanoshell of HA20C10/QCHI 
capsules was demonstrated. The amount of NR loaded in the wall and its release were also 
investigated. We further showed that the hydrophobic molecule can be delivered 
intracellularly in dendritic cells. This part of work has been reported in Advanced Materials
5
.
Then we compared the ability of incorporating of NR in the nanoshell of HA20C10/QCHI 
capsules and HA20C10/PLL capsules.
In order to analyze the behavior of these two capsules in the presence of cells, we examined 
their stability in the culture medium. In the culture medium, swelling behavior of 
HA20C10/QCHI capsules was observed. However, HA20C10/PLL capsules whose the wall 
consists of a crosslinked film did not show any destabilization whatever the environmental 
conditions.
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Based on these results, we chose HA20C10/PLL capsules to solubilize the anti-cancer agent,
paclitaxel, which is used for the treatment of breast, ovarian and lung cancer. The cytotoxicity 
of PTX-loaded capsules was examined on breast cancer cells (MDA MB 231). This part of 
work has been reported in Journal of Controlled Release
6
.
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2.5. Complementary results 
 
2.5.1. Replacement of quaternized chitosan (QCHI) as a 
polycationic partner of alkylated HA by poly(L-lysine) 
(PLL)
Previous work demonstrated the synthesis of various alkylamino hydrazide derivatives of HA 
and their ability to form planar polyelectrolyte multilayers with quaternized chitosan (QCHI) 
and a polypeptide, poly(L-lysine).
3
Based on these results, we prepared capsules using PLL as 
a polycation. Compared to HA20C10/QCHI capsules, the HA20C10/PLL capsules are not 
stable after core decomposition. Shell crosslinking is thus required to reinforce the mechanical 
property of the shell, allowing to obtain stable capsules after core decomposition.
Crosslinking was performed by an amine-acid coupling reaction using the water-soluble 
carbodiimide 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 400 mM) and N-
hydroxysulfosuccinimide (sNHS, 100 mM). Comparison of the fluorescence intensity of the 
HA20C10/QCHI and HA20C10/PLL capsules, prepared by LbL assembly of HA20C10 pre-
incubated with the same amount of Nile Red (NR) revealed a lower fluorescence intensity for 
the HA20C10/PLL capsules (Figure CR 2.1). 
Figure CR 2. 1. Confocal microscopy images of a) crosslinked (HA20C10/PLL)4.5 capsules; b) 
(HA20C10/QCHI)4.5 capsules exhibiting a highly localized red fluorescence in their nanoshell due to 
the specific entrapment of Nile Red molecules in hydrophobic nanodomains. Scale bars: 10 µm.
We quantified the amount of NR loaded in the nanoshell by UV-visible spectrometry using a
fluorescence microplate reader (Infinite 1000, Tecan, Austria) after extraction of NR from the 
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capsules with ethanol. Using a calibration curve for NR in ethanol, we deduced a mean NR
mass per capsule. The number of capsules per mL of suspension was determined using a 
Petroff-Hausser counting chamber. The results are presented in Table CR 2.1.
Table CR 2. 1. Effective loading of NR in the hydrophobic nanoshell of capsules. 
Capsule Amount inserted per capsule (pg/cap.)
HA20C10/QCHI 0.17 ± 0.06
HA20C10/PLL 0.09 ± 0.04
The results shown in Table CR 2.1. confirmed the CLSM observations : the amount of NR
loaded in the HA20C10/PLL capsules is lower than that in the HA20C10/QCHI. This may be 
related to shell crosslinking which could squeeze out some NR molecules from the shell. In 
addition, the semi-rigid character of QCHI and its high molar mass (compared to PLL) may 
result in the formation of nanoshells with many entanglements which can stabilize the 
hydrophobic molecule in the nanoshell.
2.5.2. Stability of the capsules in culture media
We investigated the stability of HA20C10/QCHI and HA20C10/PLL capsules in culture 
medium (RPMI 1640 Gibco with or without 10% fetal bovine serum provided by Bertin 
pharma). Figure CR 2.2 gives an overview of the HA20C10/QCHI capsules behavior in 
different conditions (temperature, presence of proteins or hydrophilic molecules).
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Figure CR 2. 2. Deformation of (HA20C10/QCHI)5 capsules (A) in culture medium without fetal 
bovine serum at 22°C; (B) one day after incubation in culture medium with fetal bovine serum at 
22°C; (C) 4 days after incubation in culture medium with fetal bovine serum at 22°C; (D) in phosphate 
buffer saline (PBS) containing albumin from bovine serum (BSA) on 10 g/L at 22°C; (E) in PBS 
buffer containing BSA on 35 g/L at 22°C; (F) loaded with Nile Red in the nanoshell in PBS buffer 
containing BSA on 35 g/L at 22°C; (G) loaded with Nile Red in the nanoshell in PBS buffer 
containing dextran on 35 g/L at 22°C;(H) one day after incubation in culture medium with fetal bovine 
serum at 37°C; (I) 4 days after incubation in culture medium with fetal bovine serum at 37°C. BSA: 
Mw=66000 g/mol; dextran: Mw=70000 g/mol.
First, when (HA20C10/QCHI)5 capsules were immersed in the culture medium containing 
fetal bovine serum at 22°C, we observed, after one day, the swelling of some capsules
(Figure CR 2.2.B and C) contrary to the same capsules in the culture medium without serum
(Figure CR 2.2.A). We attributed this phenomenon to a destabilization of interactions 
between the biopolyelectrolytes due to the formation of new hydrophobic and/or electrostatic 
interactions between the proteins and the biopolyelectrolytes. To verify this hypothesis, we 
immersed the capsules in phosphate buffer saline (PBS) containing only one protein, albumin 
from bovine serum (BSA), at a concentration of 10 g/L (Figure CR 2.2.D). The capsules 
were found to swell in such conditions. At a BSA concentration of 35 g/L, the capsules 
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decomposed upon swelling (Figure CR 2.2.E). A similar behavior was observed when NR 
was incorporated within the wall (Figure CR 2.2.F). In order to confirm the mechanism 
responsible for the swelling of the capsules, we analyzed the effect of addition of the 
hydrophilic polymer dextran (Mw = 70000 g/mol) at the same concentration of BSA (35 g/L) 
in the solution. In this case, no swelling of the capsule was observed at 22 °C (Figure CR 
2.2.G). This result thus supported our hypothesis suggesting disruption of the multilayer shell 
due to hydrophobic and/or electrostatic interactions between the proteins and the 
biopolyelectrolytes. Moreover, we observed strong uncontrolled deformation of the capsule
walls at higher temperature (37°C) (Figure CR 2.2.H and I). We assumed that at higher 
temperature, the chains mobility could increase as well as the hydrophobic interactions
between the multilayer and the proteins, resulting in the decomposition of the shells.
In contrast, HA20C10/PLL capsules maintained their morphology and size in all conditions, 
which demonstrated the significant mechanical reinforcement of the shell by chemical 
crosslinking the layers.
As HA20C10 used above was prepared from a HA sample of 200 000 g/mol (HA200), we
then prepared an alkylated derivative from a HA sample of 350 000 g/mol (HA350) to assess 
the impact of the HA molar mass on the capsule stability. Figure CR 2.3 shows that in the 
same external conditions, capsules prepared from alkylated HA350 deformed less than 
capsules containing alkylated HA200, suggesting more cohesive interactions in the former 
case.
Figure CR 2. 3. Deformation of (A) (HA20C10-HA350/QCHI)5 capsules and (B) (HA20C10-
HA200/QCHI)5 in culture medium with fetal bovine serum at 22°C. Scale bars: 20 µm.
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In order to have a deeper insight into the role of the molar mass on the behavior of alkylated 
HA in aqueous solution, we compared the viscoelastic properties of the two derivatives by 
dynamic rheological measurements. Figure CR 2.4 shows the variation of the storage, G, 
and loss, G, moduli as a function of the frequency for the two samples at 10 g/L in 
phosphate buffer saline. 
Figure CR 2. 4. Comparison of the storage and loss modulus as a function of frequency for solution of 
HA20C10-HA200 and HA20C10-HA350 derivatives (10 g/L in PBS (pH 7.4)) at 25°C.
As can be observed from this figure, the storage modulus is higher than the loss modulus,
over the entire range of frequencies covered, indicating that the 2 solutions behave like a 
highly elastic physical gel. When the molar mass is increased, the values of the G and G 
modulus appear to increase. These data thus support our hypothesis suggesting the presence 
of more cohesive interactions in the former case of capsules formed with HA20C10-350.
Moreover, in order to determine the critical concentration required for gel formation from 
these derivatives, we measured the dynamic moduli as a function of frequency for different 
polymer concentrations. The dynamic mechanical behavior at gel point for chemically 
crosslinking systems is characterized by a scaling relationship between the dynamic moduli 
and the ?????????? ?????????????????as well as ?? ?????????? ???????????? ????? ?????? ?????c =
???????????????????.7 This relationship may be applied to physically cross-linking systems.8,9
Based on these theoretical aspects, we determined the gel point for these two derivatives by 
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the observation of a frequency-independent value of delta (?) as a function of the polymer 
concentration (Figure CR 2.5). As expected, we found that the gel point of HA20C10-350 is 
lower than that of HA20C10-HA200.
Figure CR 2. 5. Determination of the gelation concentration of (A) HA20C10-HA350 and (B) 
HA20C10-HA200.
2.5.3. Drug loading in HA20C10/PLL capsules 
Using the hydrophobic nanoshell based on HA20C10 and PLL, we replaced the model 
hydrophobic dye of NR by the hydrophobic anti-cancer drug paclitaxel (PTX) to form a drug 
loaded capsules. The result with breast cancer cells was reported in an article (Annexes)
6
.
We used Oregon green labeled paclitaxel (OG-PTX) as a tracer, which was added at fixed 
concentration (1/20) to PTX solutions. To estimate the absolute OG-PTX concentration, a 
calibration curve for the fluorescence of OG-PTX as a function of its concentration was 
acquired. The effective concentration of PTX in the capsules was calculated knowing the 
amount of OG-PTX incorporated in the capsules by fluorescence intensity measurements by 
Tecan instrument after extraction of OG-PTX from capsules with methanol. We used indirect 
method to determine the quantity of PTX, because PTX adsorb at 230 nm, this is the limit of 
Tecan instrument. We also used high-performance liquid chromatographic (HPLC) 
procedures for the PTX quantitative determination. Because of the very low concentration in 
solution, it was difficult to obtain a reliable value from this method.
After the measurements of fluorescence intensity of OG-PTX, we found that the effective 
concentration of PTX was to be of 17 fg (10
-15
g) per capsules. This value was taken as 
positive reference for the tests with cancer cell using PTX in solution. Unloaded and PTX-
loaded capsules were added to MDA-MB-231 cell culture and observed over 3 days. The 
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cytotoxicity of the capsules was evaluated by counting the cell number and by measuring the 
cell viability using a MTT assay. The PTX-loaded microcapsules were found to decrease the 
viability and proliferation of MDA MB 231 breast cancer cells, while unloaded microcapsules 
did not impact cell viability.
2.6. Conclusion
In order to encapsulate hydrophobic molecules, we have synthesized two types of capsules 
based on HA20C10 which present hydrophobic nanodomains in aqueous solution. With 
QCHI, stable capsules could be obtained after core removal. In contrary, HA20C10/PLL 
needed chemical crosslinking of multilayer shell to maintain the stable form. Comparison of
the ability of incorporating Nile Red in these two capsules, HA20C10/QCHI capsules loaded 
more NR than HA20C10/PLL capsules. But, the study of stability of the capsules in culture 
media showed that the HA20C10/PLL capsules maintained their morphology and size in all 
experimental conditions, which demonstrated the significant mechanical reinforcement of the 
shell by chemical crosslinking. Finely, we chose HA20C10/PLL capsules to encapsulate an 
anti-cancer agent, paclitaxel. The PTX-loaded capsules were found to decrease the viability 
and proliferation of MDA MB 231 breast cancer cells, and the empty microcapsules did not 
impact cell viability. Our results highlight the potential of capsules based on alkylated-HA 
containing hydrophobic nanodomains for hydrophobic drug delivery.
Chapter 2 Hydrophobic shell loading of biopolyelectrolyte capsules based on alkylated 
hyaluronic acid 
 
 
81 
 
References
 
(1) Cui, D., 2011.
(2) Szarpak, A.; Pignot-Paintrand, I.; Nicolas, C.; Picart, C.; Auzely-Velty, R. Langmuir 2008, 24,
9767.
(3) Kadi, S.; Cui, D.; Bayma, E.; Boudou, T.; Nicolas, C.; Glinel, K.; Picart, C.; Auzely-Velty, R. 
Biomacromolecules 2009, 10, 2875.
(4) Cui, D.; Szarpak, A.; Pignot-Paintrand, I.; Varrot, A.; Boudou, T.; Detrembleur, C.; Jerome, 
C.; Picart, C.; Auzely-Velty, R. Advanced Functional Materials 2010, 20, 3303.
(5) Cui, D.; Jing, J.; Boudou, T.; Pignot-Paintrand, I.; De Koker, S.; De Geest, B. G.; Picart, C.; 
Auzély-Velty, R. Advanced Materials 2011, 23, H200.
(6) Boudou, T.; Kharkar, P.; Jing, J.; Guillot, R.; Pignot-Paintrand, I.; Auzely-Velty, R.; Picart, C. 
Journal of Controlled Release 2012, 159, 403.
(7) Winter, H. H.; Chambon, F. J. Rheol. (N. Y.) 1986, 30, 367.
(8) Lin, Y. G.; Mallin, D. T.; Chien, J. C. W.; Winter, H. H. Macromolecules 1991, 24, 850.
(9) Desbrieres, J. Polymer 2004, 45, 3285.
Chapter 2 Hydrophobic shell loading of biopolyelectrolyte capsules based on alkylated 
hyaluronic acid 
 
 
82 
 
 
83 
 
Chapter 3
Cyclodextrin/Paclitaxel complex in 
biodegradable capsules for breast 
cancer treatment
Chapter 3 Cyclodextrin/Paclitaxel complex in biodegradable capsules for breast cancer 
treatment 
 
 
84 
 
Chapter 3 Cyclodextrin/Paclitaxel complex in biodegradable capsules for breast cancer 
treatment 
 
 
85 
 
3.1. Résumé (fr)
Ce chapitre porte sur le développement de capsules destinées à la vectorisation dun agent 
anti-cancéreux, le paclitaxel (PTX). L'encapsulation de PTX est obtenue par complexation
hôte-invité avec la ?-cyclodextrine ??-CD) greffée sur lacide hyaluronique (HA), constituant 
la paroi des capsules. La structure torique de la ?-CD délimite une cavité dont la particularité 
est dêtre hydrophobe. La partie extérieure est au contraire hydrophile et confère à la ? -CD 
une bonne solubilité dans leau. Lexistence de la cavité hydrophobe permet dhéberger une 
molécule de PTX partiellement, ce qui permet daugmenter sa solubilité en milieu aqueux 
dun facteur 100 (solubilité du PTX seul dans leau = 0.4 ?M). Dans ce travail, nous avons 
cherché à combiner la complexation hôte-invité et les propriétés de transport des capsules
pour former un nouveaux système de délivrance du PTX.
Le dérivé HA-cyclodextrine (HA-CD) a été préparé par une réaction de couplage de type 
"thiol-ène", effectuée en milieu aqueux. Cette réaction, mise au point au sein de notre 
laboratoire, permet le greffage simple, rapide, efficace, et dans des conditions douces de 
molécules variées sur des polysaccharides porteurs de fonctions alcène. Elle consiste dans le 
cas présent en l'addition radicalaire d'un dérivé de ? -CD monofonctionnalisée avec de l'acide 
mercaptopropionique sur le HA modifié par des groupements pentènoate.
La complexation ?????-CD a été démontrée par RMN 1H. Les études sur la solubilité du
PTX en milieu aqueux en présence de la ? -CD naturelle, du dérivé HA-CD ou dun dérivé 
méthylé ???????-CD, ?????????????????????????????????-CD naturelle (heptakis-(2,6-di-O-methyl) 
?-CD (DM-?-CD)), ont montré que le dérivé HA-CD présentait un fort pouvoir solubilisant 
comparativement à la ? -CD naturelle. Ceci a été attribué à laugmentation de la solubilité de 
la cavité de CD par couplage avec lacide hyaluronique dans la mesure où les propriétés de 
complexation de la CD greffée sont similaires à la CD non modifiée. Par ailleurs, cette 
hypothèse est confortée par le fait que la DM-?-CD présente un pouvoir solubilisant 
nettement supérieur à celui de ????-CD naturelle alors que leurs propriétés de complexation 
sont quasi-équivalentes.
Pour synthétiser les capsules à partir de HA-CD, nous avons tout dabord vérifié sa capacité à 
former des films multicouches plans par complexation avec la poly(L-lysine) (PLL). Le suivi 
de la formation des films par microbalance à cristal de quartz avec mesure de la dissipation 
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(QCM-D) a montré une croissance du film HA-CD/PLL similaire à celle du film HA/PLL.
Compte tenu de ce résultat et du fait que des capsules de HA/PLL peuvent être obtenues sous 
réserve que les couches de polymères soient réticulées chimiquement, nous avons dans une 
seconde phase entrepris la synthèse de capsules HA-CD/PLL en réticulant le film multicouche 
par couplage amine-acide en présence dun carbodiimide hydrosoluble. Lencapsulation du 
PTX a été réalisée par pré-complexation préalable du PTX par le HA-CD dans la solution 
aqueuse utilisée lors du dépôt couche-par-couche. La quantité de PTX incorporé dans les 
capsules de HA-CD/PLL sest avérée être similaire à celle obtenue avec les capsules 
préparées à partir de HA20C10. Les capsules de HA-CD/PLL peuvent libérer le PTX sur une 
période de 5 jours sans relargage rapide au début (burst effect). Des études préliminaires ont 
montré que les capsules inhibent la prolifération de cellules cancéreuses (cellules du cancer du 
sein MDA MB 231), contrairement aux capsules "contrôles" ne contenant pas de PTX.
Ces résultats ont ainsi montré la faisabilité dobtenir de nouveaux systèmes transporteurs 
permettant une libération contrôlée de principes actifs peu solubles de leau en combinant les 
propriétés de complexation originales doligosaccharides naturels avec lassemblage couche-
par-couche en conditions physiologiques de biopolymères hydrosoluble biocompatibles sur 
des particules sacrificielles. 
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3.2. Introduction
Complexation of the anti-cancer drug paclitaxel ??????????-???????-CD derivatives such as 
heptakis-(2,6-di-O-methyl) ?-CD (DM-?-CD), hydroxypropyl-?-CD  was investigated with 
the purpose to propose new PTX formulations.
1-3 ?-CD can increase the solubility of 
paclitaxel. Moreover, the PTX??-CD complex showed a greater antitumoral activity than the 
free drug at high dilution factors. It can allow the transfer of the drug from the CD cavity to 
tumor cells due to the reversibility of host-guest complexation. 
By grafting aliphatic chains on the ?-CD cavity, amphiphilic ?-CD derivatives that can self-
assemble into nanoparticles in aqueous solution can be obtained. New PTX formulations 
based on nanoparticles were thus prepared from a mixture of PTX and an amphiphilic ?-CD 
(6-O-CAPRO-?-CD which is modified on the primary face with 6C aliphatic esters) by the 
nanoprecipitation technique.
4,5
Irache et al. incorporated hydroxypropyl-?-CD/PTX 
complexes in poly(anhydride) nanoparticles by a solvent displacement method
6,7
. These 
different approaches for the synthesis of CD nanoparticles showed however limitations 
associated with sample polydispersity, the necessity for an oil phase and/or burst effect during 
drug release (more than 50% PTX release was observed in the first hour
4
).
????? ??? ???? ?????????? ???? ?????????? ??? ?-CD modified chitosan-poly(acrylic acid) 
nanoparticles as PTX delivery systems.
8
These NPs were synthesized by the radical 
??????????????? ??? ???????? ????? ???? ????????? ??????????? ?-CD in chitosan solution. PTX was 
loaded into NPs in a mixture of ethanol/water. This NPs preparation procedure is complicated, 
and the encapsulation efficiency was relatively low. However, the in vitro drug release profile 
of PTX showed a sustained manner for more than one week  under simulated physiological 
conditions (PBS, pH 7.4) and at pH 5.7 (Figure 3.1).
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Figure 3. 1. The release profile of PTX from CSPAACD NPs in the PBS with different pH value.
8
These different studies show the potential of using host-guest complexation for designing 
hydrophobic drug carrier systems with tunable functionalities for the treatment of cancer.
However, to circumvent some limitations of these systems, which are generally associated 
with the procedure of their preparation, new approaches to engineer CD-based carriers
9,10
would be highly desirable.
In this chapter, we design a new approach of layer-by-layer capsules containing the 
cyclodextrin/paclitaxel complex as drug carriers. This strategy was realized by incorporation 
of CD-polymers to combine the benefits of CD inclusion complexes and of biodegradable 
polymer matrix based on polyelectrolyte complexation.
?-cyclodextrin was grafted onto hyaluronic acid using a thiol-click reaction (HA-CD). The 
enhancement of the water-solubility of PTX through host-guest interactions with the natural 
?-CD, HA-CD as well as with DM-?-CD was studied.
After confirmation of assembly of HA-CD and poly(L-lysine) in multilayer films on a planar 
solid substrate, we investigated the generation of capsules made from (HA-CD/PLL) films 
and the PTX loading and release from the nanoshell. At end, we studied the capacity of (HA-
CD/PLL) capsules to deliver PTX to MDA MB 231 breast cancer cells.
This study has been submitted for publication. In the complementary results, we discussed 
that the importance of behavious of polymers in solution in the process of formation of 
capsules.
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3.3. Publication (submitted)
Cyclodextrin/Paclitaxel complex in biodegradable capsules for breast 
cancer treatment
Jing Jing, Anna Szarpak-Jankowska, Raphael Guillot, Isabelle Pignot-Paintrand, Catherine 
Picart and Rachel Auzély-Velty
3.3.1. Introduction
Delivery of drugs is currently a great challenge in the field of nanobiotechnology, especially 
for hydrophobic compounds, which constitute a great part of the currently available drugs.
11-13
Many of these compounds have been found to have limited clinical effectiveness due in part 
to their high toxicity, low solubility, and/or other poor pharmaceutical parameters. It has been 
demonstrated that conjugation of a poorly water-soluble molecule to a water-soluble polymer 
(called prodrug approach) can greatly enhance its aqueous solubility and reduce its 
cytotoxicity in vitro and in vivo.
14
Nanoparticles are alternative materials that have shown 
huge potential for encapsulating and delivering poorly water-soluble compounds, especially in 
anti-cancer therapy.
15,16
These systems provide a more flexible approach compared to 
prodrugs which are limited to hydrophobic drugs possessing a functionality for their chemical 
grafting on the polymer chain. However, even after decades of development, there are a few 
examples of nanotechnology therapeutic products that have been approved for clinical use.
15
One of the major obstacles is the initial burst release of the encapsulated drug which carries 
an increased risk of toxicity. Moreover, most of the methods to produce polymeric 
nanoparticles involve the use of toxic solvents and surfactants, which require intensive 
postprocessing purification.
Cyclodextrins (CDs) are water-soluble cyclic oligosaccharides which can include various 
guest molecules into their hydrophobic cavity allowing the solubilization, stabilization and 
transport of hydrophobic drugs.
17
Worldwide 3040 different drugs are nowmarketed as 
cyclodextrin complexes.
18
Although the use of CDs as solubilizers in the pharmaceutical field 
has been documented for decades, more advanced CD-based drug delivery systems still need 
to be developed. In recent years, the nanoscale association of these host molecules with 
particles or polymers lead to the development of drug delivery platforms with unique stimuli-
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responsiveness and adjustable drug release characteristics. By immobilizing CD on magnetic 
nanoparticles, it was thus shown the ability to trigger the release of hydrophobic drugs 
incorporated in the CD through the use of induction heating.
19
By the layer-by-layer (LbL) 
assembly of poly(carboxymethyl-?-cyclodextrin) complex with a small molecule and 
positively charged degradable poly(?-aminoesters), nanoscale coatings for small molecule 
delivery capable of programmable release kinetics could be obtained.
12
These surface-eroding 
films were prepared under mild conditions.
Extension of this technology to LbL-based hollow capsules may offer new opportunities for 
designing carriers with tunable functionalities in the nano/micrometer range. These capsules, 
also called polyelectrolyte multilayer capsules consist of two distinct compartments: the 
multilayer shell and the aqueous cavity. Such a structure may be advantageously used to 
achieve a bi-compartment delivery for both hydrophobic and hydrophilic drugs with 
synergistic effects for the treatment of diseases, like cancer. In general, drugs are loaded into 
the aqueous cavity with high loading efficiency. However, this implies that the drugs have 
good water-solubility and a relatively high molecular weight to avoid the leakage from the 
capsules. As many anticancer drugs such as paclitaxel, doxorubicin and camptothecin, are 
small hydrophobic molecules, it is still a challenge to load these drugs in the hydrophilic 
multilayer shell. Until now, few strategies have been reported for incorporation of poorly 
water-soluble molecules in the capsule shell. Caruso et al. reported prodrug approach in which 
the hydrophobic cancer drug paclitaxel (PTX) was covalently coupled to poly(L-glutamic 
acid) and embedded inside the capsule shell.
20
As an alternative strategy for noncovalent 
sequestering of hydrophobic drugs, we developed hydrophobic nanoshells based on 
decylamino hydrazide derivatives of hyaluronic acid (HA).
21
However, this strategy, which is 
based on the non-specific binding of hydrophobic molecules to alkylated HA in the shell, 
poses difficulty to precisely control drug release. 
Here, we describe a new kind of LbL-based hollow capsules based on hyaluronic acid-
cyclodextrin conjugates that combine severable favorable features as a hydrophobic drug 
carrier, including CD inclusion complexation, unique biological functions of hyaluronic acid 
(HA) and transport properties of capsules. Using paclitaxel as a model anticancer drug, we 
show that these systems can selectively bind the anticancer drug in the shell and release it in a 
selective and controlled manner to breast cancer cells.
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3.3.2. Materials and Methods
Materials
The sample of bacterial sodium hyaluronate (HA) with a weight-average molecular weight of 
200 kg/mol was supplied by ARD (Pomacle, France). The molecular weight distribution and 
the weight-average molecular weight were determined by size exclusion chromatography 
using a Waters Alliance chromatograph (USA) equipped with two online detectors: a 
differential refractometer and a light scattering detector (MALLS) from Wyatt (USA); the 
solutions were injected at a concentration of 1 mg/mL in 0.1 M NaNO3. The polydispersity 
index (PDI) of the sample is Mw/Mn ~ 1.5. 6-monodeoxy-6-monoamino-?-cyclodextrin 
hydrochloride, heptakis-(2,6-di-O-methyl) ?-CD (DM-?-CD), pentenoic anhydride, 3-
mercaptopropionic acid (MPA), ethylenediaminetetraacetic acid (EDTA), phosphate buffer 
saline (PBS, pH 7.4), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
hydroxysulfo-succinimide (sNHS), and all other chemicals were purchased from Sigma-
Aldrich-Fluka and were used without further purification. Paclitaxel and oregon green-labeled 
paclitaxel (OG-PTX) were purchased from Invitrogen (USA). 2-Hydroxy-1-[4-(2-
hydroxyethoxy)phenyl]-2-methyl-1-propanone (Irgacure 2959) was kindly provided by Ciba 
Specialty Chemicals (Basel, Switzerland). Deuterium oxide was obtained from SDS (Vitry, 
France). The water used in all experiments was purified by a Elga Purelab purification 
system, with a resistivity of 18.2 M?? ???? ???? ?-cyclodextrin (?-CD) derivative 
monofunctionalized with MPA (CD-SH), used for the synthesis of CD-modified HA (HA-
CD), was prepared in the laboratory as previously described.
22
The pentenoate-modified HA 
with a degree of substitution (DS; defined as the number of moles of ?-CD molecules per 100 
disaccharide repeating units) of 9 was synthesized as previously described.
22
Methods
Synthesis of HA-CD
To a solution of HA-pentenoate (80 mg, 1.57 ? 10-2 mmol) in ultrapure water containing 
Irgacure 2959 (0.05% w/v) as a photoinitiator, CD-SH (20 mg, 1.57 × 10
-2
mmol) dissolved in 
1 ml of water was added. The grafting of CD-SH moieties was performed under UV radiation 
(? = 365 nm) for 10 min. The product was purified by diafiltration (ultramembrane Amicon 
YM10) with ultrapure water and was recovered by freeze-drying (95 mg). The degree of 
substitution of HA-CD was found to be 9 ± 1 by 
1
H NMR (Figure SI 3.9).
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1
H NMR (400 MHz, D2O) ? (ppm): 4.95 (anomeric protons of CD), 4.55 (anomeric proton of 
the N-acetylglucosamine unit), 4.25 (anomeric proton of the glucuronic acid units), 2.8-2.5 (2 
CH2CO, CH2-S-CH2), 1.85 (CH3-CO from HA), 1.7-1.2 (2 CH2).
Synthesis of (HA-CD/PLL) capsules and quantification of OG-PTX incorporated in 
capsules
Microcapsules were prepared according to the method described for the synthesis of 
(HA/PLL) capsules using calcium carbonate particles as a sacrificial template.
23
PTX was pre-
complexed with HA-CD by adding 34.2 µL of a PTX/ OG-PTX mixture (5 g L
-1
or 5.85 mM)
in methanol in the HA-CD solution (4 mL) at 1 g L
-1
. The CaCO3 particles were coated layer-
by-layer by incubating them at a concentration 2 % (w/v) in solutions of HACD-PTX (at 1 g
L
-1
) and PLL (at 2 g L
-1
), both in 0.15 M NaCl (pH 6.5). After the desired number of layers 
was deposited, the multilayer shell was crosslinked using EDC (400 mM) and sNHS (100 
mM) in 0.15 M NaCl and the CaCO3 core was removed by treatment with an aqueous solution 
of EDTA (0.1 M, pH 7.2). The dissolved ions resulting from the decomposition of CaCO3
were then removed by dialysis against pure water, using spectra Por dialysis bags with a 
molecular weight cut off of 10 kDa.
The amount of OG-PTX incorporated in the capsules was determined by fluorescence 
intensity measurements after extraction of PTX/OG-PTX from capsules with methanol 
according to an established procedure
21
. The suspension of capsules (100 ?L at ~ 6×107
capsules/mL) in PBS was centrifugated (4000 rpm, 4 min, 20 °C) and the supernatant was 
removed. After addition of methanol, the suspension was again centrifugated (9000 rpm, 4 
min, 20 °C) and the supernatant containing OG-PTX was recovered. This process was 
repeated two times to ensure the full extraction of OG-PTX from the capsules. Then the 
solutions were analyzed using the fluorescence microplate reader (Infinite 1000, Tecan, 
Austria) with excitation and emission wavelengths set at 496±10 nm and 524±10 nm, 
respectively. To estimate the absolute OG-PTX concentration, a calibration curve for the 
fluorescence of OG-PTX as a function of its concentration was acquired (Figure SI 3.10). 
The effective concentration of PTX per capsule was calculated knowing the ratio of 
unlabeled/labeled PTX, the molecular weight of PTX and OG-PTX and the average number 
of capsules per mL which was determined using a Petroff-Hausser counting chamber.
Solubility studies
Two PTX stock solutions were prepared in methanol (A: 1 g L
-1
(1.17 mM); B: 5 g L
-1
(5.85
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mM)). The solution A (1.7 µL) was added to an aqueous solutions (1 mL) of ?-CD ([CD] = 6 
mM), and the solution B (8.5 µL and 8.4 µL) was added to aqueous solutions (1 mL) of HA-
CD ([CD] = 0.157 mM) and DM-?-CD ([CD] = 6 mM), respectively. The resulting mixtures 
were stirred for 4 h at room temperature and methanol was allowed to evaporate slowly under 
a stream of nitrogen. The suspensions were then filtered through 0.45 ?m membrane filter 
(Millipore) and analyzed by UV spectrometry. The concentration of PTX in the solution was 
calculated using the Beer-Lamber law, A = ? C l, where A is absorbance, C is the 
?????????????? ?????????? ?? ??? ???? ????? ??????? ??? ???? ????? ???????? ????? ???? ?? ??? ???? ???????????
??????????????????????
Release kinetics of paclitaxel from (HA-CD/PLL) capsules
The suspension of PTX-loaded capsules was divided in samples of 200 µL. Each sample was 
dispersed in 1.5 mL PBS in an eppendorf at 37°C. Periodically (2 times per day), 1 mL 
release medium was removed and 1 mL fresh PBS was added to each eppendorf. At time x, 
one sample was treated to determine the amount of PTX retained in the capsules. PTX was 
extracted from the capsules with methanol and the methanolic solution was analyzed by UV 
spectrometry. This process was performed in duplicate.
Physicochemical characterization
1
H NMR spectra of CD and HA derivatives dissolved in deuterium oxide (6 mg/mL) were 
performed at 25 and 80 °C, respectively, using a Bruker spectrometer operating at 400 MHz. 
The buildup of (HA-CD/PLL)i, (HA-CD-PTX/PLL)i, (HA/PLL)i films (where i denotes the 
number of layer pairs) was followed by in situ quartz crystal microbalance with dissipation 
monitoring (QCM-D, D300, Qsense, Sweden) according to the experimental protocol that has 
been described in our previous publications.
24,25
For SEM observations, a drop of capsules 
suspension is deposited on fresh clived mica and air drying. The samples were coated with a 2 
nm layer of carbon and observed in secondary electron imaging mode with a FEI Quanta 250 
FEG-SEM using an accelerating voltage of 3kV or sputtered with 8nm layer of Au/Pd and 
observed in secondary electron imaging mode with a Jeol JSM610 SEM using an accelerating 
voltage of 8kV.
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In-vitro biocompatibility studies
Cell Culture
MDA-MB-231 cells were cultured in DMEM (Gibco, Invitrogen, USA) without pyruvate
supplemented with 10 % heat-inactivated foetal bovine serum (FBS, PAA Laboratories, 
France), 100 U/mL penicillin G and 100mg/mL streptomycin (Gibco, Invitrogen, USA) in a
37 °C, 5% CO2 incubator. Cells were subcultured prior to reaching 60-70% confluence. For 
all experiments, MDA-MB-231 cells were seeded at 5 000 cells per well in 96-well plates in 
200 µL of medium and were allowed to grow for a total of four days. PTX in solution, 
unloaded and PTX-loaded microcapsules diluted to low (LD, 30 capsules/cell), medium (MD,
60 capsules/cell) or high density (HD, 120 capsules/cell) were added to the cells 24 h after 
cell plating. 
Viability and proliferation assays
Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma) assay. At given time intervals, 25 µL of a MTT solution (1.5 mg/mL in PBS) 
were added to each well. The plates were then incubated for 75 min, allowing viable cells to 
reduce the yellow MTT to dark-blue formazan crystals, which were subsequently dissolved in 
200 µL of DMSO. Absorbance of the plate was measured using the microplate reader at 550 +
5 nm and at 650 + 5 nm for the reference wavelength. Cell proliferation over time was 
quantified by counting the total number of cells in each well. Briefly, cells were detached with 
0.25 % Trypsin-EDTA solution for 5 minutes at 37 °C and then quantified using a Malassez 
chamber. Experiments were performed in triplicate, with three 3 wells per condition in each 
experiment. 
Immuno-stainings
Cells were fixed in 3.7 % formaldehyde in PBS for 20 min and permeabilized for 4 min in 
TBS (0.15 M NaCl, 50 mM Tris-HCl, pH 7.4) containing 0.2 % Triton X-100. Slides were 
blocked in TBS containing 0.1 % BSA for 1 h, and were then incubated with monoclonal anti-
tubulin (Sigma) (1:200) antibodies in TBS with 0.2 % gelatin for 30 min. AlexaFluor-643 goat 
anti-mouse IgG (Invitrogen) was then incubated for 30 min. Finally, nuclei were stained using 
????????????????????????????????????????????????????????????????????????????????????????
microscopy (LSM 700, Zeiss) using a 63X objective. Images were acquired with Zen 2010 
software.
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Statistical analysis
All the results are expressed as mean values ± standard error of the mean (SEM). Statistical 
comparisons were based on an analysis of variance (ANOVA) for pairwise comparisons (p < 
0.05 was considered significant).
3.3.3. Results and discussion
To prepare capsules able to selectively entrap hydrophobic molecules within the nanoshell 
through host-guest complexation, HA modified by ?-cyclodextrin was layer-by-layer 
assembled with poly(L-lysine) (PLL), a biocompatible and biodegradable polypeptide, on 
sacrificial colloidal particles (Figures 3.2.A and B). HA was selected as a polyanion due to 
its interesting biological properties. Indeed, HA is a natural glycosaminoglycan, which can be 
specifically recognized by the CD44 receptor that is over-expressed by several cancer cells.
26-
29
For example, to develop breast cancer-targeted drug delivery systems, HA have been 
previously reported as targeting ligand for HA-paclitaxel conjugates,
30
HA-grafted 
liposomes,
29,31
as well as HA-coated poly(D,L-lactide-co-glycolide) nanoparticles
32
.  
Moreover, we previously demonstrated that by using calcium carbonate particles and 
carefully optimizing the assembly conditions, stable non-aggregated (HA/PLL) capsules can
be obtained after crosslinking of the (HA/PLL) film through EDC/sNHS mediated 
amidation.
23
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Figure 3. 2. Strategy for the synthesis of capsules with host-guest complexes in the nanoshells. A) 
Structure of ?-CD, paclitaxel and of the biopolymers (HA-CD and PLL) forming the nanoshell. B) 
Schematic representation of the fabrication of stable (HA-CD/PLL) capsules by crosslinking the (HA-
CD/PLL) multilayer wall before dissolution of the calcium carbonate core templates. C). Partial 
1
H
NMR spectra (400 MHz, 25 °C, D2???????????-?????????????????????????????????-CD (10 mM) and 
paclitaxel added at a concentration 2.5 µM.
HA was functionalized by ?-cyclodextrin using a "thiol-ene reaction". We recently reported 
the potential of this coupling strategy for the modular functionalization of polysaccharides.
22
The reaction consisted in the radical addition in aqueous solution of a ?-cyclodextrin 
derivative monofunctionalized with mercaptopropionic acid onto pentenoate-modified HA. A 
quantitative coupling yield was obtained, leading to a HA-CD derivative with a DS of 9 from 
1
H NMR analysis (Figure SI 3.9). 
1
H NMR spectroscopy was also used to demonstrate the 
complexation of PTX by the natural ?-CD cavity (Figure 3.2.C). It is observed here that PTX 
induces large shifts in the NMR signals of the H-3 and H-5 protons located in the cavity, in 
contrast to the H-2 and H-4 protons located outside the cavity, which clearly demonstrates the 
formation of an inclusion complex. This allows to improve the solubility of paclitaxel in 
water.
2
In fact, PTX is characterized by a low solubility in water (0.4 ?M or 0.34 ?g/mL),33
due to its high hydrophobicity. Therefore, PTX is difficult to administer and requires 
solubilization in a Cremophor
?
EL (CrEL, a polyoxyethylated castor oil) and ethanol mixture 
PLLHACDA)
B)
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O
OH
OHHO
OO
1
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(Taxol
?
), which often leads to adverse side effects such as hypersensitivity reactions
34
. The 
enhancement of the water-solubility of PTX through host-guest interactions with the natural 
?-CD, HA-CD as well as with the heptakis-(2,6-di-O-methyl) ?-CD (DM-?-CD), which has a
30 fold higher aqueous solubility,
35
is shown in Figure 3.3.
Figure 3. 3. Complexation of PTX by HA-CD in aqueous solution: dependence of paclitaxel solubility 
?????????????????????????????????????????-CD, HA-CD and DM-?-CD.
In the case of the natural ?-CD, the water-solubility of PTX is increased ~ fivefold for a 
PTX:?-CD molar ratio of 2.57 × 10-4 ([?-CD] = 6 mM), whereas in the case of HA-CD, the 
same increase is achieved for a PTX:?-CD molar ratio of 1.10 × 10-2 ([?-CD] = 0.16 mM). As 
the inclusion performances of the natural ?-??????????????? ?-CD are of the same order of 
magnitude, the extremely high solubilization potential obtained with HA-CD is related to the 
high solubility in water of the host polysaccharide. As shown in Figure 3.3, a similar 
conclusion could be drawn comparing the solubilization power of the natural ?-CD with that 
of DM-?-CD. 
Assembly of HA-CD (with and without PTX) and PLL in multilayer films was confirmed by 
following (HA-CD/PLL) film deposition on a planar solid substrate by QCM-D (Figure 3.4). 
Film growth was found to be exponential and very similar to that of HA/PLL
23
. Exponential 
growth could be related to the diffusion of PLL within the film architecture as previously 
observed for HA/PLL films
36
.
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Figure 3. 4. Growth of (HA-CD/PLL) films with and without PTX in 0.15 M NaCl (pH 6.5) as 
measured by QCM-D on gold coated crystal.  A) Schematic representation of a layer-by-layer self-
assembled film of HA-CD/PLL. B) Differences in the QCM frequency shifts measured at 15 MHz are 
plotted for each polyanion and PLL layer. Data are given at 15 MHz for HA-CD (?? and HA-CD/PTX 
(????????????????????????????????? ). C) Viscous dissipations for each polyanion and PLL layer.
We then investigated the generation of capsules made from (HA-CD/PLL) films and the PTX 
loading and release from the nanoshell. To this end, Oregon Green labeled PTX (OG-PTX)
was pre-complexed with HA-CD, and the resulting HA-CD/PTX complex was assembled 
layer-by-layer with PLL on calcium carbonate microparticles. After shell cross-linking by 
amide bond formation between HA and PLL and core dissolution by treatment with an 
aqueous solution of EDTA,
23
we successfully obtained hollow capsules. Observations of the 
OG-PTX-loaded capsules made of four (HA-CD/PLL) layer pairs and one HA layer in PBS 
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solution by CLSM confirmed their spherical shape with a size of 4.2 ± 0.2 µm (measured on 
three different capsule batches) and green capsule shells (Figure 3.5). 
Figure 3. 5. Microscopy observations of ((HA-CD/PTX)/PLL)4/HA capsules. A) and B) SEM 
observations of the dried hollow capsules. C) CLSM images of capsules exhibiting a localized green 
fluorescence in their nanoshell due to complexation of OG-PTX by CD molecules in the nanoshell. D) 
Magnified image of a capsule and corresponding fluorescence intensity profile along its diameter, 
confirming the selectivity of OG-PTX incorporation in the nanoshell.
Importantly, the intensity profile along a diameter confirmed the selective incorporation of 
OG-PTX in the shell, as well as its impressive stability after core removal. Furthermore, 
fluorescence microscopy revealed that the drug-loaded capsules were well-dispersed in 
phosphate buffered saline. The SEM images also indicate diameters in the order of ~ 5 µm for 
the dried capsules (Figure 3.5).
We quantified the amount of PTX entrapped in the capsules by fluorescence intensity 
measurements using OG-PTX. After extraction of PTX from the nanoshell with methanol,
21
the effective concentration of PTX in 100 µL of a capsule suspension at 6 × 10
7
capsules per 
mL was found to be 0.914 µM, thus corresponding to ~13 fg of PTX per capsule. New 
batches of PTX-loaded capsules were then treated over time in order to examine the release of 
PTX under simulated physiological conditions (PBS, pH 7.4, 37 °C).
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As can be seen from Figure 3.6, PTX was released according to a two-step process with 
about 20 % of the drug released in the first ~ 4 h, after which there was a steady and 
controlled increase in release for up to 120 h. This sustained release profile, making PTX 
available within a period of five days, is attributed to the CD moieties which entrap the drug. 
Indeed, addition of DM-?-CD in the aqueous suspension of capsules triggered payload release 
with about 80 % of PTX released in ~ 20 h (Figure SI 3.11). The very small initial burst may 
be due to PTX encapsulated in the layers close to the surface rather to non-specific adsorption 
of PTX to HA. Indeed, a similar profile could be obtained in conditions limiting this potential 
phenomenon, i.e. by decreasing the [PTX]/[HA-CD] ratio during LbL film deposition. Taken 
together, these results highlight the ability of the multilayer shell to retain the vast majority of 
PTX within the capsule, which could potentially limit toxicity.
Figure 3. 6. In vitro release profile of paclitaxel from the ((HACD-PTX)/PLL)4/HA capsules in PBS.
We then investigated the capacity of (HA-CD/PLL)4-HA capsules to deliver PTX to MDA-
MB-231 breast cancer cells, a cell line known to be sensitive to PTX
37
. After extraction of 
PTX from the nanoshell, the effective concentration of PTX in 100 µL of a microcapsule 
suspension at 6×10
7
microcapsules/mL was found to be of 0.914 µM, thus corresponding to 
~13 fg of PTX per microcapsules. This value was taken as the highest positive reference for 
tests using PTX in solution (= sPTX). Unloaded and PTX-loaded capsules at different 
densities were added to MDA-MB-231 cell culture and observed over three days. The 
cytotoxicity of the capsules was evaluated by counting the cell number and by measuring the 
cell viability using a MTT assay
21
. Unloaded microcapsules added at increasing 
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concentrations to the cells did not induce any cytotoxic effect, even when added at high 
density (HD, ?120 caps./cell) to the cell culture (Figures 3.7.A,A and SI 3.12). Addition of 
PTX in solution (Figures 3.7.B,B) lead to a significant decrease of cell number and cell 
metabolic activity, as anticipated.
Notably, the PTX-loaded capsules exhibited an important effect on MDA-MB-231 cells 
(Figures 3.7.C,C), strongly limiting their proliferation and metabolic activity. At day 3, the 
number of cells cultivated in the presence of the PTX-loaded capsules was between 7.2 to 8.6 
fold lower than the cells cultivated in the absence of capsules or in the presence of unloaded 
capsules. MDA-MB 231 are known to express CD44,
27,30
one of the hyaluronan receptor.
Indeed, we verified that CD44 is highly expressed by the cancer cells (Figure SI 3.13).
Figure 3. 7. MDA-MB-231 cell response to unloaded microcapsules in solution, to PTX in solution 
and to PTX-loaded (HA-CD/PLL)4/HA microcapsules. MDA-MB-231 cell number and MTT 
metabolic activity were quantified after one and 3 days in the presence of (A,A) unloaded 
microcapsules added at increasing concentrations (LD, MD or HD), (B,B) with PTX added in 
solution to the cells at increasing concentration (i.e. 1/80, 1/40 and 1/20 corresponding to LD, MD and 
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HD); (C,C) PTX-loaded microcapsules added at increasing densities (LD, MD or HD) in the culture 
medium. Data represent mean ± SEM of three wells. Experiments have been performed in triplicate. 
*,p < 0.05. 
In the presence of (HA-CD/PLL)4/HA capsules, we noted that the capsules were in close 
contact with the MDA-MB 231 cells and that several capsules interacted with the cells 
(Figures 3.8.A,A).
Figure 3.8. Microscopic observations of capsule/MDA-MB 231 cell interactions after 24 of culture. 
(A,A) Interaction of HA-containing capsules with MDA-MB-231 cells (nuclei stained in blue, ?-
tubulin in pink). (B) The interaction is inhbited by adding soluble HA to the culture medium.(C-E) 
Immuno-staining of ?-tubulin (pink) and nuclei (blue) in representative MDA-MB-231 cells after 24 h 
of culture (C) in growth medium, (D) in contact with soluble PTX at 0.914 µM and (E) in contact with 
PTX-loaded microcapsules at MD density (60 capsules/cell).
When soluble HA was added to the culture medium, the interaction was fully inhibited 
(Figure 3.8.B). Thus, the interaction of the HA containing capsules and the cancer cells 
appears to be specifically mediated by the CD44 receptor.
MDA-MB231 cells are also known to secrete hyaluronidase, an enzyme known to specifically 
degrade hyaluronan,
38
which is known to be overexpressed in malignant breast cancer cells
39
.
Hyaluronidase is often used as a marker for tumor detection.
40
It may also well be that the 
cells locally degrade the HA-containing microcapsules. 
Next we investigated the effect of PTX on cell internal organization. Indeed, PTX is known to 
drastically affect cell internal structures, especially nucleus and microtubule organization
41
.
Soluble PTXControl capsules PTX loaded capsulesC D E
Control Soluble HAA A B
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We thus examined by immuno-staining the organization of ?-tubulin and of the nucleus 
(Figures 3.8.C-E). On control cells (no capsules or unloaded capsules), the nuclei were intact 
and the microtubule network was well organized (Figures 3.8.C and data not shown). When 
PTX was added in the solution, bundles of microtubules were visible and the nuclei were 
fragmented (Figure 3.8.D). In the presence of PTX-loaded capsules, the fragmentation of the 
nuclei was particularly visible at high density and bundles of microtubules were also visible 
after one day of culture (Figure 3.8.E). This stabilization of the microtubules resulted in 
defects in the cell mitosis and the presence of large, multinucleated cells. As a consequence, 
these deficiencies in cell division lead to a very low cell proliferation, as shown by the 
proliferation assay (Figure 3.7). 
All together, our data suggest that the mechanism of action of the PTX-loaded capsules is 
based on the combined action of several phenomena: specific interactions with MDA-MB 231 
cancer cells via the CD44 receptor, passive transfer of PTX from the CD cavities to the 
hydrophobic lipid membrane of the cells, and local degradation of the capsules by 
hyaluronidase enzyme secreted by these cells. 
3.3.4. Conclusion
In summary, we designed and prepare under mild physiological conditions a new kind of LbL 
capsules containing the hydrophobic anticancer drug paclitaxel in the shell. The synthesis of 
these capsules relied on the very high affinity of PTX to hyaluronic acid grafted with ?-CD 
through inclusion complexation and the ability of HA-CD-PTX to be layer-by-layer 
assembled with poly(L-lysine) on sacrificial colloidal particles. These capsules, combining 
the inclusion capacity of ?-CD and the unique biological properties of HA, exhibited 
controlled release properties and were effective at killing breast cancer cells. This cytotoxicity
seems to be the result of favourable effects related to HA which can specifically interact with 
the cancer cells overexpressing the CD44 receptor, and be degraded by the hyaluronidase 
enzyme secreted by these cells. All together, these results indicate that these HA-CD based 
capsules have potential in controlled delivery of hydrophobic drugs to cancer cells.
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3.4. Supporting information
 
Figure SI 3. 9.
1
H NMR spectrum (400 MHz, 80 °C, 6 mg/mL in D2O) of cyclodextrin-modified 
hyaluronic acid (DS = 9).
 
Figure SI 3. 10. Calibration curve for the fluorescence of OG-PTX in methanol as a function of its 
concentration in solution. 
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The suspension of PTX-loaded capsules was divided in samples of 200 µL. Each sample was 
dispersed in 1.5 mL PBS in an eppendorf at 37°C. At time t = 7 h, 1 mL of PBS release 
medium was removed and a solution (1 mL) of DM-?-CD ([DM-?-CD] = 6 mM) was added. 
After one night, a sample was treated by methanol to extract PTX from the capsules. The 
analysis of the methanolic solution by UV spectrometry indicated that about 80 % of PTX 
was released (experiment performed in triplicate). In order to establish the concentration of 
DM-?-CD required for full complexation of PTX entrapped in the capsule shell, we 
determined the amount of PTX left in the 200 µL of capsules suspension. 
Figure SI 3. 11. In vitro release profile of paclitaxel from the ((HACD-PTX)/PLL)4/HA capsules 
triggrered by addition of  DM-?-CD ([DM-?-CD ] = 6 mM) at t = 7h (red curve). 
 
Chapter 3 Cyclodextrin/Paclitaxel complex in biodegradable capsules for breast cancer 
treatment 
 
 
106 
 
 
Figure SI 3. 12. Brightfield images of MDA-MB-231 cells after 3 days of culture (A) in contact with 
unloaded microcapsules at increasing density, (B) in growth medium in the presence of soluble PTX, 
(C) in contact with PTX-loaded microcapsules at increasing densities.
1/20 1/40 1/80
Soluble PTX
Control capsules
PTX loaded capsules
A
B
C
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Figure SI 3.13. Immuno-staining of the CD44 receptor in MDA-MB-231 cells.
 
3.5. Complementary results
- Synthesis of cyclodextrin grafted HA (HA-CD)
HA-CD was synthesized by a mild and rapid method which was developed in our 
laboratory
22
. Pentenoate-modified HA (HApt) was reacted with thiol-functional CD by thiol-
ene ????????? ?????????? ?????? ??? ?????? ??? ?? ???? ???? ??? ???? ????????? ??? ???? ?????-soluble 
photoinitiator Irgacure 2959 (Scheme CR 3.1). The molar mass of HA is Mw = 200000 g/mol.
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Scheme CR 3. 1. Synthesis of HA-CD by thiol-ene chemistry.
We synthesized three samples of HA-CD (see Table CR 3.1). Their structure was confirmed 
by 
1
H NMR which also allowed to determine the degree of substitution. 
Table CR 3. 1. Chemical characteristics (degree of substitution, DS) of HA-CD samples synthesized 
by thiol-ene chemistry.
Reference
HApt HA-CD
DS
a
pt DSCD
a
DSpt
a
HA-CD1 20 10 10
HA-CD2 20 15 5
HA-CD3 9 9 0
a
derived from 
1
H NMR integration.
The product HA-CD1 was not perfectly soluble in water. This may be attributed to the 
presence of pentenoate groups along the HA-chains. These hydrophobic groups may include 
into the CD cavities, resulting in the formation of intra- or interchain associations. We then 
synthesized HA-CD2 with a lower DS in pentenoate groups. This derivative appeared to be 
soluble in water. However, when we added this solution to CaCO3 particles to prepare 
capsules, formation of aggregates could be observed quasi-instantaneously by optic 
microscopy (Figure CR 3.14. A, B). This was attributed to the formation of inclusion 
complexes between the pentenoate groups and the CD cavities, favoring associations between 
the polysaccharide chains. To decompose these associations, we added sodium adamandane 
acetate (ADAc) (4 molar equivalent of ADAc with respect to CD) in the solution of HA-CD2
and the mixture was left under stirring overnight. Adamandane is known to be a good guest 
X =
HA-CD
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molecule for ?-CD.42 When we added the HA-CD/ADAc mixture to the suspension of CaCO3
particles, no aggregate was observed (Figure CR 3.14.C). However, after addition of the 
second layer of poly(L-lysine), aggregates appeared (Figure CR 3.14.D). This phenomenon 
may be due to the fact that upon rinsing the particles during the LbL assembly, part of ADAc 
molecules is removed from the solution. As a result, new associations between the HA chains
can be formed again. The aggregates became much bigger after the deposition of the next 
HA-CD layer (Figure CR 3.14.E). 
Figure CR 3. 14. Optical microscopy observation after depositing of the first layer of HA-CD2 onto 
CaCO3 template (A) and (B); in the presence of sodium adamandane acetate (C); continued to deposit 
the second layer of PLL (D); continued to deposit the third layer of HA-CD (E).
Finally, we synthesized HA-CD3 in which all pentenoate groups were converted into 
thioethers by the radical addition of the CD-thiol derivative; with this compound, we could 
successfully prepare capsules.
This work showed that the behaviour of polymers in solution has a crucial role in the process
of formation of capsules. The polysaccharide chains must be perfectly soluble in water to be 
able to cover the template as a layer, allowing the deposition of the next layers to obtain 
nanoshells.
5 µm
A) B)
C) D) E)
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3.6. Conclusion
Using hyaluronic acid ?????????????-CD (HA-CD), we have succeeded to incorporate PTX 
selectively in the nanoshell of capsules through inclusion complexation. These PTX-loaded 
capsules exhibited controlled release profile and were effective to reduce the proliferation and 
metabolic activity of MDA MB 231 cells. This cytotoxicity seems to be the result of 
favourable effects related to HA which can specifically interact with the cancer cells 
overexpressing the CD44 receptor. The combination of cyclodextrin/drug complexation and 
LbL polyelectrolyte capsules offers a novel plateform for hydrophobic drug delivery.
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4.1. Résumé (fr)
Ce chapitre présente une nouvelle classe de nanogels à base dacide hyaluronique (HA), 
capables dencapsuler des molécules hydrophobes selon un procédé simple en milieu aqueux. 
Ces nanogels sont obtenus par auto-association en milieu aqueux de dérivés de HA modifié 
par un copolymère thermosensible de diéthylèneglycolméthacrylate et 
doligoéthylèneglycolméthacrylate (poly(DEGMA-co-OEGMA)), induite par une élévation 
de la température à 37 °C. Le copolymer poly(DEGMA-co-OEGMA) a été synthétisé selon le 
procédé de polymérisation RAFT (Reversible Addition Fragmentation chain Transfer). En 
variant la proportion des monomères DEGMA et OEGMA, il est possible dajuster la valeur 
de la LCST (Lower Critical Solution Temperature) sur une large gamme de températures 
allant de 28 à 90 °C. Dans ce travail, le copolymère utilisé (DEGMA:OEGMA = 95:5) 
possède une LCST de 32°C. La température de transition « pelote-nanoparticule » des dérivés 
HA greffés de chaînes poly(DEGMA-co-OEGMA) avec des degrés de substitution (DS, 
nombre de substituants en moyenne toutes les cents unités de répétition) compris entre 3 et 6, 
a été déterminée en mesurant le point de trouble des solutions par spectroscopie UV. Au-
dessus de cette température (voisine de 35 °C pour les trois copolymères « hybrides »), le 
HA-poly(DEGMA-co-OEGMA) conduit en quelques secondes à la formation de 
nanoparticules (ou nanogels). Ces valeurs ont pu être confirmées par des analyses par 
calorimétrie différentielle à balayage. La taille des nanogels dépend du DS du copolymère 
hybride. Des mesures de diffusion dynamique de la lumière ont montré quelle augmente avec 
le DS. 
Ces nanoparticules peuvent solubiliser le Nile Red par simple ajout de quelques microlitres de 
solution de Nile Red dans léthanol à la solution de HA-poly(DEGMA-co-OEGMA) (1 mL) 
et chauffage à 37°C. Lincorporation du Nile Red dans les nanogels a été mise en évidence 
par microscopie de fluorescence qui fait apparaître des tailles homogènes. Afin dévaluer la 
capacité des nanogels à transporter des agents anti-cancéreux faiblement solubles dans leau 
et à les délivrer dans des cellules cancéreuses, les particules de gel ont été chargées en 
paclitaxel (PTX). Nous avons choisi le HA-(poly(DEGMA-co-OEGMA)) ayant un DS de 3 
pour faire les tests avec des cellules CD44+ et CD44- (cellules du cancer ovarien SKOV-3,
surexprimant le récepteur CD44, et cellules de carcinome colique nexprimant pas le CD44 à 
leur surface, respectivement). Les nanogels chargés en PTX ont montré une cytotoxicité plus 
élevée vis-à-vis de la lignée SKOV-3 par comparaison avec la lignée HCT-8/E11, mais 
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également avec le PTX seul et lAbraxane
?
(nanoparticule de paclitaxel lié à de l'albumine 
sérique humaine). Ces résultats suggèrent que ces nanogels pourraient savérer être des 
candidats intéressants pour la libération thérapeutique dans le traitement de cancer.  
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4.2. Introduction
Cellular HA receptors CD44 and RHAMM are overexpressed in many types of cancer cell, 
demonstrating enhanced binding and internalization of HA
1,2
. Consequently, to increase the 
concentration of anticancer agent at the target site and decrease it elsewhere in the body, two 
platforms have been exploited so far: i) direct conjugation of cytotoxic drugs to low-
molecular-mass HA, when HA itself functions as a carrier and a homing device; and ii) 
physical incorporation of a drug within a nanoparticulate carrier to which HA is attached as a 
targeting coating.
In both cases, we talk about HA based architectures of submicrometer size, as only 
nanoobjects can circulate long enough in the blood vessels without elimination by the the 
reticuloendothelial system (RES), accumulate in tumor tissue by the enhanced permeability 
and retention (EPR) effect, and finally be internalized by cells through the endocytic pathway. 
The literature studies reported below demonstrate selective accumulation of the HA 
nanocarriers in tumor tissues likely due to the combination of the EPR effect and the HA 
targeting property. However, accumulation in the RES organs (liver and spleen) is also 
observed because HA molecules expose the nanocarriers to the HA receptors identified in 
these organs.
Figure 4. 1. Structure of Cy5.5-labeled hyaluronic acid nanoparticles in aqueous solution.
3
Kim et al. investigated the in vivo biodistribution of amphiphilic hyalulronic acid-??-cholanic 
acid (HA-CA) self-assembled conjugates labeled with near-infrared fluorescence dye cyanine 
5.5 (Cy5.5) (Figure 4.1).
3,4
It was demonstrated that Cy5.5-labeled HA NPs (average 
diameter = 350-400 nm) are efficiently taken up by SCC7 cancer cells (squamous cell 
carcinoma cell) which overexpress CD44. When the NPs were systemically administrated into 
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the tail vein of tumor-bearing mice, most of the nanoparticles were found in tumor and liver 
sites (Figure 4.2). When comparing with pure HA polymer (Mw = 234400 g/mol), the 
fluorescence intensity of NPs at the tumor site was 4-fold higher which suggests that the 
preferentially accumulation of NPs in tumor tissues is due to a combination of passive 
targeting and active targeting mechanisms. For pure HA polymers, the fluorescence intensity 
quickly vanished in the body after injection, indicating fast clearance from the body.
Figure 4. 2. (a) Near-infrared fluorescence (NIRF) images of dissected organs harvested from SCC7 
tumor-bearing mice after 48 h post-injection. (b) Quantification of the ex vivo tumor targeting 
characteristics of HA-NPs in SCC7 tumor-bearing mice. All data represent mean ± SE (n = 3).
4
Another example was reported by Yadav et al. 
5
who synthesized doxorubicin (DOX)-loaded  
HA self-assembled NPs based on HA-poly(ethylene glycol)-b-polycaprolactone copolymer 
chains (HA-PEG-PCL).
5
In vivo tumor growth inhibition study was carried out in ehrlich 
ascites tumor (EAT) tumor-bearing mice model and compared with NPs made of  methoxy 
poly(ethylene glycol)-b-polycaprolactone (MPEG-PCL)). The mean tumor volume of mice 
after 20 days of treatment with the DOX-loaded HA-PEG-PCL NPs (average diameter = 100-
200 nm) was 3.2, 2.6, and 1.8 times lesser when compared with the mice treated with PBS 
buffer, plain DOX, and DOX-loaded MPEG-PCL NPs respectively (Figure 4.3). Significant 
higher accumulation at the tumor site and tumor growth inhibition by HA-PEG-PCL NPs was 
probably due to the combination of two mechanisms, i.e. selective uptake by EAT cells via 
receptor-mediated endocytosis and EPR effect. The receptor-mediated endocytosis was 
promoted by the HA moiety on the NPs, which was supposed to facilitate the recognition of 
NPs by EAT; after cell surface binding, the NPs might be internalized into the targeted cells. 
In order to evaluate the potential significance of the NPs uptake by various tissues, the 
biodistribution of these NPs was examined in mice. The percentage of distribution to tissue in 
different organs for the free drug and the drug encapsulated in NPs shown higher 
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concentration in tumor in comparison with the pure DOX and DOX-loaded MPEG-PCL NPs. 
But liver and kidney accumulation were observed in all cases (free DOX, DOX-loaded HA-
PEG-PCL NPs and DOX-loaded MPEG-PCL NPs).  
Figure 4. 3. In vivo tumor growth inhibition study of various formulations in EAT-bearing mice.
5
These in vivo examples show the benefits of NPs based on HA for the treatment of tumors. 
Further investigations are also needed to avoid undesirable accumulation in the liver and the 
spleen if these organs are not the targets for the treatment. More sophisticated intelligent 
systems based on HA are still required to navigate bioactive molecules to the target organs/ 
tissues and cells. HA has a great potential to achieve this goal and combat tumor progression 
and metastasis.
In this chapter, we introduced a new class of nanogels based on hyaluronic acid which is able 
to encapsulate hydrophobic molecules in a simple process in aqueous solution. These 
nanogels were obtained by self-assembly of HA derivatives modified with a thermoresponsive 
copolymer. Different derivatives by varying the copolymer degree of substitution were 
synthesized. Their LCST, critical aggregation concentration and size were investigated. In 
order to evaluate the potential of the nanogels for the delivery of hydrophobic anti-cancer 
drugs and examine the role of HA in nanogels to cancer cells, we studied in vitro cell viability 
assay by using two types of cancer cells: human ovarian cancer cells (SKOV-3 cells which are 
positive for the CD44 receptor) and human colorectal cancer cells (HCT-8/E11 cells which 
are negative for the CD44 receptor). This work has been reported in Journal of Materials
Chapter 4 Tunable self-assembled nanogels composed of well-defined thermoresponsive 
hyaluronic acid - polymer conjugates
120
Chemistry, B. In the complementary part, we present the differential scanning calorimetry
results for different thermoresponsive HA derivatives.
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4.3. Publication (J. Mater. Chem. B, DOI: C3TB20283F)
Tunable self-assembled nanogels composed of well-defined 
thermoresponsive hyaluronic acid - polymer conjugates
Jing Jing, David Alaimo, Elly De Vlieghere, Christine Jérôme, Olivier De Wever, Bruno G. 
De Geest, and Rachel Auzély-Velty
Controlled release technology is expected to have a profound impact in many biomedical 
fields including anti-cancer therapy.
6,7
Over the past decade, various self-assembled 
nanoparticulate carriers such as liposomes, polymeric micelles, and nanoparticles have been 
widely explored to improve the water solubility of chemotherapeutic agents, to reduce their 
cytotoxicity and to enhance their therapeutic effectiveness.
7,8
Among these nanomaterials, 
self-assembled gel nanoparticles (also called nanogels) made of hydrophobically modified 
biopolymers are particularly attractive for drug delivery.
9,10
Their size can be easily varied 
from one hundred to several hundred nanometers, their interior network comprising 
hydrophobic domains can be used to incorporate poorly water-soluble drugs and their 
hydrophilic shell can be exploited to control their biological fate and targeting ability. In this 
regard, several studies have focused on the use of hyaluronic acid (HA) for the design of anti-
cancer drug carriers due to its interesting biological properties. Indeed, HA is a natural 
glycosaminoglycan, specifically recognized by the CD44 receptor that is over-expressed by 
several cancer cells including human breast epithelial cells
11
and human ovarian tumor cells
12
.
In this context, self-assembled hydrogels nanoparticles based on the grafting of bulky 
hydrophobic groups (5?-cholanic acid,13,14 pyrene,15 poly(lactic-co(glycolic acid) (PLGA),16
poly(ethylene glycol)- polycaprolactone
17
) on HA were developed for targeted delivery of 
hydrophobic anticancer drugs.
These nanoparticles showed enhanced tumor targeting ability and therapeutic efficacy, 
compared to the free anti-cancer agent. These important features make nanogel particles 
promising platforms for drug delivery with the possibility to introduce other functionalities to 
improve their performances. In particular, one of the limitations of these systems lies in the 
incorporation of drugs, which involves the use of organic solvents to solubilize the polymers, 
or high energy input (i.e. sonication or high shear homogenisation) with potential risk of 
contamination or degradation of the HA-conjugate. 
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In this paper we report on a novel mild and straightforward procedure for the encapsulation 
of hydrophobic molecules that circumvent the above mentioned issues. Our method relies on 
the temperature-triggered self-assembly of tunable thermosensitive HA derivatives. Such 
temperature-triggered approach allows solubilizing all components at room temperature, 
while drug loaded nanogel particles are spontaneously formed above a specific temperature 
(obviously below the physiological temperature of 37 °C), termed the lower critical solution 
temperature or LCST. Above this LCST, hydrophobic domains are formed that allow the 
accumulation of hydrophobic drugs.
The synthesis route for the thermosensitive HA derivatives described in this paper, is based 
on a combination of reversible addition-fragmentation chain transfer (RAFT) polymerization 
allowing to obtain well-defined thermosensitive polymers with tunable LCST and, thiol-click 
chemistry for their subsequent grafting on HA. The thermo-responsive properties of the HA-
conjugates as well as the morphology and size of the obtained nanogels were investigated. 
Finally, these systems were screened in an in vitro setting for the delivery of the hydrophobic 
cancer drug paclitaxel to ovarian cancer cells that overexpress the CD44 receptor. We 
compared the cytotoxicity of PTX-loaded HA NPs with that of Abraxane, a commercially 
available and highly potent PTX nanoformulation that is clinically used in treatment of 
ovarian cancer,
18
to verify the potential of the nanogels in drug delivery.
Structures of the thermosensitive HA precursors, final HA-conjugates, HA-based nanogels 
and synthetic approach are shown in Scheme 4.1. The copolymer used for the modification of 
HA was prepared from diethyleneglycolmethacrylate (DEGMA) and 
oligoethyleneglycolmethacrylate (OEGMA). This copolymer belongs to a new class of 
thermoresponsive polymers which have emerged as a promising alternative to poly(N-
isopropylacrylamide) due to their biocompatibility similarly as common 
poly(ethyleneglycol) (i.e. PEG or PEO)  and their tunable LCST by varying the DEGMA to 
OEGMA monomer composition.
19,20
The copolymer, further denoted as poly(DEGMA-co-
OEGMA) was synthesized in a 95:5 ratio of DEGMA to OEGMA by the RAFT 
polymerization method
21
using 2,2?-azobis(2-methylpropionitrile) (AIBN) as initiator and 4-
cyano-4-(phenylcarbonothioylthio)pentanoic acid as chain transfer agent (CTA). The RAFT 
method offers the advantage of high end-group fidelity. Moreover, this end-group can easily 
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Scheme 4. 1. (A) Synthesis of poly(DEGMA-OEGMA) by the RAFT polymerization method. (B) 
Synthesis of thermosensitive HA conjugates by grafting poly(DEGMA-co-OEGMA) (blue chains) 
onto HA (green chains). (C) Schematic representation of temperature-triggered self-assembly (blue 
chains becoming red) of the HA-conjugates into nanogels that allow accumulation of hydrophobic 
compounds (yellow discs).
be converted to a thiol that can then be readily conjugated to maleimides via Michael addition 
to construct complex structures.
22
Experimental details are listed in Supporting Information. A 
good correlation between the targeted degree of polymerization (DP) and the experimental 
molecular weight determined via size exclusion chromatography (SEC) as well as the narrow 
C
Poly(DEGMA-co-OEGMA)
Hyaluronic acid
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polydispersity (i.e. PDI ~ 1.1) indicates excellent control over the RAFT polymerization. The 
LCST in water of poly(DEGMA-co-OEGMA) (1 g/L) was determined by measuring the 
turbidity as a function of the temperature and was found to be 32 °C, which is in accordance 
to the values reported in literature.
19
Subsequently, poly(DEGMA-co-OEGMA) was grafted 
onto HA (Mw = 200000 g/mol). Therefore, 10% of the HA carboxylic acid groups were first 
modified with aminoethylmaleimide (AEM) via carbodiimide mediated amide-coupling. After 
purification, the resulting HA-AEM was reacted with poly(DEGMA-co-OEGMA) on which 
the RAFT end-group was converted to a thiol by aminolysis using n-butylamine. By varying 
the poly(DEGMA-co-OEGMA) to HA-AEM ratio, HA-poly(DEGMA-co-OEGMA) 
conjugates with different degree of substitution (DS; defined as the number of poly(DEGMA-
OEGMA) chains per 100 disaccharide repeating units) were synthesized. After 12 h reaction, 
an excess of mercaptopropionic acid (MPA) was added to convert the remaining maleimide 
units to a carboxylic acid. The conjugates were subsequently purified via dialysis and their 
structural integrity was ascertained using 
1
H NMR analysis (Figure SI 4.6 in Supporting 
Information). This revealed a DS of 3, 4 and 6 for the respective conjugates, which 
corresponds to approximately 60 % of the targeted DS. Successful grafting was further 
confirmed by FT-IR spectroscopy (Figure SI 4.7 in Supporting Information). In the IR 
spectra of the HA conjugates, a significant change in the relative intensities of the band at 
1720 cm
-1
corresponding to the carbonyl stretching of the methacrylate comonomer units and 
of the band at 1602 cm
-1
attributed to the asymmetric carbonyl stretch from the carboxylate 
group of HA can be observed with an increasing degree of substitution.
The thermo-responsive properties of the HA-poly(DEGMA-co-OEGMA) conjugates are 
shown in Figure 4.4.A. The LCST values of the respective HA-poly(DEGMA-co-OEGMA) 
conjugates, as determined via turbidity measurements, were all situated around 35 °C, 
independent on the degree of substitution of the conjugates. Dynamic light scattering 
performed at 40 °C revealed a monomodal distribution of the hydrodynamic radius (Rh) of the 
temperature-induced assemblies (Figure 4.4.C). These data demonstrate that poly(DEGMA-
co-OEGMA) modified HA is able to assemble into nanogel structures by a temperature-
induced mechanism. This was additionally supported by comparing the two-dimensional 
1
H-
13
C HSQC NMR spectra of HA-poly(DEGMA-co-OEGMA)  recorded at different 
temperatures (Figure SI 4.8 in Supporting Information). A drastic decrease of the intensity of 
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the proton signals of the grafted copolymer could be observed by heating the samples from 25 
to 40 °C. 
Figure 4.4. Temperature-responsive behavior of the HA-poly(DEGMA-co-OEGMA) conjugates in 
PBS (pH 7.4 and 0.15 M NaCl). (A) Transmittance plots as a function of temperature for HA-
poly(DEGMA-co-OEGMA) with a DS of respectively 3 (?), 4 (?) and 6 (?) at a concentration Cp =
5 g/L. (B) Intensity ratios (I338/I333) calculated from pyrene excitation spectra for HA-poly(DEGMA-
co-OEGMA) with a DS of respectively 3 (?), 4 (?) and 6 (?). (C) DLS size distribution of HA-
poly(DEGMA-co-OEGMA) nanogels at 40 °C (Cp = 0.5 g/L). The average Rh values are 95 nm (DS 
3), 105 nm (DS 4) and 159 nm (DS 6). (D) Fluorescence microscopy image at 40 °C of HA-
poly(DEGMA-co-OEGMA) nanogels (DS 3) loaded with Nile Red (Cp = 2 g/L). (E) Scanning electron 
microscopy image of HA-poly(DEGMA-co-OEGMA) nanogels (Cp = 2 g/L; DS 4).
In contrast, the HA proton signals which were masked by the copolymer proton signals at 25 
°C became clearly visible at 40°C, thereby allowing assignment of the protons/carbons of the 
HA backbone. Interestingly, the Rh was found to vary between 95 and 159 nm, depending on 
the DS of the HA-poly(DEGMA-co-OEGMA) conjugates, with a higher DS leading to higher 
Rh. This is in contrast to structures assembled from HA modified with bulky hydrophobic 
groups (such as e.g. 5?-cholanic acid).13 Indeed, the type of assembly formed by 
hydrophobically modified polyelectrolytes (such as HA) is reported to strongly depend on 
whether inter- or intra-chain hydrophobic association occurs.
23
Polyelectrolytes with bulky 
hydrophobic groups and/or a high degree of substitution exhibit a strong tendency towards 
intra-molecular association, resulting in single-molecule assemblies. 
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The HA-poly(DEGMA-co-OEGMA) conjugates reported in the present paper have long 
temperature-sensitive pending moieties that are likely to entangle with each other when 
surpassing the LCST, forming both intra- and inter-chain entanglements. Therefore, we 
speculate that with increasing DS, the extend of inter-chain binding increases, leading to 
increase in size of the formed nanogels. Here we have deliberately chosen to use a low DS to 
obtain nanogels which are predominantly composed of HA, as we aim to exploit further on 
the CD44-receptor binding properties of HA. Additionally, when attempting to graft an 
elevated amount of poly(DEGMA-co-OEGMA), phase-separation between poly(DEGMA-co-
OEGMA) and HA in the reaction mixture is likely to occur. 
Importantly, these nanogels are stable over time (when kept above the LCST) and do not 
further aggregate. Additionally, nanogel formation was found to be reversible as the solutions 
turned clear upon cooling and became turbid upon re-heating. The critical aggregation 
concentration (CAC) of the HA-poly(DEGMA-co-OEGMA) conjugates was determined by 
fluorescence spectroscopy using pyrene as fluorescent probe.
24
Pyrene was simply added as 
concentrated ethanolic solution to the respective HA-poly(DEGMA-co-OEGMA) solutions. 
Figure 4.4.B ???????????????????????????????????????????????????????????????????????????????
These curves were recorded, in phosphate buffered saline (i.e. pH 7.4 and 0.15 M NaCl) at 37 
°C, thus reflecting physiologically relevant conditions. The CAC was estimated from the 
threshold concentration (as shown in Figure SI 4.9 in Supporting Information) that yielded 
self-assembled nanogels and yielded values of 0.02 g/L for HA-poly(DEGMA-co-OEGMA) 
conjugates with a DS of respectively 3, and 0.01 g/L for a DS of 4 and 6. The slight decrease 
in CAC with increasing DS, might contribute to the hypothesis that a higher DS of pending 
poly(DEGMA-co-OEGMA) moieties facilitates the formation of inter-chain entanglements.
The formed nanogels were visualized by adding Nile Red (as concentrated ethanolic 
solution) to a solution of HA-poly(DEGMA-co-OEGMA) followed by imaging on a 
fluorescence microscope equipped with a controlled heating stage set at 40 °C. Nile Red 
exhibits a dramatic increase in fluorescence intensity when it is accommodated in a 
hydrophobic environment compared to a hydrophilic environment.
25
As shown in Figure 
4.4.D, spherically shaped particles are formed that exhibit strong fluorescence. These findings 
demonstrate that the HA-poly(DEGMA-co-OEGMA) nanogels can encapsulate hydrophobic 
molecules in the hydrophobic domains that are formed above the LCST of the HA-
poly(DEGMA-co-OEGMA) conjugates. Further proof of the formation of solid nanogels was 
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obtained from scanning electron (SEM) analysis by drying at 45 °C a heated (also at 45 °C) 
droplet of HA-poly(DEGMA-co-OEGMA) in pure water (to avoid recrystalization of PBS 
salts) onto mica, followed by SEM imaging. Figure 4.4.E shows the formation of slightly 
deflated spherical particles. Control experiments with non-modified HA that was deposited 
onto mica under identical conditions as the nanogels did not show the formation of particles 
(Figure SI 4.10 in Supporting Information).
In the last part in this work, we evaluated the potential of the nanogels for the delivery of 
hydrophobic anti-cancer drugs. As these nanogels are based on HA, which binds to the CD44 
receptor, they hold potential for targeted delivery to ovarian cancer cells that often 
overexpress this receptor. First we incubated human ovarian cancer cells (SKOV-3 cells; 
these are positive for the CD44 receptor as confirmed by Western blotting (Figure SI 4.11 in 
Supporting Information) with Nile Red loaded nanogels at 37 °C, to assure the HA-
poly(DEGMA-co-OEGMA) conjugates to be in the self-assembled nanogel state. For these 
biological experiments we have chosen HA-poly(DEGMA-co-OEGMA) conjugates with a 
DS of 3 as these yielded the smallest particles which would favor their cellular internalization. 
As shown by fluorescence microscopy (Figure 4.5.A), the Nile Red payload is being 
internalized by the SKOV-3 cells.
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Figure 4.5. (A) Confocal microscopy images of human ovarian cancer cells (SKOV-3) incubated with 
Nile Red loaded HA-poly(DEGMA-co-OEGMA) (DS 3) nanogels. The panel A1 depicts the red 
fluorescence channel and the panel A2 depicts the DIC channel. (B) Cell viability of SKOV-3 and 
HCT/8E-11 cells treated with controls and the respective PTX formulations. (n=5; *: p<0.001; n.s.: not 
statistically significant)
Secondly, we loaded the HA-poly(DEGMA-co-OEGMA) nanogels with paclitaxel in 
identical fashion as we did for pyrene and Nile Red earlier in this paper, i.e. by simply adding 
a concentrated methanolic solution of PTX to a HA-poly(DEGMA-co-OEGMA) solution at 
room temperature followed by increasing the temperature to 37 °C. We opted for a PTX 
concentration of 30 µM in the HA-poly(DEGMA-co-OEGMA) stock solutions, resulting in 
an effective PTX concentration of 25 µM in the HA-poly(DEGMA-co-OEGMA) nanogels 
(Entrapment efficiency = 80 %, see Supporting Information). Next we evaluated whether 
formulating PTX in HA-poly(DEGMA-co-OEGMA) nanogels enhances the potency of PTX 
as well as providing a higher selectivity towards CD44 positive cells. Therefore in a first 
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series of preliminary experiments we used Abraxane to determine the optimal concentration 
range of PTX to eradicate SKOV-3 cells in an in vitro setting. 
These experiments indicated that Abraxane treatment of SKOV-3 cells for 2.5 h followed 
by replacement of the medium and one week culturing and finally MTT analysis of the cell 
viability, induced a 40% reduction of the cell viability for a PTX concentration of 0.1 µg/mL 
(Figure 4.5.B). Subsequently, we treated SKOV-3 cells with PTX loaded HA-poly(DEGMA-
co-OEGMA) nanogels at a PTX concentration of 0.1 µg/mL. As controls we took PTX in 
PBS, PTX in PBS mixed with native  non-modified  HA and Abraxane. Note that for these 
experiments always identical concentrations of PTX were used. Pure culture medium 
(DMEM) and DMSO were used as respectively negative and positive control. Furthermore, 
besides SKOV-3 cells, that overexpress the CD44-receptor, we also used HCT-8/E11 cells 
that do not overexpress the CD44 receptor (as verified by Western blotting (Figure SI 4.11 in 
Supporting Information). As shown in Figure 4.5.B, encapsulation of PTX in HA-
poly(DEGMA-co-OEGMA) nanogels strongly enhances the potency of PTX compared to 
PTX in PBS or PTX mixed with native HA. Firstly, PTX loaded HA-poly(DEGMA-co-
OEGMA) nanogels are even more potent than Abraxane. Secondly, when comparing the 
effect of PTX treatment on SKOV-3 and HCT-8/E11 cells a reduction of potency of the PTX 
loaded HA-poly(DEGMA-OEGMA) nanogels is observed while the potency of Abraxane 
treatment is similar for both cell lines. Figure SI 4.12 in Supporting Information shows cell 
viability data recorded for PTX concentrations of 0.1 µg/ml and 0.2 µg/ml, respectively, 
demonstrating that the same extend of SKOV-3 cell eradication, requires a two-fold increase 
of PTX concentration formulated as Abraxane, relative to PTX loaded in HA-poly(DEGMA-
co-OEGMA) nanogels. Taken together, these findings suggest that formulating PTX in the 
thermosensitive HA-nanogels allows significant dose sparing which is highly important in 
reducing cytotoxic side-effect to healthy tissues.
Summarizing, we have shown for the first time that grafting thermosensitive polymers onto 
hyaluronic acid allows temperature-triggered assembly into nanogels, with the particle size 
depending on the degree of substitution. Hydrophobic molecules (dyes and drugs) could be 
loaded into these nanogels by simple mixing. Nanogel-mediated delivery of the hydrophobic 
anti-cancer drug paclitaxel showed enhanced potency and selectivity in the eradication of 
CD44 positive human ovarian cancer cells in vitro. These results suggest that these nanogel 
carriers hold great potential for the delivery of chemotherapeutics in anti-cancer therapy. 
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Future work will focus on in vivo delivery of PTX loaded nanogels to xenografted ovarian 
tumours.
4.4. Supporting information
Materials
The sample of bacterial sodium hyaluronate (HA) with a weight-average molecular weight of 
200 kg/mol was supplied by ARD (Pomacle, France). The molecular weight distribution and 
the weight-average molecular weight of this HA sample were determined by size exclusion 
chromatography using a Waters GPC Alliance chromatograph (USA) equipped with a 
differential refractometer and a light scattering detector (MALLS) from Wyatt (USA); the 
solution was injected at a concentration of 5 ? 10-4 g/mL in 0.1 M NaNO3. The polydispersity 
index (PDI) of the sample is Mw/Mn ~ 1.5. 4-Cyano-4-(phenylcarbonothioylthio)pentanoic 
acid, di(ethylene glycol) methyl ether methacrylate (DEGMA), oligo(ethylene glycol) methyl 
ether methacrylate (OEGMA, Mn = 475 g mol
-1
), 2,2?-azobis(2-methylpropionitrile) (AIBN),
N-(2-aminoethyl)maleimide trifluoroacetate salt (AEM), 3-mercaptopropionic acid (MPA)
and, all other chemicals were purchased from Sigma-Aldrich-Fluka and were used without 
further purification. The water used in all experiments was purified by a Elga Purelab 
purification system, with a resistivity of 18.2 M??cm.
Methods
1
H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz with 
deuterium oxide (D2O) or deuterated chloroform (CDCl3) (SDS, Vitry, France) as a solvent.
Two-dimensional HSQC experiments were acquired using 2K data points and 256 time 
increments. The phase sensitive (TPPI) sequence was used and processing resulted in a 
1K?1K (real-real) matrix. Chemical shifts are given relative to external tetramethylsilane 
(TMS = 0 ppm) and calibration was performed using the signal of the residual protons or 
carbons of the solvent as a secondary reference. Fourier transform infrared spectroscopy (FT-
IR) measurements were performed on a RX1 spectrometer (Perkin Elmer, UK) with 
horizontal ATR accessory. For each sample, 32 scans were recorded between 4000 and 400 
cm
-1
with a resolution of 2 cm
-1
using Spectrum software V 5.0.0. The spectrum analysis was 
performed by using Origin 7.0 software.
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The molecular weight and polydispersity index of the block copolymer was measured by size-
exclusion chromatography (tetrahydrofuran, flow rate: 1 mL/min) at 40 °C with a Waters 600 
liquid chromatrograph equipped with a differential refractometer and a light scattering 
detector (MALLS) from Wyatt. 
The transmittance of the polymer solutions at 500 nm was measured on a Varian Cary 50 
UV/Vis Spectrophotometer equipped with a temperature controller.
Pyrene emission spectra were measured on a Perkin Elmer luminescence LS 50B spectrometer 
between 360 and 500 nm. Pyrene solubilized in ethanol was added up to a concentration of 
10
-7
M in the polymer solution and excited at 334 nm. The I1/I3 ratio of the intensities of the
first and the third peaks of fluorescence spectrum of pyrene was used to study the formation 
of hydrophobic domains resulting from the association of the copolymer chains.
Dynamic light scattering (DLS) experiments were carried out using an ALV laser goniometer,
which consists of a 22 mW HeNe linear polarized laser operating at a wavelength of 632.8 
nm, an ALV-5000/EPP multiple ??digital correlator with 125 ns initial sampling time, and a
temperature controller. The accessible scattering angles range from 50?????????? The aqueous 
solutions of the HA-poly(DEGMA-co-OEGMA) conjugates (0.5 g/L in PBS) were filtered 
directly into the glass cells through 0.22 ?m MILLIPORE Millex LCR filter. Data were 
collected using digital ALV Correlator Control software and the counting time for measuring 
the elastic or the quasi-elastic scattering intensities varied for each sample from 180 to 300 s. 
The relaxation time distributions, A(t), were in the sequence obtained using CONTIN analysis 
of the autocorrelation function, C(q,t). Diffusion coefficients D were calculated from 
following equation:
?
?
q2
q?0 ? D (1)
where ??is relaxation frequency (? = ?-1), and q is the wave vector defined as following 
equation:
??????? 2sin4 ???nq (2)
where ? is the wavelength of the incident laser beam (632.8 nm), ? is the scattering angle, and 
n is the refractive index of the media. Consequently, the hydrodynamic radius (Rh) was 
calculated from the Stokes-Einstein relation as follows:
Chapter 4 Tunable self-assembled nanogels composed of well-defined thermoresponsive 
hyaluronic acid - polymer conjugates
132
?
Rh ? kBT
6??? q2 ? kBT6??D (3)
where kB is the Boltzmann constant, T is the temperature, and ? is the viscosity of the
medium.
Confocal Laser Scanning Fluorescence Microscopy (CLSM) was performed on a Leica SP5 
confocal microscope equipped with a 63x oil immersion objective.
Synthesis of Poly(DEGMA-co-OEGMA)
A mixture of 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (0.114 g, 0.4066 mmol), 
DEGMA (8 g, 42.50 mmol), OEGMA (1.06 g, 2.23 mmol) and AIBN (0.004 g, 0.024 mmol) 
was dissolved in toluene (20 mL) and N2 gas was purged for 30 min to the solution. The
reaction vessel was sealed and then put into a pre-heated oil bath at 80 °C for 21 h 30. The 
resulting mixture was precipitated in cold diethyl ether (200 mL) to give the random 
copolymer as a waxy liquid in 82 % yield (6.56 g). SEC (THF) Mn: 16900 g/mol. PDI: 1.1.
1
H
NMR (400 MHz, CDCl3??? (ppm) : 7.47, 7.38 (H of aromatic ring), 4.11 (CH2OCO), 3.69-
3.57 (CH2O), 3.40 (CH3O), 1.92-1.63 (CH2), 1.26-0.88 (CH3).
Synthesis of HA-poly(DEGMA-co-OEGMA)
The first step consisted in the aminolysis reaction of poly(DEGMA-co-OEGMA) with n-
butylamine, which leads to thiol-capped copolymer chains. Thus, the copolymer (1 g) was 
introduced in a flask placed under a nitrogen atmosphere. CH2Cl2 (10 mL) was added, and 
after complete dissolution of the polymer, n-butylamine (10 mL, 0.1 mol) was added to the 
solution. The reaction mixture was stirred for 10 min at room temperature. During this period, 
the originally pink solution became pale yellow. A waxy liquid (0.80 g) was recovered by 
precipitation in diethyl ether. The thiol-capped copolymer was then reacted with HA-AEM 
(DS = 10). This derivative was prepared by dissolving HA (0.60 g, 1.49 mmol) in pure water 
to a concentration of 6 g/L. N-(2-Aminoethyl)maleimide trifluoroacetate salt (0.285 g, 1.12 
mmol) and N-hydroxysulfosuccinimide sodium salt (0.162 g, 0.75 mmol) were added to this 
solution. The pH of the reaction medium was then adjusted to 4.75. Next, an aqueous solution 
of N-(3-dimethylaminopropyl)-N?-ethylcarbodiimide hydrochloride (0.054 g, 0.28 mmol) was 
added slowly to the mixture. The pH of the reaction medium was maintained at 4.75 by 
addition of 0.5 M HCl. The reaction was allowed to proceed at room temperature until no 
further change in pH was observed (i.e. 4 hours). The modified HA was purified by 
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diafiltration through a membrane Amicon YM 30. The diafiltration was stopped when the 
filtrate conductivity was lower than 10 ?S. Next, the solution of the HA-AEM derivative was 
diluted with pure water to obtain a final volume of 360 mL, and divided into portions of 60 
mL (i.e. into portions of 0.1 g of HA-AEM). After addition of a 10-fold concentrated solution 
of PBS (6.6 mL) to one of the portions, poly(DEGMA-co-OEGMA) (0.412 g, 0.024 mmol) 
was added and the mixture was stirred at 4 °C (pH 7.4) for 12 h. After addition of MPA (21 ?L, 0.24 mmol) and stirring again at 4 °C for 6 h, the HA-poly(DEGMA-co-OEGMA) was 
purified by diafiltration through a membrane Amicon YM 30. The product was then 
recovered by freeze-drying as a white powder in (0.340 g) with a DS in copolymer chains of 6 
from 
1
H NMR integration. 
The synthesis of the other poly(DEGMA-co-OEGMA) samples with DS=3 and 4 was 
performed using a similar procedure, with different amounts of the copolymer, i.e. 0.206 and 
0.288 g, respectively, per HA-AEM portion.
Figure SI 4. 6.
1
H NMR spectrum (400 MHz, 6 mg/mL in D2O, 25 °C) of HA-poly(DEGMA-co-
OEGMA), DS = 6. *These signals mask the H-2, H-2, H-3, H-3, H-4, H-4, H-5, H-5 and H-6
proton signals of HA.
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Figure SI 4.7. FT-IR spectra of initial HA, poly(DEGMA-co-OEGMA) and of the HA-copolymer 
with DS = 3, 4 and 6.
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Figure SI 4.8. 1D 
1
H NMR and 2D 
1
H-
13
C HSQC NMR spectra (400/100 MHz, 20 mg/mL in D2O) of 
HA-poly(DEGMA-co-OEGMA) with DS = 3 at 25 °C (A) and 40 °C (B). The HA protons located in 
the ? 3.1-3.6 ppm region, which were masked by the copolymer proton signals in the 1D spectrum at 
25 °C, became clearly visible at 40°C due to the decrease of the proton signals of the copolymer. The 
assignment of the carbon signals of HA is given in spectrum B and the cross-peaks corresponding to 
the copolymers are marked in red.
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Figure SI 4. 9. Plots of the intensity ratios of I338/I333 for three different HA-poly(DEGMA-co-
OEGMA) from pyrene excitation spectra as a function of concentration.
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Scanning electron microscopy observation of nanogels. 
Drops of solutions in pure water of respectively poly(DEGMA-co-OEGMA) modified HA 
and non-modified HA, pre-heated at 45 °C were deposited onto mica-coated copper stubs 
(also pre-heated at 45 °C) and allowed to air drying at 45 °C. The samples were coated by 2 
nm of electron beam evaporation carbon and observed in secondary electron imaging mode 
with a Zeiss ultra 55 FEG-SEM (CMTC-INPG, Grenoble) at an accelerating voltage of 3 kV, 
using an in-lens detector.
Figure SI 4. 10. Scanning electron microscopy images of (A) poly(DEGMA-co-OEGMA) modified 
HA (DS 4) and (B) non-modified HA.
Encapsulation of hydrophobic molecules in thermosensitive HA Nanogels.
To a solution (0.5 mL) of HA-poly(DEGMA-co-OEGMA) (DS = 3) at 2 g/L at room 
temperature, a solution of Nile Red in ethanol (1 mg/mL or 3.14 mM) was added to obtain a 
NR concentration of 10 ?M. The mixture was stirred in a water bath at 40 °C and ethanol was 
allowed to evaporate slowly under a stream of nitrogen. 
To solutions (0.5 mL) of HA-poly(DEGMA-co-OEGMA) (DS = 3) at 2 g/L at room 
temperature, a solution of paclitaxel in methanol (1 mg/mL or 1.17 mM) was added to obtain 
PTX concentrations of 80, 60, 30 and 20 ?M. The mixtures were stirred in a water bath at 40 
°C and methanol was allowed to evaporate slowly under a stream of nitrogen. The solutions 
containing PTX at 30 and 20 ?M remained clear whereas that containing PTX at 60 and 80 
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?M contained small particles in dispersion. In vitro cell experiments were thus conducted 
using the 30 µM sample for which the entrapment efficiency (EE) was found to be 80 %. It 
was determined by centrifugation (10000 rpm for 10 min) to remove non-encapsulated PTX 
and quantification by high-performance liquid chromatography (HPLC) of PTX loaded in the 
nanogels. To this end, PTX was extracted from the nanogels with acetonitrile. Isocratic 
reverse-phase HPLC was performed using a Nucleodur C18 column at 25 °C. The mobile 
phase consisted of acetonitrile/water (45:55, v/v) with a flow rate of 0.9 mL/min. The signals 
were recorded by UV detector at 227 nm. A calibration line was conducted to determine the 
PTX concentration in the range of 0.140 ?M, and the r2-value of peak area against PTX 
concentration was at least 0.999.
The encapsulation efficiency was calculated based on the following equation :
EE (%) = weight of PTX in nanogels/weight of the feeding PTX ? 100%
In vitro cell culture assays.
Cell lines. Human colorectal cancer cell line HCT-8/E11,(Vermeulen, S.J.; Bruyneel, E.A.; 
Bracke, M.E.; Debruyne, G.K.; Vennekens, K.M.; Vleminckx, K.L.; Berx, G.J.; Vanroy, 
F.M.; Mareel, M.M. Cancer Research 1995, 55, 4722-4728) and human ovarium cancer cell 
line SKOV-3 (ATCC, Manassas, VA) were maintained in DMEM (Invitrogen, Carlsbad, CA)
supplemented with 10% FBS and antibiotics.
Protein analysis. For Western blot analysis cell lines were harvested in Laemmli lysis buffer. 
Cell lysates (25 µg) were suspended in reducing sample buffer and boiled for 5 minutes at 95 
°C. Samples were run on 8% SDS-PAGE, transferred to PVDF membranes, blocked in 5% 
non-fat milk in PBS with 0.5% Tween-20, and immunostained with the following primary 
antibodies: mouse monoclonal anti-CD44s (clone BBA10) (R&D systems, Minneapolis, 
MN), and mouse monoclonal anti-tubulin (Sigma-Aldrich, St.-Louis, MO). Figure SI 4.11
shows a photograph of the obtained blots.
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Figure SI 4.11. Western blot analysis of cell lysates.
Cell viability assay. Cells were seeded at a density of 10000 cells / well into 24-well plates. 
After 24 h, cells were treated for 2.5 h with PTX dispersed in PBS, PTX mixed with non-
modified HA, PTX formulated as Abraxane (purchased from Celgene) and PTX formulated in 
thermosensitive HA nanogels. The latter formulation was kept at 40 °C to assure the presence 
of nanogels. The cells were thermostated at 37 °C during the addition of the respective 
samples, again to assure the HA to be preset as nanogels. All experiments were run in five 
fold. Cultures were washed and conditioned with fresh medium for 6 days. The effect on cell 
viability was determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) metabolic viability assay. This is a sensitive, quantitative and reliable assay 
that measures the conversion of the yellow MTT substrate into a dark blue formazan salt by 
cellular dehydrogenases. Optical densities were obtained by measuring the dissolved 
formazan crystals with a spectramax paradigm multi-mode microplate detection platform 
(Molecular devices, Sunnyvale, CA) at 570 nm. Figure SI 4.12 shows a resume of the cell 
viability data obtained from adding different concentrations of PTX.
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Figure SI 4. 12. Cell viability of SKOV-3 and HCT/8E-11 cells treated with controls (no PTX added) 
and the respective PTX formulations.
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4.5. Complementary results 
- Analysis of the thermal behavior of aqueous solutions of 
the HA-poly(DEGMA-co-OEGMA) derivatives by 
differential scanning calorimetry
In order to have a better insight into the self-association mechanism of the HA-poly(DEGMA-
co-OEGMA) copolymer, differential scanning calorimetry (DSC) experiments were 
performed on solutions of the HA-poly(DEGMA-co-OEGMA) derivatives having different 
DS. The samples prepared in PBS were analyzed on a microDSCIII (Setaram). The difference 
in heat flow between the sample and the reference (PBS solution) was observed by increasing 
the temperature from 10 °C to 60 °C at a rate of 0.25 °C/min and then, decreasing the 
temperature from 60 °C to 10 °C.
Figure CR 4. 13. DSC curve of HA-poly(DEGMA-co-OEGMA) (DS = 3) at a concentration of 5 g/L 
in PBS buffer. The temperature increased from 10 °C to 60 °C and then, descended from 60 °C to 
10°C at 0.25 °C/min.
In all experiments, endothermic peaks were produced upon heating the solutions as a result of 
the self-association of the HA-poly(DEGMA-co-OEGMA) copolymers caused by the 
dehydration of the poly(DEGMA-co-OEGMA) chains (Figure CR 4.13). Table CR 4.1.
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presents les thermodynamics characteristics of solutions of the hybrid copolymers and of the 
poly(DEGMA-co-OEGMA) copolymer derived from DSC measurements. We found that the
temperature of the beginning of the coil-to-nanoparticle transition was identical for all the 
three samples (DS 3, 4 and 6) and corresponds to the LCST value of the poly(DEGMA-co-
OEGMA) copolymer (32 °C). The temperature at the maximum of the endothermic peak was 
in good agreement with the cloud point determined from the transmittance measurements 
(~35°C) (Figure 4.1.A). Interestingly, the values of this temperature decreases as the DS of 
the hybrid copolymers increases, indicating stronger hydrophobic interactions for the HA 
derivatives containing higher amounts of poly(DEGMA-co-OEGMA) chains. The relative 
enthalpy value (?H value per poly(DEGMA-co-OEGMA) chain) obtained for solutions of the 
HA derivatives by DSC measurements was closed to the ? H value obtained from the 
poly(DEGMA-co-OEGMA) copolymer (?H ~ 35 kJ mol-1).
Table CR 4. 1. Thermodynamic characteristics obtained by DSC measurements in PBS buffer from 
10°C to 60°C at 0.25 °C/min.
Sample
C
(g L
-1
)
TTr
a
(°C)
Tmax
b
(°C)
?H c
(J g
-1
)
ncopolymer
d
(mol)
?H/ncopolymer
(J mol
-1
)
e
HA-poly(DEGMA-co-
OEGMA)   DS 3
5 32.15 36.23 0.0571 1.63×10
-7
350594
HA-poly(DEGMA-co-
OEGMA)   DS 4
5 32.17 36.09 0.0643 1.83×10
-7
350757
HA-poly(DEGMA-co-
OEGMA)   DS 6
5 32.20 35.88 0.0745 2.10×10
-7
355365
10 31.30 34.83 0.1406 4.19×10
-7
335331
poly(DEGMA-co-
OEGMA)
3 32.06 36.00 0.0623 1.77×10
-7
351164
1.5 33.00 36.64 0.0322 8.87×10
-8
363001
a
Temperature of the beginning of the coil-to-nanoparticle transition;
b
Temperature at the maximum of 
the endothermic peak; 
c
Enthalpy value for 1 g of sample; 
d
Amount of copolymer on mole correspond 
to 1 mL of sample; 
e
Relative enthalpy value per one mole of copolymer.
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4.6. Conclusion
We have synthetized thermoresponsive hyaluronic acid derivatives. Their LCST value 
revealed the LCST of grafted copolymer. At the body temperature, HA-copolymer was shown 
to self-assemble into nanogels with the ability to encapsulate hydrophobic molecules into 
their hydrophobic domain. The size of nanogel was found to vary depending on the DS of 
copolymer. In vitro cell viability studies showed that with incorporating the hydrophobic anti-
cancer drug paclitaxel, the nanogels exhibited high effective and selectivity in the eradication 
of CD44 positive human ovarian cancer cells. These results suggest that these temperature-
triggered nanogels hold great potential for hydrophobic drug delivery.
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General conclusion (en)
Polysaccharides, due to their outstanding merits such as safety, non-toxicity and
biodegradability, have received more and more attention in the field of drug delivery.
Hyaluronic acid is a highly hydrated polysaccharide of great biological interest. It can be 
easily chemically modified, resulting in many kinds of functional polysaccharide derivatives. 
In this thesis, we have synthesized different types of HA derivatives in aqueous media. These 
comprise alkylated HA derivatives, HA-cyclodextrin conjugates, and hybrid copolymers 
made of HA and of a thermosensitive ethylene glycol copolymer.
The alkylated HA derivatives were studied in a previous work done in our laboratory. These 
amphiphilic polysaccharides can self-associate in aqueous solution, due to the formation of 
hydrophobic nanodomains of alkyl chains. The latter show good ability to incorporate 
hydrophobic dyes and drugs, such as nile red and paclitaxel, respectively. ?-Cyclodextrin 
molecules were grafted onto HA by a mild and rapid thiol-ene reaction. The resulting HA-
CD could bind several paclitaxel molecules via the pendant CD cavities. The high increase of 
paclitaxel solubility in water was attributed to the high hydrophilic character of HA.
Based on the ability of alkylated HA and cyclodextrin grafted HA to accomodate hydrophobic 
molecules paclitaxel into their hydrophobic nanocavities, we then demonstrated the 
formation of polyelectrolyte multilayer capsules based on these HA derivatives. These 
capsules were prepared by the layer-by-layer deposition of oppositely charged 
polyelectrolytes on CaCO3 particles, followed by decomposition of the carbonate core. These 
carriers have attracted a great deal of interest due to their multicompartment structure with the 
possibility to introduce a high degree of functionality at the nanometer scale within the shell.
The loading of PTX in the nanoshell was achieved by first complexing PTX with HA 
derivatives in solution and then, depositing these PTX-containing polyelectrolytes alternately 
with poly(L-lysine) according to the layer-by-layer technique. The capsules made from alkyl 
HA showed durability of drug entrapment under physiological conditions after several days.
Interestingly, HA-CD lead to capsules which showed sustained release of PTX within a 
period of five days. In the two cases, the PTX loaded capsules were found to decrease the 
viability and proliferation of MDA MB 231 breast cancer cells, while unloaded capsules did 
not impact cell viability. Due to these promising results, these hydrophobic polysaccharide 
nanoshells open new avenues for applications of hydrophobic drug-carrier systems in 
nanomedicine.
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Thiol modified poly(diethyleneglycolmethacrylate - oligoethyleneglycolmethacrylate 
(poly(DEGMA-co-OEGMA)) was reacted with a HA-maleimide conjugate to obtain HA-
poly(DEGMA-co-OEGMA). The LCST value of this HA-copolymer was determined to be 
around 35°C via turbidity measurements. At the body temperature, HA-copolymer was thus 
shown to self-assemble into nanogels with the ability to encapsulate hydrophobic molecules
into their hydrophobic domain. The size of nanogel was found to vary between 190 and 320
nm, depending on the DS of the HA-poly(DEGMA-co-OEGMA) conjugates. In vitro cell 
culture studies showed that with incorporating the hydrophobic anti-cancer drug paclitaxel, 
the nanogels exhibited high efficiency and selectivity in the eradication of CD44 positive 
human ovarian cancer cells. These results suggest that these temperature-triggered nanogels
hold great potential for the delivery of chemotherapeutics in anti-cancer therapy.
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Conclusion générale (fr)
Polysaccharides suscitent un intérêt croissant dans le domaine de délivrance de médicaments 
en raison de leurs propriétés exceptionnels telles que la non-toxicité et la biodégradabilité.
L'acide hyaluronique est un polysaccharide fortement hydraté. Grâce à sa présence naturelle 
dans le corps humain et aux nombreuses possibilités de modifications chimiques de ce 
polysaccharide, l'acide hyaluronique est un bon candidats pour la conception de transporteurs 
de principes actifs. Dans cette thèse, nous avons synthétisé différents types de dérivés du HA 
en milieu aqueux. Ceux-ci comprennent les dérivés alkylés du HA, HA-cyclodextrine 
conjugués et des copolymères «hybrides» composés de HA et d'un copolymère
thermosensible de l'éthylène glycol.
Les dérivés alkylés du HA ont été étudiés dans les travaux précédent au sein du laboratoire.
Ces polysaccharides amphiphiles peuvent s'auto-associer en solution aqueuse par la formation 
de nanodomaines hydrophobes par des chaînes alkyle. Le dernier présente une forte capacité 
d'incorporer d'une sonde fluorescente and un médicament hydrophobe, tels que le nile red et 
le paclitaxel, respectivement. ????-cyclodextrine a été greffé sur le HA par une réaction douce 
et rapide de couplage de type "thiol-ène". Le HA-CD peut encapsuler les molécules de 
paclitaxel par la présence de la cavité hydrophobe de cyclodextrine. La forte augmentation de 
la solubilité du paclitaxel dans l'eau a été attribué au caractère hydrosoluble de HA.
Basé sur la capacité d'accueillir des molécules hydrophobes paclitaxel dans leurs hydrophobes 
"nanocavités", nous avons ensuite montré la formation de multicouches de polyélectrolytes de 
capsules à partir de ces dérivés du HA. Ces capsules ont été préparés par dépôt couche par 
couche de polyélectrolytes de charges opposées sur les particules de CaCO3, suivie de sa
décomposition. La paroi de ces capsules "multicompartiments" est donc constituée d'un film 
multicouche de polymères permettant d'introduire diverses fonctionnalités. L'insertion des 
molécules paclitaxel dans la paroi des capsules a été réalisée par pré-complexation avec les 
dérivés du HA en solution, et ensuite déposition ces PTX-polyélectrolytes avec le poly(L-
lysine) selon la technique de couche par couche. Les capsules à base de HA alkylé ont montré 
une durabilité d'incorporation des molécules hydrophobe dans les conditions physiologiques 
pendent plusieurs jours. Les molécules incorporées ne libèrent pas. Mais, les capsules à base 
de HA-CD ont pu libérer le PTX sur une période de 5 jours. Dans les deux cas, les capsules 
chargées de PTX ont été trouvés qu'elles permettent de réduire la viabilité et la prolifération 
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des cellules cancéreuses. Ces multicouches ouvrent de nouvelles voies vers des applications 
en nanomédecine, comme systèmes transporteurs de médicaments hydrophobes.
L'acide hyaluronique modifié par maleimide a été réagit avec 
poly(diethyleneglycolmethacrylate - oligoethyleneglycolmethacrylate  (poly(DEGMA-co-
OEGMA)) modifié par thiol afin d'obtenir le copolymère «hybrides» thermosensible. La 
valeur de la LCST de ce copolymère de HA est autour de 35 °C en déterminant par les 
mesures du point de trouble des solutions. Au-dessus de cette température, le HA-
poly(DEGMA-co-OEGMA) conduit à la formation des nanogels avec la capacité d'encapsuler 
des molécules hydrophobes dans leur domaine hydrophobe. La taille des nanogels dépend du 
DS du copolymère hybride en variant entre 190 et 320 nm. Les nanogels chargés en PTX ont 
montré une cytotoxicité plus élevée avec des cellules du cancer surexprimant le récepteur 
CD44. Ces résultats suggèrent que ces nanogels thermosensible pourraient s'avérer être des 
candidats intéressants pour la libration thérapeutique dans le traitement de cancer.  
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Design and evaluation of hydrophobic drug delivery systems based on chemically 
modified polysaccharides: toward new approaches for anti-cancer therapy
This work focused on the design of hydrophobic drug carrier made of chemically modified 
polysaccharide, especially derivatives of hyaluronic acid (HA).
The layer-by-layer capsules possessing a fascinating multicompartment structure have recently as 
attractive vehicles used for biomedical applications. In order to encapsulate the anti-cancer 
hydrophobic drugs, paclitaxel (PTX), within the wall of capsules, alkylated derivatives and 
cyclodextrin (CD) conjugate of HA were synthesized. The alkylated HA derivatives can self-associate 
in aqueous solution to form hydrophobic nanodomains of alkyl chains which show good ability to 
incorporated hydrophobic molecules. The HA-cyclodextrin conjugates could bind selectively PTX
molecules via the pendant CD cavities. The capsules were prepared by depositing these PTX-
containing polyelectrolytes alternately with poly(L-lysine). When breast cancer cells were incubated 
with these two types of PTX-loaded capsules, their viability was found to strongly decrease.
Self-assembled nanogels based on HA were also investigated. A thermosensitive copolymer of 
diethyleneglycolmethacrylate and oligoethyleneglycolmethacrylate was grafted onto HA chains in 
order to allow temperature-induced self-assembly into nanogels with tunable size. These nanogels can 
be easily loaded with hydrophobic molecules and hold potential for paclitaxel delivery towards human 
ovarian cancer cells.
Conception et évaluation de systèmes transporteurs de principes actifs hydrophobes à 
base de polysaccharides modifiés: vers de nouvelles approches pour la thérapie anti-
cancéreuse
Ce travail de thèse porte sur la conception de transporteur de médicament hydrophobe basé sur les 
polysaccharides chimiquement modifiées, notamment de dérivés dacide hyaluronique.
Les capsules couche par couche possédant une structure multicompartiment suscitent un intérêt 
important pour des applications biomédicales. Afin dencapsuler des médicaments hydrophobes anti-
cancéreuse, le paclitaxel (PTX), dans la paroi de capsules, les dérivés alkylé du HA et HA-
cyclodextrine (CD) conjugué ont été synthétisés. Les HA alkylés peuvent sauto-associer en solution 
aqueuse pour former des nanodomaines hydrophobes par des chaînes alkyles qui montrent une bonne 
aptitude pour incorporer les molécules hydrophobes. Les HA-cyclodextrines peuvent encapsuler 
sélectivement des molécules PTX via les cavités de CD. Les capsules ont été ensuite préparées en 
déposant alternativement ces PTX-polyélectrolytes et le poly(L-lysine). Lorsque les cellules 
cancéreuses du sein ont été incubées avec ces deux types de capsules chargées en PTX, leur viabilité a
diminué fortement.
Une nouvelle classe de nanogels à base de HA a été également étudiée. Ces nanogels sont obtenus 
avec une taille réglable par auto-association en milieu aqueux de dérivés de HA modifié par un
copolymère thermosensible de diéthylèneglycolméthacrylate et oligoéthylèneglycolméthacrylate, 
induite par une élévation de la température. Ces nanogles sont capables dencapsuler facilement des 
molécules hydrophobes. En chargeant en PTX, ces nanogles présentent un potentiel important pour 
transporter le PTX vers les cellules cancéreuses ovariennes.
